This file is my personal attempt at capturing the Hsp90 literature. With few exceptions it contains ALL papers with and about the cytosolic forms of Hsp90 with three important exceptions: (i) Expression analyses of the Hsp90 genes (my overview is Hsp90 protein-centered); (ii) the exploding pharmacological literature in which Hsp90 inhibitory drugs are used without any further genetic or biochemical analyses of Hsp90 biology; (iii) medicinal chemistry, notably the development of new drugs, and the clinical literature on their use. This monster file has grown organically over quite a number of years and hence, it is not always as organized as you might wish. However, if you search with key words, chances are you'll find everything. How to cite it? Refer to our web site (https://www.picard.ch) and/or cite the primary papers mentioned in here.

Available chapters: (navigate by clicking on the chapter titles and/or by clicking on the colored fields and arrows on the right)

- General
- Genetics
- Hsp90 interacting proteins
- Other in vivo analyses
- Pharmacology
- Biochemistry
- Structure
- Hsp90 chaperone machine
- Mapping of Hsp90 domains
- Hsp90 and disease
- Cell surface and extracellular Hsp90
- Unusual stuff
- Hsp90 relatives
- References

General:

♦ Reviews: Pratt, 1990; Pratt, 1993; Smith and Toft, 1993; Jakob and Buchner, 1994; Pratt, 1997; Pratt and Toft, 1997; Csermely et al., 1998; Buchner, 1999; Caplan, 1999; Yahara, 1999; Cheung and Smith, 2000; Kimmins and MacRae, 2000; Pearl and Prodromou, 2000; Krishna and Gloor, 2001; Pratt et al., 2001; Richter and Buchner, 2001; Young et al., 2001; Mayer et al., 2002; Nollen and Morimoto, 2002; Picard, 2002 (see also Morimoto, 2002); Pratt and Toft, 2003 (see also MacLean and Picard, 2003); Prodromou and Pearl, 2003; Citri et al., 2004b; Picard, 2004; Pratt et al., 2004; Riggs et al., 2004; Sreedhar et al., 2004; Wegele et al., 2004; Pearl, 2005; Sangster and Queitsch, 2005; Terasawa et al., 2005; Whitesell and Lindquist, 2005; Zhao and Houry, 2005; Pearl and Prodromou, 2006; Picard, 2006; Stirling et al., 2006; Caplan et al., 2007; Neckers, 2007; Pearl et al., 2008; Picard, 2008; Smith and Toft, 2008; Wandinger et al., 2008; Miyata, 2009; Neckers et al., 2009a; Echeverria and Picard, 2010; Taipale et al., 2010; Trepel
et al., 2010; Jackson, 2012; Röhl et al., 2013; Erlejman et al., 2014; Flynn et al., 2015; Mayer and Le Breton, 2015; Zuehlke et al., 2015; Prodromou, 2016; Varholomaiov et al., 2016; Verma et al., 2016; Radli and Rudiger, 2017; Schopf et al., 2017; Verba and Agard, 2017; Hoter et al., 2018; Radli and Rudiger, 2018; Sima and Richter, 2018; Biebl and Buchner, 2019.

Special review issue on Hsp90, edited by Picard, 2012: Altieri et al., 2012; Didenko et al., 2012; Echtenkamp and Freeman, 2012; Geller et al., 2012; Hartson and Matts, 2012; Haslbeck et al., 2012; Jhaveri et al., 2012; Johnson, 2012; Kadota and Shirasu, 2012; Li et al., 2012a; Li et al., 2012c; Makhnevych and Houry, 2012; Marzec et al., 2012; Mollapour and Necker, 2012; Prodromou, 2012; Roy et al., 2012; Sanchez, 2012; Theodoraki and Caplan, 2012; Whitesell and Lin, 2012.


Reviews on Hsp90 as drug target and effects of Hsp90 inhibitors: Ochel et al., 2001; Piper, 2001; Maloney and Workman, 2002; Neckers, 2002; Workman, 2002; Isaacs et al., 2003; Maloney et al., 2003; Neckers and Ivy, 2003; Workman, 2003; Workman, 2004; Chiosis et al., 2006; Chiosis and Neckers, 2006; Sharp and Workman, 2006; Kim et al., 2009; Porter et al., 2010; Neckers and Workman, 2012; Sawarkar and Paro, 2013; Schwartz et al., 2015; Mandato et al., 2016; Tukaj and Wegrzyn, 2016; commentary on criteria for developing and validating Hsp90 inhibitors (Neckers et al., 2018); Gestwicki and Shao, 2019; Zininga and Shonhai, 2019. And many many more.

Other focused reviews:
- Meeting reviews: Caplan et al., 2003; Jackson et al., 2004; Richter et al., 2007a; Mayer et al., 2009; Vaughan et al., 2010; Chiosis et al., 2013; Schwenkert et al., 2014; Van Oosten-Hawle et al., 2017; Blair et al., 2019b.
- Methods: General biochemistry (Buchner et al., 1998); single molecule FRET (Gotz et al., 2016). Whole range of chaperone-related methods in a Methods Mol. Biol. volume (Calderwood and Prince, 2018): Cortes et al., 2018; Cox and Johnson, 2018; Davenport et al., 2018; Hoskins et al., 2018; Kumar et al., 2018; Reidy, 2018; Sager et al., 2018b; Taipale, 2018; Verkhivker, 2018; Voruganti et al., 2018; Yoveva and Sawarkar, 2018; Yuno et al., 2018.
- On proposed role of Hsp90 in chromatin remodeling and epigenetic programming relating to cancer (Rudin et al., 2005; Siegal and Rushlow, 2012; Zabinsky et al., 2019). Chromatin and DNA-related functions (Gvozdenov et al., 2019b).
- Role of chaperones in evolution (Rutherford, 2003; Sangster et al., 2004; Jarosz et al., 2010; Zabinsky et al., 2019), and genome stability (Kaplan and Li, 2012). Primer article on Hsp90 as buffer and potentiator of genetic variations (Schell et al., 2016).
- Hsp90 in plants (Krishna and Gloor, 2001; Sangster and Queitsch, 2005; Xu et al., 2012b; di Donato and Geisler, 2019).
- Hsp90-SGT1 in innate immunity of plants (Kadota et al., 2010).
- Hsp90 for plant RNA viruses (Verchot, 2012).
- Hsp90 and telomeres (DeZwaan and Freeman, 2010).
- Hsp90 in neurodegenerative diseases (Luo et al., 2010; Salminen et al., 2011; Pratt et al., 2015; Bohush et al., 2019; Gracia et al., 2019; Gupta et al., 2020).
- Hsp90 complex and steroid receptors (Grad and Picard, 2007; Echeverría and Picard, 2010; Galigniana et al., 2010; Cano et al., 2013; Cato et al., 2014; Mazaira et al., 2018; Baker et al., 2019).
- Secreted Hsp90 (Cheng et al., 2010; Li et al., 2013d), as biomarker (Taha et al., 2019).
- Fungal Hsp90 (Leach et al., 2012; Cowen, 2013; O'Meara and Cowen, 2014; O'Meara et al., 2017).
Miscellaneous parasites (Angel et al., 2014; Rochani et al., 2014; Seraphim et al., 2014; Devaney and Gillan, 2016; Woodford et al., 2016b).

Single molecule analyses (Mashaghi et al., 2014; Avellaneda et al., 2017).

Transcellular chaperone signaling and non-cell-autonomous organismal proteostasis (van Oosten-Hawle and Morimoto, 2014; Miles et al., 2019).

Interaction with clients (Karagoz and Rüdiger, 2015).

Focus on Hsp90α and its gene HSP90AA1 (Zuehlke et al., 2015), and on Hsp90β (Haase and Fitze, 2016).

Innate and adaptive immunity (Tamura et al., 2016; Zininga et al., 2018).

Cancer (Calderwood and Gong, 2016; Isaacs and Whitesell, 2016; Vartholomaiou et al., 2016).

Structure by SAXS (Borges et al., 2016).

Proteomics (Weidenauer et al., 2017).

Hsp90 and co-chaperones in tauopathies (Shelton et al., 2017b).

New co-chaperones (Sager et al., 2018a).


Stress response and adaptation (Joshi et al., 2018); buffering stress and environmental impact to prevent birth defects (Zohn, 2020).

Hsp90/Hsp70 collaboration (Genest et al., 2019; Morán Luengo et al., 2019).

Epichaperome (Wang et al., 2019c).

Signal transduction (Streicher, 2019).

Mitochondrial import (Becker et al., 2019).

R2TP of Plasmodium falciparum (Seraphim et al., 2019).

Hsp90 and other Hsps in STAT3/STAT5 signaling pathway (Jego et al., 2019).

♦ most abundant soluble cytosolic protein (~ 1% of total protein) even before heat-shock (Lai et al., 1984), poorly induced. Concentration depending on cells is 10 - 150 µM (Nollen and Morimoto, 2002; see also Finka and Goloubinoff, 2013); about 17.5. µM in budding yeast (Ghaemmaghami et al., 2003). Hsp90α estimated to be 2.8% in colon cancer cell lines (Wang et al., 2010).

♦ often overexpressed in cancer (e.g. Neckers, 2002; Whitesell and Lindquist, 2005; Pick et al., 2007; Kubota et al., 2010; and many more).

♦ isoforms / genes:
  - human Hsp90α (gene HSP90AA1) and Hsp90β (gene HSP90AB1)
  - yeast (S. cerevisiae) HSP82 and HSC82
  - only one gene in Drosophila (Hsp83)
  - zebrafish has one Hsp90β and two clustered Hsp90α genes (Hsp90α1 and Hsp90α2 proteins only 91% identical)
  - isoforms are highly similar (90±5%), few clear cases of isoform-specific functional differences (for possible exceptions, see below).

♦ expression of isoforms is differentially regulated (see for example Sreedhar et al., 2004):
  - human Hsp90α ~ mouse Hsp86 (~ S. cerevisiae Hsp82): heat-inducible
  - human Hsp90β ~ mouse Hsp84 (~ S. cerevisiae Hsc82): constitutive, growth factor inducible

♦ very highly conserved: identity 60% between human and yeast, 40% between human and E. coli (HtpG).

♦ essential for viability in yeast (one of two isoforms is sufficient) (Borkovich et al., 1989), Drosophila (van der Straten et al., 1997; Yue et al., 1999), and C. elegans (Birnby et al., 2000). HtpG dispensable in E. coli (Bardwell and Craig, 1988), Actinobacillus (Winston...
et al., 1996), *Bacillus subtilis* (Versteeg et al., 1999) and *Porphyromonas* (Sweier et al., 2003; Kawano et al., 2004), not found in archaea (Chen et al., 2006a).

- **Hsp90 as a capacitor for evolution** in *Drosophila* (Rutherford and Lindquist, 1998 {discussed in Cossins, 1998; Yahara, 1999}; even including epigenetic changes in an inbred background {Sollars et al., 2003}) and *Arabidopsis* (Queitsch et al., 2002; Sangster et al., 2007). Hypothesis about the evolutionary role of Hsp90 during the pre-Cambrian glaciation and Cambrian explosion (Baker, 2006b; Baker, 2006a). Hsp90 potentiates the rapid acquisition of drug resistance in fungi in a calcineurin-dependent fashion (Cowen and Lindquist, 2005). However, although bristle numbers in *Drosophila* depend on Hsp90, Hsp83 mutations have no effect on phenotypic variance (Milton et al., 2003; Milton et al., 2005; see also Debat et al., 2006). Hsp90 controls both qualitative and canalized quantitative traits (Carey et al., 2006; Milton et al., 2006; Salathia and Queitsch, 2007; see also Samakovli et al., 2007). Existence of Hsp90-buffered variation and effect of Hsp90 on it and on developmental stability in plants (Sangster et al., 2008a; Sangster et al., 2008b). May be mediated at least in part by its positive and negative interactions with Trx and Pc, respectively (Tariq et al., 2009). Alternatively, Hsp90 prevents phenotypic variations in *Drosophila* by promoting the biogenesis of piRNAs that repress expression and transposition of transposons (Specchia et al., 2010); it does so by interacting with Piwi along with Hop, thus playing an important role in canalization (Gangaraju et al., 2011; discussed by Ruden, 2011). Hsp90 system as a protein-folding reservoir that promotes both evolutionary stasis and change; thermal stress and Hsp90 inhibition increase (“normalize”) the correlation between phenotype and genotype (Jarosz and Lindquist, 2010). Higher levels of Hsp90 correlate with lower phenotypic variation of inherited mutations (Burga et al., 2011; Casanueva et al., 2012). Fitness benefit also seen in wild *Drosophila* populations (Chen and Wagner, 2012). In gene duplicates, the Hsp90 client can evolve faster than the non-client paralog (Lachowiec et al., 2013). Hsp90 buffers phenotypic eye size changes in cavefish (Rohner et al., 2013). Hsp90 client status of kinases promotes evolutionary rate, but the ancestral kinase may not have been a client (Lachowiec et al., 2015). However, experimental evidence in yeast argues that Hsp90 is not involved in genetic canalization, does not phenotypically buffer against the effects of new mutations, but rather enhances/potentiates them (Geiler-Samerotte et al., 2016). GWAS analysis for male genital development in *Drosophila* treated with Hsp90 inhibitor reveals large numbers of SNPs (Takahashi et al., 2018). Buffer for poliovirus capsid evolution balancing protein aggregation and stability (Geiler et al., 2018).

- Evolution of Hsp90 family: chloroplast Hsp90 may derive from ER form and not cyanobacteria while mitochondrial Hsp90 from eubacteria other than α-proteobacteria such as *E. coli* (Emelyanov, 2002; see also Stechmann and Cavalier-Smith, 2003; Stechmann and Cavalier-Smith, 2004). Use of Hsp90 sequences for single-gene phylogenetic analysis of eukaryotes (Stechmann and Cavalier-Smith, 2003). Further analyses indicate that organellar Hsp90s are not derived from endosymbionts, that mitochondrial Trap1 (only in animalia and protista) and Grp94 (lost in some fungi) originated separately from ancestors of HtpG early in the formation of eukaryotic cells whereas the cytosolic Hsp90s (duplicated in vertebrates) and chloroplast Hsp90 (duplicated in higher plants) arose from Grp94 (Chen et al., 2005a; Chen et al., 2006a). These also define subfamily-specific signature sequences (Chen et al., 2006a). Coevolution with Hop (Travers and Fares, 2007). Evolutionary plasticity of Hsp90 and cochaperones (Johnson and Brown, 2009). A naturally occurring *Drosophila* variant in charged linker affects genetic variation of canalized traits (Sgrò et al., 2010). Duplication event in vertebrates timed (Pantzartzi et al., 2013). Duplicated in plants occurred before monocot eudicot split, and vertebrates and seed plants used different mechanisms for functional diversifications (Carretero-Paulet et al., 2013). Bioinformatic analysis reveals
that human and parasite Hsp90s differ by several distinct features (Faya et al., 2015). Experimental testing in yeast of fitness of reconstructed ancestral Amorphea Hsp90 and its substitutions shows pervasive contingency and irreversibility (Starr et al., 2018).

- For more genetic and biochemical interactions of yeast Hsp90 isoforms Hsp82 and Hsc82, see http://www.yeastgenome.org; for yeast 2-hybrid interactions of *C. elegans* Hsp90 (C47E8.5), see Li et al., 2004.

- By global analysis in yeast, the Hsp90 complex can be classified as a stress-inducible chaperone complex as opposed to a chaperone linked to protein synthesis (CLIPs) which also associates with nascent polypeptides (Albanèse et al., 2006).

- Network analysis highlights Hsp90-FKBP complexes as important in responses of circadian rhythms to environmental signals (Yan et al., 2008).

- Coevolutionary analysis of Hsp90 in bacteria reveals role in flagellar assembly, chemotaxis and secretion, and association of gain/loss of Hsp90 with preference for multiple habitats (Press et al., 2013).

- *Catarrhinus* primates (including humans) may also have an N-terminally (122 aa) extended version of Hsp90α (encoded by two far upstream exons), which still binds co-chaperones normally but has only half the normal ATPase activity (Tripathi and Obermann, 2013).

- Interaction network with Hsp90, Hsp70 and Hsp40 are part of the very small core of Hsf1-dependent genes in yeast and upon heat-shock in mammalian cells (Solís et al., 2016).

**Genetics:**

- Genetic analyses in *budding yeast* (*S. cerevisiae*) of in vivo functions for viability (Borkovich et al., 1989; Kimura et al., 1994; Minami et al., 1994; Nathan and Lindquist, 1995; Louvion et al., 1996; Palmer et al., 1995; Obermann et al., 1998; Panaretou et al., 1998; Panaretou et al., 1999; Meyer et al., 2003; Piper et al., 2003b; Francis and Thorsness, 2011), spindle pole body duplication (Zarzov et al., 1997), steroid receptor regulation (Picard et al., 1990; Bohen and Yamamoto, 1993; Bohen, 1995; Nathan and Lindquist, 1995; Fang et al., 1996; Panaretou et al., 1999; Fang et al., 2006), retinoid receptors (Holley and Yamamoto, 1995), dioxin receptor (AhR) regulation (Carver et al., 1994; Whitelaw et al., 1995; Cox and Miller III, 2003; Cox and Miller III, 2004; Yao et al., 2004), src activity (Xu and Lindquist, 1993; Nathan and Lindquist, 1995; Nathan et al., 1997; Xu et al., 1999), p53 folding (Blagosklonny et al., 1996), *de novo* folding and recovery after heat inactivation of few proteins (Nathan et al., 1997), heme regulation of Hap1 (Zhang et al., 1998; Lee et al., 2002; Lee et al., 2003), HSF function (Duina et al., 1998; Harris et al., 2001), pheromone signaling and Ste11 accumulation (Louvion et al., 1998; Panaretou et al., 1999), regulation of Gcn2 (Donzé and Picard, 1999), α-complementation of β-galactosidase (Abbas-Terki and Picard, 1999), sensitivity to high salt (Imai and Yahara, 2000) and heat (Cheng et al., 1992; Imai and Yahara, 2000), sensitivity to Hsp90 inhibitors (Piper et al., 2003a; Piper et al., 2003b), maltose utilization via Mal63 (Bali et al., 2003). Microtubules aberrant in mutant strains (Yue et al., 1999), and assembly and maintenance of proteasome (Imai et al., 2003). Overexpression (Grandin and Charbonneau, 2001), deletion (Askree et al., 2004; Toogun et al., 2008), or point mutations (Toogun et al., 2008) shorten telomere length. E381K mutation shortens replicative and extends chronological life span (Harris et al., 2001). Mutations stabilize an Hsp90 degradation substrate (McClellan et al., 2005). Role in acquiring resistance to anti-fungal drugs (Cowen and Lindquist, 2005). Activating role of Ppt1 (Wandinger et al., 2006). Required for adaptation to high osmolarity by a Hog1-independent pathway; osmosensitivity of *hsp90* mutant strains suppressed by Cdc37
overexpression (Yang et al., 2006b). Comprehensive survey of effects of Hsp82 point mutants on ATPase activity, co-chaperone interaction, and GR and v-Src function (Hawle et al., 2006), and molybdate sensitivity (Millson et al., 2009). Survey of complementation and co-chaperone interactions of Hsc82 mutants (Johnson et al., 2007). Ability of Hsp90 isoforms to complement various functions (Millson et al., 2007). Hsp90 mutants show secretion and vacuole targeting defects (McClellan et al., 2007). Monomeric Hsp82 is defective (Wayne and Bolon, 2007) but forced dimer is superstabilized and functional (Wayne et al., 2010; Pullen and Bolon, 2011). Hsp90/Hsp70 machineries required for rapid galactose induction, possibly for removal of nucleosomes at target promoters (Floer et al., 2008). Plasmodium Hsp90 and human Hsp90α and Hsp90β support viability and confer differential sensitivities to Hsp90 inhibitors (Wider et al., 2009). In vivo requirements of Ydj1 for Hsp90 clients such as GR and Ste11 include farnesylation (Flom et al., 2008). Hsp90 function, possibly nuclear, is required for sporulation (Tapia and Morano, 2010). AtHsp90.1 and AtHsp90.2 (Song et al., 2010a), and AtHsp90.3 (Xu et al., 2010) complement. Required, and in particular ability to interact with Sti1, for Hsp104-mediated curing of prions (Reidy and Masison, 2010; Gorkovskiy et al., 2017). L34I mutant mimics radicicol resistance of H. fuscoatra Hsp90 (Prodromou et al., 2009). Other point mutants can partially mimic the GA resistance of S. hygroscopicus htpG (Millson et al., 2011). Non-phosphorylatable Hsp82 mutant Y24F is viable (Mollapour et al., 2010). Use of Hsp82 complementation to study fitness of mutant library (Hietpas et al., 2011) and relationship between expression levels and fitness of mutants (Jiang et al., 2013). Both ts mutant and overexpression perturbs Sir2 homeostasis and gene silencing (Laskar et al., 2011). Hsp82 point mutant T101I shows unstable polysomes at low temperature (Franzosa et al., 2011). Viability and chaperone function of phosphorylation sites (Soroka et al., 2012). Aha1 overexpression can suppress impaired activity of yeast Hsp82 with charged linker from Plasmodium Hsp90 (Tsutsumi et al., 2012). hsc82 W296A affects cAMP signaling (Flom et al., 2012). A Δhsp82 strain is hypersensitive to Hsp90 inhibitor-induced aneuploidy (Chen et al., 2012a) and conversely, Hsp90 function is compromised in aneuploid strains (Oromendia et al., 2012). Hsp90 mutations and inhibitors destabilize hepatitis C virus core protein and its growth inhibitory effects (Kubota et al., 2012). Point mutants modeled on htpG substrate binding mutants affect various chaperone functions (Genest et al., 2013). Low levels of Hsp90 or higher temperature lead to morphological heterogeneity (elongated buds in a subset of cells) because of compromised Cla4 and Cdc28 functions, and strain Δ1278b becomes invasive (Hsieh et al., 2013). Hsp90 isoforms selectively, and in opposite ways, control the balance between resistance, apoptosis and necrotic cell death in response to acetic acid stress (Silva et al., 2013). ATP binding and ATPase requirements in vivo (Panaretou et al., 1998; Mishra and Bolon, 2014). Differential effects of Δsqt2 and Sgta/Sgt2 overexpression on steroid receptor functions (Paul et al., 2014). CDC37 and HSP82 are required for normal nutrient starvation response as suggested by proteomic analysis (Rødkær et al., 2014). Slow growth phenotype of yeast complemented with human Hsp90α is exacerbated by deletion of aha1 but not hch1 (Synoradzki and Bieganowski, 2015). Required for homologous-recombination mediated DNA repair of double-strand breaks, rendering a panel of hsp82 mutant strains more sensitive to MMS and UV (Suhane et al., 2015). Hsp82 overexpression upregulates Cup9 expression (Laskar et al., 2015). No isoform-selectivity or effect of overexpression on {URE3} prion, but MEEVD truncation mutant is defective (Kumar et al., 2015). Comprehensive mapping of amino acid requirements in N-terminal domain for growth and some clients indicate a number of constraints and intriguing client-specific requirements (Mishra et al., 2016; see comments in Zuehlke and Neckers, 2016). Phosphorylation by Mps1 modulates client chaperoning and sensitizes yeast to Hsp90 inhibitors (Woodford et al., 2016c). Hsp90 represses RAD53 expression thereby
augmenting genomic instability (Khurana et al., 2016). Combinatorial exploration of the fitness landscape of the 582-590 region of Hsp82 (Bank et al., 2016). Mutations in allosteric regulation points are viable but E431K ad F364A/F421A are defective for GR activity (Rehn et al., 2016). Initially reported lethality of ATPase-defective mutant E33A (Obermann et al., 1998; Panaretou et al., 1998), unlike that of the ATP binding mutant D79N (Obermann et al., 1998; Panaretou et al., 1998), could not be confirmed (Zierer et al., 2016). ATPase activity and in vivo activity in yeast do not correlate (Zierer et al., 2016; see also Maharaj et al., 2016); what is important is a certain dwell time in the open state (Zierer et al., 2016). Hsp82 chimeras with Grp94 N- or M2-C domains are viable (Maharaj et al., 2016). Y606 mutant, notably phosphoserine mutant Y606E (equivalent of phosphorylated Y627 in human Hsp90α), impairs client accumulation and activity (Zuehlke et al., 2017). A107N, which stabilizes the closed state, suppresses defects of W585T and HCH1 overexpression (Zuehlke et al., 2017). Overexpression of human Tsc1 leads to toxicity, which can be suppressed by phosphomimetic Aha1 Y223E high Hsp90 affinity mutant (Woodford et al., 2017). Co-chaperones are differentially required for the activity of exogenous clients and conformation of GR (Sahasrabudhe et al., 2017). Series of temperature-sensitive mutants in M domain point out regions required for direct interaction with Hsp70 (Kravats et al., 2018); these and mutants notably in C-terminally located region lead to Sti1-dependence (Reidy et al., 2018). Drosophila Hsp83 complements (Lauwers et al., 2018). HSC82 (not HSP82) is required for K48-ubiquitination-mediated degradation of cytoplasmic proteins, but not K11-ubiquitination-mediated degradation of nuclear proteins (Samant et al., 2018). Δsti1 and Δhgh1 cause large decrease in Hsp90 "availability", as assayed with GR reporter (Alford and Brandman, 2018). Impact of the NxNNWWH motif of Aha1 on growth and chaperoning of cells with Hsc82 S25P (Mercier et al., 2019). Growth with either Hsc82 or Hsp82 (at similar levels) similar, but strain with Hsc82 is more affected by high temperature and by radicicol (Girstmair et al., 2019). Impact of short or long-term inactivation of Hsp90 on genome-wide DNA binding Gvozdenov et al., 2019a).

* genetic interactions in **budding yeast**: synthetic lethality between Δhsc82 and cdc37-1 (Kimura et al., 1997), and Δcpr7 and Δhsc82 or hsp82G170D (Duina et al., 1996). A Δhch1 Δaha1 strain with low levels of Hsp90 is temperature-sensitive (Lotz et al., 2003). Cdc37 overexpression can rescue v-Src but not GR activity in a strain with the Hsp82 G170D ts mutant (Kimura et al., 1997). Synthetic effects between Δcpr7 and Δhsc82 on HSF activity (Duina et al., 1998) and growth on maltose (Bali et al., 2003). Synthetic lethality and allele-specific complementation between HSP90 and STI1 (Chang et al., 1997, see also Flom et al., 2005; Flom et al., 2006). A fragment of Hsp82 suppresses the Ste4-induced growth arrest (Edwards et al., 1997). Synthetic lethality between mps1-1 and hsc82 (Jones et al., 1999), and skp1 and hsp90 (Stemmann et al., 2002). Overexpression (perhaps in a subtly isoform-specific fashion) suppresses ts cell cycle arrest and GA hypersensitivity of a hsf mutant (Morano et al., 1999). Δhsc82 derepresses invasive growth in KSS1-dependent way (Palecek et al., 2000). In a Δsti1 strain, C. elegans Hsp90 and human Hsp90β cannot support viability (Piper et al., 2003b). Synthetic effects of hsp82 mutation and overexpression with rpn (genes for 19S proteasome subunits) mutations (Imai et al., 2003). Temperature-dependent synthetic lethality between cns1-1 and hsp82ΔEEVD (Tesic et al., 2003). Overexpression of Sba1 is growth inhibitory in a Δhsc82 strain, and this depends on Hsp90 binding (Oxelmark et al., 2003). In contrast, Sba1 overexpression suppresses temperature-sensitivity and dioxin receptor signaling defect of Hsp82 G170D mutant (Cox and Miller III, 2004). P23 partially suppresses GR signaling defects of certain Hsp82 mutants (Hawle et al., 2006). Hsc82 G309S mutant particularly dependent on Sti1 to mediate interaction with Hsp70 (Flom et al., 2007). HSP82 suppresses α-synuclein toxicity (Liang et al., 2008). Genetic
interactions indicate that Hsc82/Hsp82 are involved in assembly of the mitochondrial F1F0-ATPase synthase complex (Francis and Thorsness, 2011). CPR7 essential when the charged linker of Hsp90 is deleted; this synthetic lethality can be suppressed by Cns1 overexpression as well (Zuehlke and Johnson, 2012). ∆cpr6 is synthetic sick with hsp90-A587T (Zuehlke et al., 2013). utorp21 mutation is synthetically sick with ∆hsc82 (Tenge et al., 2014). Overexpression of Hch1 impairs growth of some Hsp82 mutants (including phosphoserine mimic Y606E; Zuehlke et al., 2017) and increases sensitivity to Hsp90 inhibitors; ∆hch1 is hyperresistant (Armstrong et al., 2012). ∆hch1 is lethal in a yeast strain with hsp82 E381K (Horvat et al., 2014), but suppresses growth phenotype and reduced client accumulation and activity of Hsp82 W585T mutant (Zuehlke et al., 2017). sgt and cns1 point mutants are hypersensitive to overexpression of other co-chaperones, which must be able to bind Hsp90 but not necessarily compete directly (Johnson et al., 2014). Expression of both HSC82 and SSA2 rescue lethality of ∆hsf1 in non-stressed cells (Solís et al., 2016). Series of temperature-sensitive mutations in M domain, which are defective for interaction with Hsp70, are synthetic lethal with ∆sti1 (Kravats et al., 2018). Hsp82 overexpression can maintain Tor1 activity in cells overexpressing molecular chaperones (Peric et al., 2017). Two N-terminal and C-terminal clusters of point mutants lead to Sti1-dependence, and additional co-chaperone deletions differentially affect growth; Sti1-dependence can be relieved by intramolecular suppressing point mutants (Reidy et al., 2018). Hsp90 mutants genetically interact with ∆emc2 and multiple emc (components of ER membrane complex) deletions are hypersensitive to Hsp90 inhibitors and defective for GR function (Kudze et al., 2018). Complementation experiment with Hsp90 from other yeasts (N. castelli, K. lactis and Y. lipolytica) shows relative salt resistance for strain with Y. lipolytica Hsp90 and a wider phenotypic variation and Hsp90-related protein network adaptations in a laboratory evolution experiment than with wild-type (Koubkova-Yu et al., 2018; see also discussion in Helsen et al., 2019).

- genome-wide 2-hybrid screen and interaction with Cdc37 in budding yeast (Millson et al., 2004).
- suppressors in yeast: Protein phosphatase 2C is a multicopy suppressor of Hsp90 ts mutation in S. pombe (Shiozaki et al., 1994). Budding yeast: allele-specific complementation between HSP90 and STI1 (Chang et al., 1997). Allele-specific suppression of hsp90 ts mutations by SSF1, HCH1, and CNS1 (Nathan et al., 1999). Deletion of SCH9 (codes for a PKB-kinase) suppresses defects of strain with low levels of Hsp90 (Morano and Thiele, 1999). Cna2 overexpression suppresses salt sensitivity of Hsc82 overexpression strains (Imai and Yahara, 2000).
- genetic analyses in fission yeast (S. pombe): a point mutation in Swo1 (Hsp90) suppresses lethality of Wee1 overexpression, is synthetically lethal with cdc2 mutations (but does not affect Cdc2 levels and in vitro kinase activity) (Muñoz and Jimenez, 1999) and suppresses effects of overexpressed Mic1 and Swe1 from budding yeast (Goes and Martin, 2001). Synthetic lethality between swo1 and Wos2 (p23) overexpression (Muñoz et al., 1999). Swo1 overexpression suppresses some radicicol effects (Ki et al., 2001). Genetic and biochemical interactions with mg3 and myo2 indicate role in formation of actomyosin ring (Mishra et al., 2005). Hsp90 required in glucose/cAMP repression pathway (Alaabamy and Hoffman, 2008). Required as silencing factor for the formation of heterochromatin at pericentromeric regions through siRNA loading of Ago1 (Okazaki et al., 2018; Kato et al., 2019; see also Kato et al., 2019). Hsp90 required with co-chaperone TTT to promote incorporation of PIKK pseudokinase Tra1 into SAGA (Elías-Villalobos et al., 2019).
- genetic analysis in the fungus Podospora anserina: mod-E1 mutation in single Hsp90 gene gives thermosensitivity, developmental defects and suppresses vegetative incompatibility (Loubradou et al., 1997).
genetic analyses in *Drosophila*: Hsp83 (and Cdc37) mutations impair signaling by torso (Doyle and Bishop, 1993), sevenless (Cutforth and Rubin, 1994; van der Straten et al., 1997) and Raf (van der Straten et al., 1997). Mutant Hsp83 alleles are embryonal lethals over a deficiency of locus, but some complement other mutant alleles (van der Straten et al., 1997; Yue et al., 1999). Second-site non-complementation between *Hsp83* mutations and a *Cdc37* null allele (Kimura et al., 1997). When Hsp90 is mutant (heterozygous) or inhibited by geldanamycin or challenged at higher temperature, phenotypic variations in nearly all adult structures become apparent because of the expression of previously silent genetic determinants (Rutherford and Lindquist, 1998, discussed in Cossins, 1998). Spermatogenesis seems to be particularly sensitive to reductions in Hsp90 functions and correlates with defect in microtubule dynamics (male sterility in viable transheterozygotes and when Hsp90 is reduced) (Yue et al., 1999). Depletion of Hsp90 and Droj1 with RNAi in SL2 cells induces heat-shock response (Marchler and Wu, 2001). Hsp83 mutant flies show exaggerated homeostatic response and die after sleep deprivation (Shaw et al., 2002). Hsp83 is required for localization of some mRNAs in embryos, possibly through maintenance of Lkb1 (Song et al., 2007). Required for Trithorax (Trx) function and co-recruited to actively transcribed genes (Tariq et al., 2009; see also Sawarkar et al., 2012). Required for full female fertility (Yue et al., 1999) and proper oogenesis, in particular for "dumping" and in combination with cup alleles (Pisa et al., 2009). Hsp90 buffers circadian behavioral activity patterns (Hung et al., 2009). Mutations and RNAi interfere with cell cycle exit suggesting the APC/C activator Cdh1 may be an Hsp90 client (Bandura et al., 2013). SNPs associated with micro-environmental plasticity of female startle response (Morgante et al., 2015). Increased autophagy and degenerating egg chambers in transheterozygotes (Choutka et al., 2017). RNAi-mediated KD leads to loss of ovarian germline stem cells and heterozygous mutations accelerate loss in spag KD ovaries (Chen et al., 2018a). KD and overexpression in neural stem cells blocks and promotes reactivation, respectively, through insulin signaling pathway (Huang and Wang, 2018). KD impairs axon injury signaling through the DLK ortholog Wallenda (Karney-Grobe et al., 2018).

**Cyanobacteria**: HtpG is essential for thermotolerance (Tanaka and Nakamoto, 1999), cold acclimation (Hossain and Nakamoto, 2002), and protection against oxidative stress (Hossain and Nakamoto, 2003). Overexpression is growth inhibitory; normal levels of htpG, which is localized to the membrane fraction, is required for normal levels of its client uroporphyrinogen decarboxylase (HemE) (Watanabe et al., 2007). Thermotolerance is impaired by cyclic lipopeptide antibiotics that bind htpG (Minagawa et al., 2011).

**E. coli**: HtpG is essential for swarming (Inoue et al., 2007) and in a competitive swimming/chemotaxis assay (Press et al., 2013). Becomes more thermotolerant upon overexpression of Hsp90 from rice (Liu et al., 2009a). *E. coli* is hypersensitive to SDS upon overexpression of htpG, which also leads to filamentation, and a panel of substrate binding mutants alleviate this (Genest et al., 2013). ΔhtpG mutant has reduced β-lactamase and alkaline phosphatase activity, and impaired biofilm formation and protein at elevated temperature (Grudniak et al., 2013). Required for stability of Cas3 and its function in CRISPR system (Yosef et al., 2011). Required for production of genotoxic secondary metabolites such as colibactin and yersiniabactin and associated virulence; might protect a substrate in this pathway against degradation by ClpQ protease (Garcie et al., 2016). Overexpression of eukaryotic Hsp90 renders cells more heat-resistant (Vishwakarma et al., 2018). ΔhtpG partially rescues stress-induced growth and proteomic defects of ΔKJ mutant (Fauvet et al., 2018). Overexpression leads to filamentation because htpG binding to the tubulin homolog FtsZ prevents it from polymerization; ΔhtpG cells are slightly shorter (Balasubramanian et al., 2019).
In *Edwardsiella tarda*, a htpG mutation affects growth and resistance to oxidative stress (Dang et al., 2011).

In *Bacillus subtilis*, recovery from heat shock is retarded without htpG (Versteeg et al., 1999).

Hsp90 inhibitors affect viability and cold adaptation (slightly) of *γ*-proteobacteria (Garcia-Descaelho et al., 2011).

htpG overexpression improves butanol tolerance and adaptation in *Clostridium* (Mann et al., 2012).

Deletion of htpG impairs recovery from cold-shock in *Vibrio vulniﬁcus* (Choi et al., 2012).

htpG required for virulence in *Leptospira interrogans* (Marcisin et al., 2013; King et al., 2014).

*HtpG* of *Salmonella typhimurium* is required for intestinal persistence in pigs (Verbrugge et al., 2015).

Required in *Shewanella oneidensis* for growth under heat stress; involves TiIS as client (Honoré et al., 2017); Hsp90 and HsIVU protease have antagonistic effects for TiIS (Honoré et al., 2019).

Δ*htpG* of *Pseudomonas aeruginosa* is temperature-sensitive and displays several other phenotypes (Grudniak et al., 2018).

**Mice**: Hsp90β knock-out embryos are normal till E9/9.5, then die because of defective allantois and allantois-trophoblast interaction (Voss et al., 2000). Hypoxia-induced accumulation of HIF-1α is delayed in null fibroblasts (Katschinski et al., 2004). Spermatogenesis is disrupted in Hsp90α mutant mice because of a specific meiotic arrest in pachytene; Hsp90β levels unchanged in a panel of tissues (Grad et al., 2010; see also Kajiwara et al., 2012). Hsp90α KO have defective antigen cross-presentation by dendritic cells (Imai et al., 2011); however, MHC class II antigen presentation is increased (Li et al., 2012d). Hsp90α KO have defects in piRNA biogenesis and the PIWI protein MIWI2 is mislocalized, resulting in an increased expression of the L1 retrotransposon ORF1 in testes (Ichiyanagi et al., 2014). Hsp90α KO mice have reduced myocardial fibrosis upon pressure overload and myocardial fibroblasts produce less collagen (García et al., 2016; see also Cáceres et al., 2018). Hsp90α not absolutely required for development of tumors and metastasis in PyMT mammary carcinoma model; without Hsp90α tumor burden, but not numbers, and metastasis are reduced and proliferation and migration of isolated primary carcinoma cells is impaired (Varholomaioiu et al., 2017). Hsp90α KO mice display reduced support for development of pulmonary metastasis of injected melanoma cells (van der Weyden et al., 2017). AAV-mediated overexpression of Hsp90β exacerbates epileptic seizures in mouse model; suppressed by GA (Sha et al., 2017). Note that the original Hsp90α KO of Udono and colleagues expresses a chaperone-defective C-terminal truncation of 232 AA, but have normal extracellular Hsp90α function in skin wound healing (Bhatia et al., 2018). Hsp90α KO mice show retinitis pigmentosa and progressive blindness from week 3 after birth, correlated with photoreceptor death, defective intersegmental transport and tubulin deacetylation (Wu et al., 2019d).

**C. elegans**: null mutation of very highly expressed *daf-21* (called *hsp-90* as of 2018) gene is an early larval lethal; point mutation E292K shows defects in chemosensory responses in a dosage-dependent fashion (Bimby et al., 2000; see also Vowels and Thomas, 1994; Horikawa et al., 2015). Knock-down results suggest *daf-21* is required for Wee1 function and meiotic prophase/metaphase transition in oogenesis (Inoue et al., 2006). Knock-down impairs development of gonadal arms, a Hop-like phenotype (Gaiser et al., 2009). Hsp90 genes from other nematodes rescue at best partially (Gillan et al., 2009). *daf-21* mutation causes muscle defects (Gaiser et al., 2011). Higher levels of
Hsp90 promoter activity correlate with lower phenotypic variation, higher thermostolerance and lower reproductive fitness (Casanueva et al., 2012). Genetic evidence for repression of Hsf1 by Hsp90 (Barna et al., 2012). Compromising Hsp90 functions by proteotoxic stress, knock-down or overexpression in one tissue affects Hsp90 functions, e.g. in heat-shock response, systemically (non-cellautonomously) in other tissues through transcellular chaperone signaling (van Oosten-Hawle et al., 2013); requires the GATA factor PQM-1 in the sender tissue (O’Brien et al., 2018). Knock-down of Hsp90, Hsp70, Sgf1 and Unc45 induce Hsf1 reporter (Guisbert et al., 2013). Daf-21 interacts with the EBAX-1 gene for quality control of the SAX-3/Robo receptor involved in axon guidance (Wang et al., 2013e). Knock-down aggravates protein aggregation toxicity and reduces lifespan (Brehme et al., 2014). Hsp90 and its co-chaperones Aha1, Hop, and p23 are required for muscle integrity and motility in a unc45 mutant background (Frumkin et al., 2014). Knockdown indicates Hsp90 is required for age-dependent cilia recovery (Cornils et al., 2016). Mutation of HLH-1 transcription factor binding site in daf-21 promoter severely reduces myogenic expression and muscle proteostasis (“muscle-specific Hsp90 knock-down”) (Bar-Lavan et al., 2016). Hsp90 suppresses the mobility of transposable elements unless challenged, e.g. by moderate environmental stress (Ryan et al., 2016). RNAi affects genes involved in innate immune response and gonadal and larval development (Eckl et al., 2017). daf-21 mutants are hypersensitive to infection by the bacterial pathogen *Proteus mirabilis* (JebaMercy et al., 2016). Promotes Notch signaling in the germline (Lissemore et al., 2018). *daf-21* required for normal longevity, mitigated by *daf-16* LOF (Somogyvari et al., 2018). Weaker and/or later *daf-21* KD extends lifespan (Janssens et al., 2019).

- **Chicken** cells lacking Hsf1 and Hsf3 have 4x reduced Hsp90α and are hypersensitive to stress and GA (Nakai and Ishikawa, 2001).
- **Chicken** cells lacking Hsp90β grow more slowly and have defective B-cell receptor signaling; Hsp90α can complement, too (Shinozaki et al., 2006).
- **Leishmania** promastigotes overexpressing Hsp90 are more resistant to GA (Wiesgigl and Clos, 2001). Overexpression of radicicol-resistant point mutant allows the demonstration that Hsp90 is required at multiple life stages and that growth is improved by mutation to canonical MEEVD and that Sti1 interaction is important (Hombach et al., 2013). Impact of mutations of phosphorylation sites on viability, growth and infectivity (Hombach-Barrigah et al., 2019).
- Human polymorphism - first survey of 73 caucasian samples (Passarino et al., 2003). One of these polymorphisms in Hsp90α encodes a functionally defective point mutant (MacLean et al., 2005). The same one, Q488H, as homozygote correlates with increased breast cancer risk (Zagouri et al., 2012). Correlation of particular polymorphisms in Hsp90α and β genes and NSCLC (Coskunpınar et al., 2014) and high expression of Hsp90β with poor survival (Kim et al., 2015a).
- Knock-outs of Hsp90α and Hsp90β in human MDA-MB-231 breast cancer cells abolishes migration/invasion and proliferation, respectively (Zou et al., 2017).
- Polymorphism in flanking regions of the sheep Hsp90α gene correlate with susceptibility to scrapie (Marcos-Carcavilla et al., 2008; Marcos-Carcavilla et al., 2010), to DNA fragmentation in sperm (Ramon et al., 2014), and perhaps to climate adaptation (Salces-Ortiz et al., 2015).
- **Plants**: silencing of NbHsp90c-1 gene in tobacco leads to a stunted phenotype and a compromised hypersensitive response to pathogens, including resistance mediated by the Pto, N and Rx genes (Kanzaki et al., 2003; Lu et al., 2003). Silencing of an organellar Hsp90 also causes loss of the *Pto*-mediated response but not resistance (Lu et al., 2003). Point mutations in *HSP90.1* and *HSP90.2* of *Arabidopsis* specifically compromise RPS2 (Takahashi et al., 2003) and RPM1 functions (Hubert et al., 2003), respectively.
Also required for RPS4- (Zhang et al., 2004c), and I-2-dependent resistance (de la Fuente van Bentem et al., 2005). Hsp90.2 and Hsp90.3 required for RPP4-mediated resistance (Bao et al., 2014). In contrast, Hsp90 reduction increases resistance to herbivores (Sangster et al., 2007). Dominant-negative Hsp90.2 induces heat-shock response (Yamada et al., 2007). Compensatory changes in Hsp90 and SGT1 prove this interaction to be essential for pathogen resistance (Kadota et al., 2008; reviewed in Picard, 2008; Shirasu, 2009). Overexpression of cytosolic or organellar Hsp90 in Arabidopsis increases sensitivity to salt and drought stresses (Song et al., 2009; see also Xu et al., 2010). Specific mutations in Arabidopsis HSP90.2 that suppress all rar1 phenotypes; mutants may be independent of RAR1 co-chaperone because of increased cycling between open and closed lid conformation, independent of ATPase (Hubert et al., 2009). The 4 genes for cytosolic Hsp90 in Arabidopsis must ensure a minimal level of Hsp90 (Hubert et al., 2009). Reduced HSP90.2 activity compromises stomatal closure and ABA signaling in Arabidopsis (Clément et al., 2011). Differential effects of virus-induced silencing different HSP90 genes on seedling growth and the hypersensitive response in wheat (Wang et al., 2011). HSP90 silencing abolishes accumulation of R proteins I-2 and Mi-1 in tobacco (Van Ooijen et al., 2010). Transgenic expression of soybean Hsp90s in Arabidopsis protects against abiotic stresses and perturbs proline metabolism (Xu et al., 2013). Mutants of Arabidopsis Hsp90.2 and Hsp90.3 display enhanced disease resistance associated with increased levels of immune receptors SNC1, RPS2 and RPS4 (Huang et al., 2014). Hsp90 (RAR1 and SGT1) contribute to suppressing (!) disease tolerance/defenses to bacterial wilt disease (Ito et al., 2015). Knock-down or overexpression of HSP90.1 in Arabidopsis T-DNA integration and transformation (Park et al., 2014). Hsp90 orchestrates regulatory network for flowering (Margaritopoulou et al., 2016). Impact of hsp90.2 and Hsp90 inhibitor on circadian period (Davis et al., 2018). hsp90.2-3 mutation in Arabidopsis promotes membrane association of Ago1 (Sjögren et al., 2018). Hsp90 is involved in controlling retrograde communication between chloroplast and nucleus sustaining photosynthesis-associated nuclear gene expression when preproteins accumulate (Wu et al., 2019b). Mutation or knock-down of Hsp90 in Arabidopsis increases levels of soluble polyamines (Toumi et al., 2019).

- Dominant-negative Hsp90: ATP binding mutant blocks eNOS and Akt function in transfected tissue culture cells (Miao et al., 2008; see also Chen et al., 2017b). A point mutant of Arabidopsis Hsp90.3 behaves as a dominant-negative mutant (Huang et al., 2014). DN mutant affects HIF1α levels (Filatova et al., 2016).

- Hsp90 and IGF1R expression correlate in Ewing sarcoma, and Hsp90 overexpression with drug resistance in cell lines (Martins et al., 2008).

- Candida albicans: Hsp90 represses an environmentally triggered, and Ras1-PKA-dependent morphogenetic transition (Shapiro et al., 2009), which depends on its interaction with Cdc28 (Senn et al., 2012). Inhibition of Pck1 phenocopies inhibition/reduction of Hsp90 in rendering cells hypersensitive to drugs (LaFayette et al., 2010). Hsp90 is required for biofilm growth, maturation and dispersal both in Candida and Aspergillus; reduction of Hsp90 reduces matrix glucan levels and increases sensitivity to anti-fungal drugs (Robbins et al., 2011). Chemical genomics screen reveals extensive Hsp90 network and regulation by CK2 (Diezmann et al., 2012). Sqt1 is also involved (Shapiro et al., 2012). Compromised Hsp90 reduces calcineurin levels (Shapiro et al., 2012) and through that renders cells more resistant (!) to apoptosis (Dai et al., 2012). Pharmacological and genetic evidence suggests trehalose as negative regulator of Hsp90 (Sernees et al., 2012). Amphotericin B resistance requires high levels of Hsp90 to compensate for reduced fitness of mutants (Vincent et al., 2013). Genetic and biochemical interactions with transcription factors for biofilm formation and morphogenesis highlights Tup1 (Diezmann et al., 2015). Hsp90 depletion increases Hsf1 activity before heat-shock but compromises early heat-shock responses (Leach et al.,...
Chemical genetic screen covering 10% of genome reveals that defects in ergosterol biosynthesis and actin remodeling overwhelm Hsp90 (O'Meara et al., 2016). Depletion of Hsf1 somehow compromises Hsp90 function independent of its effect on Hsp90 expression (Veri et al., 2018). Reduction of Hsp90 levels induces homothallic mating response (Guan et al., 2019). Hsp90 impairment affects P-body and stress granule formation in response to antifungals (O'Meara et al., 2019).

- Selection for resistance to azole antifungals and geldanamycin with budding yeast and Candida also leads to point mutations in Hsp90 (Hill et al., 2013). Adaptation and resistance to drug combinations, including Hsp90 inhibitors, is associated with reduced fitness in Candida albicans (Hill et al., 2015).
- Essential for growth of Candida auris; Hsp90 depletion induces filamentous growth in several Saccharomycetales species of the CUG clade (Kim et al., 2019b).
- Required in Aspergillus fumigatus for viability, cell wall and various other functions (Lamoth et al., 2012). Acetylation of two lysine residues compromises Hsp90 function, drug resistance and virulence (Lamoth et al., 2014).
- Knock-down in mosquito reduces dehydration tolerance (Benoit et al., 2010).
- Knock-down in planarians is lethal suggesting a cytoprotective role in the gastrodermis (Conte et al., 2011).
- In Giardia, Hsp90 is encoded in two pieces through trans-splicing of the mRNA (Kamikawa et al., 2011; Nageshan et al., 2011; Nageshan et al., 2014; Iyer et al., 2019). Full-length Hsp90 is down-regulated during encystation and Hsp90 inhibitors stimulate encystation (Nageshan et al., 2014).
- Silencing in the beetle Tribolium castaneum shows Hsp90 is required at all developmental stages (Knorr and Vilcinskas, 2011).
- Aneuploid human cells have reduced Hsp90 levels (and function) because of reduced Hsf1 expression (Donnelly et al., 2014).
- Plant-mediated knock-down of Hsp90 in root-knot nematode protects plants (Liu et al., 2015).
- Neurospora; Hop/Sti1, Aha1 and p23 are required for resistance to antifungals and heat stress, possibly by regulating transcription of key resistance genes; Hop/Sti1 and p23 also required in Fusarium verticilliodes (Gu et al., 2016).
- Pea aphid Acyrthosiphon pisum: KD reduces longevity and fecundity (Will et al., 2017).
- In the grasshopper Locusta migratoria, an Alu-like transposable element has been found to disrupt the Hsp90 gene; there are no homozygotes, but heterozygotes have a competitive advantage (Chen et al., 2017a).
- Hsp90 inhibition or daf-21 knockout (viable with pleiotropic phenotype?) in nematode Pristionchus pacificus reveals role of Hsp90 in canalizing the developmental plasticity of mouth-forms (Sieriebriennikov et al., 2017).
- KD in planarian Dugesia japonica has phenotype (Dong et al., 2018).
- HtpG mutant Mesorhizobium huakuii affects lipid abundance and is defective for symbiotic root nodule formation; HtpG associates with plant non-specific lipid transfer proteins in the plasma membrane of nodule cells (Zhou et al., 2019a).

Hsp90 interacting proteins:

- Hsp90Int.db: the comprehensive interactome built with data from public protein-protein interaction databases and the literature (Echeverría et al., 2011a; see also its associated and continuously updated database at https://www.picard.ch/Hsp90Int).
Introduction of the term "molecular chaperone ensemble" for the multitude of Hsp90-cochaperone complexes that can dynamically coexist in the same cell or across different cell types (Echeverría et al., 2016).

Yeast 2-hybrid with C-terminal 100 AA of human Hsp90α yielded only FKBP51, FKBP52 and TOM34 (Young et al., 1998). Yeast 2-hybrid with Cyp40 TPR yielded only C-terminal portion of murine Hsp90 (Carrello et al., 1999).

Global analyses in budding yeast: Zhao et al., 2005; also genome-wide 2-hybrid screen with an Hsp90 ATPase mutant for yeast interactors (Millson et al., 2005). Chemical genetic screens with homozygous and heterozygous deletion libraries at different temperatures reveal roles in secretory pathway and cellular transport under normal conditions, in cell cycle, meiosis and cytokinesis at elevated temperature, as well as in transcription, ribosome biogenesis and GTP binding proteins (McClellan et al., 2007; Franzosa et al., 2011). TAP-tagged yeast Hsc82 and Hsp82 pull down large and distinct sets of proteins, and cochaperone-centric systems analysis suggests a multitude of overlapping chaperone modules (Gong et al., 2009). Proteins (e.g. Gln1) that form foci in response to stress and co-IP with Hsp82 (O’Connell et al., 2014; see also Chen et al., 2018b). Proteomic analysis of Hsp90-dependent proteome with reduced Hsp90 levels indicates that a large fraction changes with an overrepresentation of conserved, unstable, large and hub proteins (Gopinath et al., 2014). Proteomic analysis of interactions in response to DNA damage (Truman et al., 2015). Integrated genetic and physical interaction mapping reveals chaperone supercomplex and enrichment of interactions with proteins forming foci under stress (Rizzolo et al., 2017; see also Rizzolo et al., 2018). Isoform-specific interactome of C-terminally tagged Hsp90 shows few differences and an overall bias towards proteins with lower than average pl (Girstmair et al., 2019).

Global analyses in mammalian cells: co-IP with Hsp90 (Falsone et al., 2005; Te et al., 2007; Wang et al., 2010; Skarra et al., 2011; Wu et al., 2012b); pharmacological survey of kinases (Citri et al., 2006; Haupt et al., 2012); accumulation of detergent-insoluble ubiquitinated proteins in presence of GA (Falsone et al., 2007); pull-down with Hsp90 inhibitor beads (Caldas-Lopes et al., 2009). Comparative approach with IP, GA-biotin beads and Hsp90β-sepharose yields a total of 42 proteins including a modest set overlapping proteins (Tsaytler et al., 2009). TAP-tagged Hsp90 pulls out 37 known and 24 novel proteins in ligand-dependent fashion (Gano and Simon, 2010; see also Manisssorn et al., 2018). Proteomic analysis of the autophagy protein network around ATG8 proteins reveals Hsp90α/β (Behrends et al., 2010; see also Joo et al., 2011; Seguin-Py et al., 2012). Proteomics with Hsp90 complexes pulled down with PU-H71-beads identifies many cancer-specific signaling complexes (Moulick et al., 2011); these are preferentially pulled out from AML cells with hyperactivated signaling pathways (Zong et al., 2015). Survey of kinases, E3 ligases and transcription factors, and of Cdc37-dependent by immunoprecipitation (Taipale et al., 2012). Extensive biochemical probing of the chaperone network reveals global features, Hsp90-independent co-chaperone interactions, co-chaperone-mediated substrate specificities, specificity of the NUDC family of co-chaperones for proteins with β-propeller folds and an evolutionary expansion of proteins with folds correlating with respective co-chaperones (Taipale et al., 2014). See also Aha1-based proteomics (Sun et al., 2012; Sun et al., 2015). No correlation between Hsp90 inhibitor-induced degradation and co-immunoprecipitation for a panel of kinases (Jin et al., 2016). Mass spec survey of a panel of DNA/RNA helicases (Miao et al., 2018) and kinases (Miao et al., 2019). Chemical genetic screen with targeted shRNA library, affinity purification of nuclear Hsp90α and cancer co-expression analysis yields 5 components of three complexes (HCFC1, NuRD, and BAF) (Antonova et al., 2019).
Large-scale screen of disease-associated mutant alleles shows that a higher % tends to have increased binding to Hsp90 (and Grp94), and more of these are unstable and have lost their protein-protein interactions (Sahni et al., 2015).

Global analyses in E. coli: htpG associates with a number of proteins including several ribosomal proteins (Butland et al., 2005).

Global analyses in γ-proteobacteria (Garcia-Descalzo et al., 2011).

Computational prediction of chaperone networks in Plasmodium (Pavithra et al., 2007).

The composite Sba1 interaction network shows relatively little overlap with that of Hsp82, but there is a remarkable number of multiprotein complexes where Sba1 and Hsp82 affect adjacent subunits (Echtenkamp et al., 2011).

Global analysis with TAP/GFP-tagged Hsp90 in Candida albicans and impact of antifungal drugs (O'Meara et al., 2019).

Co-chaperones/chaperones

Proteins with TPR motifs: FKBP52 (=p59=hsp56=HBI=FKBP4) (Sanchez et al., 1990; Callebaut et al., 1992; Czar et al., 1994; Radanyi et al., 1994) and its high MW and membrane-associated plant homologs (Reddy et al., 1998; Kamphausen et al., 2002) including FKBP42 = TWISTED DWARF1 (TWD1) (Zhu et al., 2016b) and others, FKBP51 (=FKBP54=FKBP5) (Smith et al., 1993a; Nair et al., 1997), ceFKB-6 (Richardson et al., 2007), FKBP8 (=FKBP38) (Okamoto et al., 2006) but only as CaM-Caz+ complex (Edlich et al., 2007), FKBP36 (=FKBP6 = Shutdown in Drosophila) (Jarczowski et al., 2009), Plasmodium FKBP35 (Kumar et al., 2005; Alag et al., 2009), cyclophilin-40 (=Cpr6 and Cpr7 in yeast) (Nadeau et al., 1993; Chang and Lindquist, 1994; Hoffmann and Handschumacher, 1995; Duina et al., 1996; Ratajczak and Carrello, 1996; Warth et al., 1997; Dolinski et al., 1998; Faou and Tropschug, 2003), Hop (=p60=ST11) (Perdew and Whitelaw, 1991; Smith et al., 1993b; Chang and Lindquist, 1994; Chen et al., 1996c; Owens-Grillo et al., 1996a), plant, Tom70 (Owens-Grillo et al., 1996a; Young et al., 2003; and comments by Voos, 2003; Fan et al., 2006; see also Bhangoo et al., 2007), probably also related Tom71=Tom72 (Li et al., 2009), protein phosphatase 5 (PP5) (Chen et al., 1996b; Silverstein et al., 1997) and its yeast ortholog Ppt1 (Wandinger et al., 2006), Ah receptor-interacting protein (AIP = XAP-2 = ARA9=FKBP37.7) (Ma and Whitlock, 1997; Meyer and Perdew, 1999), Cns1 (Dolinski et al., 1998; Marsh et al., 1998; Tescio et al., 2003; Hainzl et al., 2004) and its Drosophila and human relatives Dpt47 (Crevel et al., 2001) and TTC4 (Crevel et al., 2008), CHIP (Connell et al., 2001), C. elegans UNC-45 (Barral et al., 2002), GCUNC-45 (=Unc45a) (Chadli et al., 2006), Unc45b (Taipale et al., 2014), zebra fish Steif/Unc-45b (Etard et al., 2007), DnaJC7 (=Tpr2=mDj11=CCRP) (Brychzy et al., 2003; Kobayashi et al., 2003), CRN (Hatakeyama et al., 2004), WIsp39 (=FKBP1L) (Jasur et al., 2005; McKean et al., 2010; Howell et al., 2015), NASP (Aleksseev et al., 2005; see also Campos et al., 2010), Tah1 (Zhao et al., 2005) (=Spaghetti {Giot et al., 2003; Boulon et al., 2008; Benbahouche et al., 2014} = RPAP3; see also Millson et al., 2008), Spag1 (Maurizi et al., 2018), chloroplast Toc64 (Qbadou et al., 2006) and its close plant mitochondrial homolog QM64 (Schweiger et al., 2013), TPR1 (=Tic1) (Te et al., 2007; Lotz et al., 2008). SGT for "Small glutamine-rich tetratricopeptide repeat-containing protein"; also Vpu-binding protein or α-SGT or, confusingly, even SGT1; human gene name is SGT; SGT2 in yeast): mammalian (Liou and Wang, 2005), yeast (Liou et al., 2007), and Leishmania protein (Ommen et al., 2010; Coto et al., 2018); chemical genetic interaction with Δhsp82 in yeast (McClellan et al., 2007). DYX1C1, which also contains a CS domain (Chen et al., 2009c; see also Maurizi et al., 2018). Arabidopsis proteins AtTPR1 and AtTPR2 besides many other predicted ones (Prasad et al., 2010). AtTPR7 (Schweiger et al., 2013).
Binding of TPR proteins to one Hsp90 subunit is mutually exclusive (Owens-Grillo et al., 1995; Owens-Grillo et al., 1996a; Young et al., 1998) and requires TPR motifs (Radanyi et al., 1994; Hoffmann and Handschumacher, 1995; Owens-Grillo et al., 1996a; Ratajczak and Carrello, 1996). But: evidence for Hsp90-FKBP52-Hop and Hsp90-FKBP52-p23-Hop complexes (Hildenbrand et al., 2011). Moreover, mixed Sti/Hop-PPIase-Hsp90 complexes are a favored intermediate and Sti/Hop displacement requires ATP and p23 (Li et al., 2011c). Similarly, there are ternary complexes Hsp90-Cpr6-Cpr7 (Zuehlke and Johnson, 2012). Despite mixed complexes, FKBP5s clearly compete with Hop (Ebong et al., 2016). Cns1 and Cpr7 can form mixed complexes with Hsp90 dimers (Schopf et al., 2019).

- Binding of PP5 is not GA-sensitive (Shao et al., 2002).
- Binding of TPR proteins and Cdc37 are mutually exclusive to adjacent sites (Silverstein et al., 1998); are not mutually exclusive, and Cdc37 complexes are stabilized by substrate and also contain p23 (Hartson et al., 2000; Shao et al., 2002), or perhaps not (Siligardi et al., 2004). Indeed, Cdc37 and Sti1 can interact directly (Abbas-Terki et al., 2002). Cdc37 binds ATPase domain of Hsp90 (Roe et al., 2004).
- Cdc37 is also complexed with Hsp90 in yeast system (Abbas-Terki et al., 2000).
- Cdc37 relative Harc (= CDC37L1), mutually exclusive binding through their conserved central domains (Scholz et al., 2001a; see also Cartledge et al., 2007). Does not interact with kinases (Taipale et al., 2014).
- Binding of FKBP52 may be inhibited by phosphorylation of FKBP52 by CKII within hinge between FK1 and FK2 (Miyata et al., 1997).
- p23 (Johnson et al., 1994; Johnson and Toft, 1994; Johnson and Toft, 1995; Johnson et al., 1996). Yeast p23 = Sba1 (Bohen, 1998; Fang et al., 1998); interaction stabilized by molybdate, blocked by Macbecin, dependent on ATP (Fang et al., 1998; see also Obermann et al., 1998; Grenert et al., 1999) and ATP-induced dimerization (Chadli et al., 2000; Prodromou et al., 2000). In turn, nucleotide-bound state of Hsp90 is stabilized by both p23 and molybdate (Sullivan et al., 2002; see also McLaughlin et al., 2006). Novobiocin disrupts interaction (Marcu et al., 2000a). Interaction inhibited by Hop (Johnson et al., 1998) unless Hop is also bound to Hsp70 (Hernández et al., 2002b). Mammalian p23 has been proposed to be identical to cytosolic prostaglandin E2 synthase and Hsp90 enhances cPGES activity in vitro, and in vivo stimuli that increase cPGES activity enhance association with Hsp90 and both are inhibited by GA (Tanioka et al., 2003). Stimulatory phosphorylation of p23 by CK2 is stimulated by Hsp90 (Kobayashi et al., 2004). Binds Hsp90α with 3x stronger affinity than Hsp90β (Synoradzki et al., 2018).
- p23-relative B-ind1 binds Hsp90 through FXXW motif and together with FKBP8 recruits Hsp90 to HCV replication complex (Taguwa et al., 2008).
- p23-relative AARSD1 binds Hsp90 with its CS domain, independently of the name-giving alanyl-tRNA synthetase domain, competing with p23; it only binds the Hsp90β isoform (Echeverría et al., 2016).
- Aha1/Hch1 family of ATPase-stimulating co-chaperones (Panaretou et al., 2002; Lotz et al., 2003; see comments by Mayer et al., 2002). Interaction blocked by full-length Sti1/Hop (Lotz et al., 2003; Harst et al., 2005), Cdc37 and p23 but not cyclophilins (Harst et al., 2005; see also Xu et al., 2012a), or not by p23 (Sun et al., 2012). Aha1 preferentially binds Hsp90α, and this maps to the Hsp90α middle domain (Synoradzki and Bieganowski, 2015).
Hsp70: Neurospora Hsp80 binds directly to Hsp70 (Freitag et al., 1997; Ouimet and Kapoor, 1998; Britton and Kapoor, 2002). Complex with chicken Hsp90 disrupted by novobiocin (Marcu et al., 2000a). Weak Hsp90:Hsp70 complexes exist with 2:1 stoichiometry in retic. lysate (Murphy et al., 2001). Hsp70 in Hsp90 complexes in Plasmodium falciparum (Banumathy et al., 2003). Some binding of ΔMEEVD mutant or in absence of Sti1 in yeast (Flom et al., 2007). Hsp70 interacts preferentially, and Hsp72 only in Hsp90 complexes in mammalian cells when Hsp70 is knocked down (Powers et al., 2008). Hsp70 interacts with DnaK (Genest et al., 2011). Single Hsp70 molecule binds Hsp90 complex between extended Hsp90 monomers (Southworth and Agard, 2011). Hsp70 of cyanobacterium S. elongatus directly interacts with DnaK2 and DnaJ2 (Nakamoto et al., 2014). Interaction of E. coli htpG and DnaK is stabilized by client, abolished by M-domain mutations, and complex formation facilitated by J-domain protein CbpA (Genest et al., 2015; see also Doyle et al., 2019). Involves a surface of the nucleotide-binding domain of DnaK that also binds J proteins (Kravats et al., 2017; see also Doyle et al., 2019). Direct interaction between yeast Hsp82 and yeast Ssa1 (Kravats et al., 2018; Doyle et al., 2019).

Sis1-like protein in Toxoplasma gondii (Figuera et al., 2012).

Rar1, a CHORD-containing protein distantly related to p23 (Garcia-Ranea et al., 2002) interacts through the CHORD-I domain (Liu et al., 2002; Hubert et al., 2003; Takahashi et al., 2003). Does not regulate Hsp90 ATPase alone or in combination with SGT1 (Boté et al., 2007; Hubert et al., 2009), but may promote lid cycling (Hubert et al., 2009).

SGT1 (for "Suppressor of G2 allele of SKP1 homolog"; human gene name: SUGT; do not confuse with "other" SGT1) (Hubert et al., 2003; Takahashi et al., 2003; reviewed in Picard, 2008; Shirasu, 2009), is distantly related to p23 and binds Hsp90 by its CHORD and SGT1 (CS) domain, not the TPRs (Lee et al., 2004b; see also Catlett and Kaplan, 2006; Boté et al., 2007). It can form a ternary complex with Sti1, does not regulate ATPase of Hsp90 and may act to bring in substrate through TPR domain (Catlett and Kaplan, 2006). Also ternary complexes with RAR1 (Boté et al., 2007). Hsp90 promotes its dimerization and interaction with Skp1 (Bansal et al., 2009). May function as adaptor for some clients (Catlett and Kaplan, 2006; Davies and Kaplan, 2010). Interaction with Hsp90 and nuclear localization regulated by phosphorylation (Prus et al., 2011). Depends on Hsp90 for interaction with LRR domain protein Scrib (Eastburn et al., 2012). Nematode Sgt1 also binds through CS domain, is competed by p23, barely affects Hsp90 ATPase activity and binds all Hsp90 conformations (Eckl et al., 2014).

CS-domain containing NudC (Te et al., 2007) and NudCL2 (=Nudcd2) (Yang et al., 2010). Inhibits Hsp90 ATPase (Zhu et al., 2010; Yang et al., 2018). Stabilizes cohesin subunits through Hsp90 (Yang et al., 2018).

CS-containing Siah-1-interacting protein (SIP) (Lee et al., 2004b). Direct interaction of SIP, also known as calcyclin binding protein, with Hsp90, possibly to bring in a chaperone activity and to dephosphorylate it (Góral et al., 2016).

Melusin-related mammalian CHORD-containing protein Chp1 (= Drosophila Morgana {Ferretti et al., 2010}) (=CHORDC1) through CS and other domains (Hahn, 2005; Wu et al., 2005; Michowski et al., 2010), in ADP- and CS-dependent manner (Gano and Simon, 2010); Morgana interacts with R2TP along with FKB4 and Aha1 (Palumbo et al., 2020).

Melusin: a CS and CHORD-containing molecular chaperone, related to Chp1/Morgana that binds Hsp90 through its CHORD domain; also binds SGT1 (Sbroggiò et al., 2008).

CS-containing USP19 (He et al., 2016; see also Meng et al., 2019).

Sse1 is part of the Hsp90 complex in budding yeast (Liu et al., 1999; see also Mandal et al., 2010). Sse2 probably as well, notably through its nucleotide binding domain; part of an early quality control step with Hsp70 (Mandal et al., 2010). 

- 17 -
valosin-containing protein (VCP)/p97, AAA+ chaperone, along with p23, Cdc37 (Prince et al., 2005a). Co-IP depends on presence of HDAC6 (Boyault et al., 2007).

Co-chaperones FNIP1 and FNIP2: decelerate ATPase by competing with Aha1, promoting client loading (Woodford et al., 2016a).

Tsc1, competes with Aha1, binds closed conformation (promoting ATP and drug binding), and inhibits ATPase (Woodford et al., 2017).

Molecular chaperone PhLP2A (Krzemień-Ojak et al., 2017).

ZMYND10, possibly through FKBP8 for chaperoning of axonemal dynein heavy chains (Mali et al., 2018).

Ids2 in yeast as PKA-inactivated co-chaperone for protein folding; activated by dephosphorylation upon caloric starvation (Chen et al., 2018b).

TIMP2 for extracellular Hsp90 (Baker-Williams et al., 2019).

Others (notably clients/substrates)

"stable" association with all vertebrate steroid receptors (GR, MR, ERα, ERβ, PR, AR) in the absence of hormone (Joab et al., 1984; Catelli et al., 1985; Sanchez et al., 1985; Schuh et al., 1985; Rafestin-Oblin et al., 1989; Veldscholte et al., 1992; Powell et al., 2010). Released after hormone binding. Important for high affinity ligand binding of GR (Bresnick et al., 1989), MR (Rafestin-Oblin et al., 1989). Complex confirmed by in vivo crosslinking (Rexin et al., 1992; Segnitz and Gehring, 1995). Comprehensive analysis with ERα (Dhamad et al., 2016).

PPARα, along with XAP2 (Sumanasekera et al., 2003b); PPARβ more weakly (Sumanasekera et al., 2003a); Hsp90 may be inhibitory since GA enhances PPARα/β activity (Sumanasekera et al., 2003a).

PPARγ (Nguyen et al., 2013).

CAR (Kobayashi et al., 2003; Yoshinari et al., 2003).

PXR (Squires et al., 2004; see also Kim et al., 2015b).

VDR (Marcinkowska and Gocek, 2010).

Dioxin receptor (=AhR) (Denis et al., 1988; Perdew, 1988), required for ligand regulation and DNA binding (Pongratz et al., 1992; Whitelaw et al., 1993; Antonsson et al., 1995; Coumailleau et al., 1995; Whitelaw et al., 1995; Shetty et al., 2003) and high affinity ligand binding (Pongratz et al., 1992). Ligand-dependence of Hsp90 release is p23-dependent (Kazlauskas et al., 1999). GA does not block its ligand binding but its nuclear localization (perhaps unmasking of NLS) (Kazlauskas et al., 2001). Interaction with PAS domain itself not affected by ligand (Tsuji et al., 2014). bHLH also interacts with Hsp90 (through N-terminal domain), p23 and XAP2 (Kudo et al., 2018).

Dioxya receptor (atril receptor) (Brunt et al., 1990).

Sim (McGuire et al., 1995), HIF-1α (Gradin et al., 1996; Minet et al., 1999; see also Liu et al., 2007) (possibly only Hsp90β (Trisciuoglio et al., 2010)), HIF-2α and HIF-3α (Katschinski et al., 2004). Released upon dimerization with Arnt.


transient association with pp60 v-src (Brugge et al., 1981; Oppermann et al., 1981; for review, see Brugge, 1986). Binding to c-Src expressed in retic. lysate system (Hutchison et al., 1992a). GA transiently activates Src concomitant with Hsp90 release (Koga et al., 2006). Interaction with c-Src strongly stimulated by sepsis and LPS in neutrophils (Gupta et al., 2018).

src related tyrosine kinases: yes, fps (Adkins et al., 1982; Lipsich et al., 1982), fes, fgr (Ziemiecki, 1986; Ziemiecki et al., 1986; Hartson and Matts, 1994; Nair et al., 1996) and Ick (Hartson and Matts, 1994; Hartson et al., 1996). Required for de novo folding of...
kinase domain of Ick (Hartson et al., 1998; see also Bijlmakers and Marsh, 2000). Association with a ts mutant of Hck: functionally necessary and stimulated by Cdc37 overexpression (Scholz et al., 2000); ongoing support particularly required for mutant Hck (Scholz et al., 2001b).

- **Bcr-Abl**, but not c-Abl (An et al., 2000) or perhaps yes a little bit (Moulick et al., 2011).
- regulation of eIF2-α kinase HRI (Kudlicki et al., 1987; Rose et al., 1987; Matts and Hurst, 1989; Matts et al., 1992; Mendez et al., 1992; Mendez and de Haro, 1994; Berwal et al., 2018). Hsp90 is essential for folding, maturation and maintaining conformation competent for activation (Uma et al., 1997).
- **eEF-2 kinase** (Palmquist et al., 1994; Yang et al., 2001).
- prevents aggregation of **casein kinase II**, binds catalytic CKIIα subunit (Miyata and Yahara, 1992; Miyata and Yahara, 1995), but may not affect CKII activity (Shi et al., 1994).
- activation of **CDK4** as a complex with (and via?) CDC37(p50) (Dai et al., 1996; Stepanova et al., 1996; see also Wang et al., 2002). Association with p50 (Perdew and Whitelaw, 1991; Whitelaw et al., 1991) (now known as CDC37). Binding of Cdc37 and to Cdk4 is mutually exclusive with cyclin D (Stepanova et al., 1996) and p16 (Lamphere et al., 1997). Increased interaction of some Cdk4 mutants with Hsp90 and Cdc37 (Lambert et al., 2013). Cyclins and CKIs displace Cdc37-Hsp90 from Cdk4 (Hallett et al., 2017). Both FKBP51 and FKBP52 are required to sequester Cdk4 (Hallett et al., 2017).
- in large complex with **Cdk6** and Cdc37 (Mahony et al., 1998). Cyclins and CKIs displace Cdc37-Hsp90 from Cdk6 (Hallett et al., 2017).
- **Cdk2** (Prince et al., 2005b).
- **Cyclin B**; interaction is Cdc2-independent and Hsp90 is required (nevertheless indirectly) to recruit cyclin B to centrosomes and the mitotic spindle (Basto et al., 2007).
- **Cdc2 (Cdk1)**, ~ Cdc28 in *S. cerevisiae* (Garcia-Morales et al., 2007); it is a Cdc37 client, and notably based on more recent evidence also an Hsp90 client (CaldaLopes et al., 2009). Also in *Candida albicans* (Senn et al., 2012). Hsp90 stabilizes a complex of CDK1 with EZH2 to promote phosphorylation and degradation of EZH2 (Göllner et al., 2017).
- required for activation of **Wee1** in *S. pombe* (Aligue et al., 1994; Goes and Martin, 2001), Swe1 in *S. cerevisiae* (Goes and Martin, 2001), and ortholog in *C. elegans* (Inoue et al., 2006).
- **reverse transcriptase of duck hepatitis B virus (HBV)** (Hu and Seeger, 1996; Hu et al., 1997; Cho et al., 2000a; Cho et al., 2000b; Hu and Anselmo, 2000; Gyoo Park et al., 2002; Hu et al., 2002; see also Liu et al., 2014a). Gets incorporated into capsid through this interaction and is essential for RNP formation and priming. However, see also Beck and Nassal, 2003. Hsp90 may only stimulate (Stahl et al., 2007).
- **HBV capsid** core protein dimer; Hsp90 facilitates core assembly and is incorporated into capsid through this interaction (Shim et al., 2011). Synergistic effects with Hsp70 (Seo et al., 2018).
- stabilizes p53 mutants (Blagosklonny et al., 1995; Blagosklonny et al., 1996; Sepehrnia et al., 1996; Nagata et al., 1999; see also Whitesell et al., 1998). *In vitro*, preferentially binds wild-type p53 in a BAG-1 sensitive fashion (King et al., 2001). Cancer cells with mutant p53 are more sensitive to Hsp90 and HDAC inhibitors than cells with wt p53 (Li et al., 2011a; Li et al., 2011b). Tumors with gain-of-function p53 mutants can be inhibited with Hsp90 inhibitors and/or a combination with an HDAC inhibitor (Alexandrova et al., 2015). Hsp90 protects DNA binding-competent conformation (Boysen et al., 2019) and restores native state from Hsp70-mediated unfolding in ATP hydrolysis- and HOP-dependent manner (Dahiya et al., 2019) of wild-type and mutant p53. Hsp90α and...
Hsp90β preferentially bind mutant and wild-type p53, respectively (He et al., 2019). Slows down aggregation of Zinc-free DBD (Wu and Dyson, 2019).

- **Mdm2**: stabilization of p53 mutants presumably by blocking the E3 ubiquitin ligase activity of Mdm2 (Peng et al., 2001; see also Li et al., 2011a; Li et al., 2011b). But Hsp90 promotes p53 tetramer unfolding activity of Mdm2 (Burch et al., 2004) and degradation of wild-type p53 (He et al., 2019). Mdm2 only interacts with Hsp90β (He et al., 2019).

- **stabilizes Raf-1 (= c-Raf = CRAF)** (Stancato et al., 1993; Lovric et al., 1994; Stancato et al., 1994; Wartmann and Davis, 1994; Schulte et al., 1995; Schulte et al., 1996); wild-type Hsp83 required for Raf kinase activity in *Drosophila* (van der Straten et al., 1997); ternary complex both directly and through Cdc37 (Grammatikakis et al., 1999). c-Raf complex disrupted by RanBP9/RanBPM (Atabakhsh and Schild-Poulter, 2012). CRAF unlike BRAF requires continuous Hsp90 assistance with differential requirements during folding and for activation (Mitra et al., 2016).

- **B-Raf (= BRAF)** in PC12 cells (Jaiswal et al., 1996), and V600E mutant (da Rocha Dias et al., 2005; Grbovic et al., 2006; Fukuyo et al., 2008). Hsp90, Cdc37 and FKBP5 are primarily associated with high MW BRAF complexes (Diedrich et al., 2017).

- **A-Raf (ARAF)** (Miao et al., 2019).

- stabilizes and binds Ste11 (Louvion et al., 1998).

- cytoskeleton: actin (Koyasu et al., 1986; Nishida et al., 1986; Miyata and Yahara, 1991; Kellermayer and Csermely, 1995; Park et al., 2007), tubulin (Sanchez et al., 1988; Williams and Nelsen, 1997; Garnier et al., 1998; Cambiazo et al., 1999; Weis et al., 2010) and microtubules (Fostinis et al., 1992; Williams and Nelsen, 1997; Krtková et al., 2012; see also Lange et al., 2000), and myosin (Barral et al., 2002; Srikakulam and Winkelmann, 2004; Mishra et al., 2005 Etard et al., 2008) (including Myo3B; Taipale et al., 2012), see also immunofluorescence work by Czar et al., 1996. Binds and bundles F-actin *in vitro* (Park et al., 2007). Binds ciliary β4-tubulin and promotes its polymerization (Takagi et al., 2007). Unc-45 (preferentially the α form) promotes Hsp90-dependent folding of the myosin motor domain (Liu et al., 2008a; Srikakulam et al., 2008). Tubulin acetylation favors recruitment of Hsp90 and client proteins (Giustiniani et al., 2009; see also Zhong et al., 2014). Association with F-actin and α-tubulin may play a role in phagosome formation and function (Singh et al., 2013).

- binds calmodulin in Ca2+-dependent fashion (Minami et al., 1993; see also Gambiczzo et al., 1999). Or perhaps rather the calcium-binding and chaperone protein S100A1 of the S100 family (Okada et al., 2004). Selectively oxidized calmodulin (Whittier et al., 2004) suggesting a role for Hsp90 in the oxidative stress response (Squier, 2006).

- **Proteasome** (Tsubuki et al., 1994; Wagner and Margolis, 1995; see also Verma et al., 2000). Affinity for 20S complex is 30 nM and stoichiometry of Hsp90 to 20S is 1:2 (Eleuteri et al., 2002). Proteasome is inhibited for some substrates (Tsubuki et al., 1994; Wagner and Margolis, 1995) but stimulated for others (Eleuteri et al., 2002); Hsp90 protects it from oxidative inactivation *in vitro* and *in vivo* (Conconi et al., 1998). Required for assembly and maintenance of the 19S regulatory subunit in budding yeast (Imai et al., 2003) and of the 26S proteasome in mammalian cells (Yamano et al., 2008). Hsp90 required for degradation of oxidized calmodulin (Whittier et al., 2004). Hsp90 inhibition suppresses proteasome remodeling (Nanduri et al., 2015). Hsp83 mutants in *Drosophila* have reduced proteasome activity (Choutka et al., 2017). Associated with complexes smaller than 20S (Sakellari et al., 2019). Levels of 20S components go up upon deleting/inhibiting Hsp90 in *C. albicans* (O’Meara et al., 2019).

- free By subunit of G protein (Inanobe et al., 1994).

- **Gα0** (Busconi et al., 2000).
- Gα12 interaction required for downstream signaling, but not for closely related Gα13 (Vaiškunaite et al., 2001); Hsp90 may help to target Gα12 to lipid rafts (Waheed and Jones, 2002), and connect it with Src at tight junctions (Sabath et al., 2008). Some Gα12 mutants have impaired binding (Montgomery et al., 2014).

- Hsf1 (Nadeau et al., 1993; Nair et al., 1996; Ali et al., 1998; Duina et al., 1998; Zou et al., 1998; Bharadwaj et al., 1999), along with Ras-binding protein 1 (RabBP1) and α-tubulin (Hu and Mivechi, 2003). Release from Hsf1 is stimulated by ubiquitinated cellular aggregates and this depends on sensing and segregase activities of associated HDAC6 and VCP/p97, respectively; it is independent of HDAC6-mediated deacetylation of Hsp90 (Boyault et al., 2007). Also in plants (Yamada et al., 2007). Hsp90 reduces temperature of trimerization and broadens response window in vitro (Hentze et al., 2016). Unlike Hsp70, the main role of notably the closed form of Hsp90 may be to dynamically remove trimers from DNA (Kijima et al., 2018). Yeast Hsf1 may not interact and be indirectly activated through Hsp70 titration upon compromising Hsp90 (Zheng et al., 2016).

- HsfA1, HsfA2, and HsfB1 in tomato, where B1 is targeted for degradation when associated with Hsp90 (Hahn et al., 2011; Röth et al., 2017), and HsfA1a, HsfA1b and HsfA1d in Arabidopsis (Yoshida et al., 2011; see also Ohama et al., 2016).

- MEK (Stancato et al., 1997; not according to Jaiswal et al., 1996; but see also Shinozaki et al., 2006).

- MEKK1 and MEKK3 (Bouwmeester et al., 2004; see also Fang et al., 2009).

- Mixed-lineage kinase 3 (MLK3) (Zhang et al., 2004a).

- Insulin receptor (Takata et al., 1997), more strongly to mutants (Imamura et al., 1998). Required for maturation during trafficking through ER (Ramos et al., 2007). Also in Drosophila (Huang and Wang, 2018).

- Insulin-like growth factor 1 receptor (IGF1R) (Martins et al., 2008).

- eNOS (NOS-3): association is direct and stimulated by activators of NOS signaling, association stimulates NOS activity in vivo and in vitro (García-Cardeña et al., 1998; Gratton et al., 2000; Russell et al., 2000). Hsp90 facilitates release from caveolin in presence of calmodulin (Gratton et al., 2000), and helps to recruit Akt to eNOS (Brouet et al., 2001). Hsp90 functions as a scaffold by using its central domain to bind both Akt and eNOS (Fontana et al., 2002; for discussion, see Balligand, 2002). Hsp90 stimulates eNOS activity by increasing its affinity for calmodulin at low calcium and calmodulin-independent at high calcium (Takahashi and Mendelsohn, 2003a), and by synergizing with Akt (Takahashi and Mendelsohn, 2003b). Hsp90 increases affinity of NOS-3 for globular β-actin in a ternary complex and in turn becomes degraded more rapidly (Ji et al., 2007). Recombinant Hsp90 shifts eNOS activity from producing superoxide to NO (Sud et al., 2007). Lower amounts of Hsp90 in eNOS tissues than in neuronal tissues protects NOS insufficiently from cleavage by calpain (Averna et al., 2007; Averna et al., 2008b). Upon brief exposure to Ca2+, Hsp90 promotes release of eNOS complex from caveolae and protection from recruited calpain (Averna et al., 2008a). Evidence for isoform-specific activity: eNOS associates with both Hsp90 isoforms but Hsp90α and Hsp90β overexpression increase and reduce activity, respectively, correlating with increased/reduced eNOS dimerization and Akt activation (Cortés-González et al., 2010; see also Chen et al., 2014). However, in intra-renal transfections, both isoforms protect against ischemia/reperfusion damages and effects on eNOS (Barrera-Chimal et al., 2014). IKKβ competes with eNOS for binding to middle domain and thereby attenuates eNOS activity (Natarajan et al., 2015). Association augmented by AIP peptide correlating with reduced interaction of Hsp90 with Akt (Lamoke et al., 2015). VEGF-stimulated interaction with Hsp90 requires SDF2 (Siragusa et al., 2015). PP2A promotes dissociation of Akt-Hsp90-eNOS complex (Bharath et al., 2015). Hsp90 enhances affinity of eNOS for cofactors NADPH, L-arginine, and calmodulin (Chen et al., 2017b).
nNOS (NOS-1): activity and accumulation of transfected but not in vitro translated nNOS depends on Hsp90 (Bender et al., 1999). Stimulates calmodulin binding in purified system (Song et al., 2001), and inhibits production of superoxide (Song et al., 2002). Estrogen promotes association of nNOS with Hsp90 and activity (Houlihan et al., 2009). Prevents CHIP-dependent nNOS ubiquitination (Peng et al., 2009) by competing against Hsp70-CHIP (Peng et al., 2012).

iNOS (NOS-2): Hsp90 behaves as an allosteric enhancer (Yoshida and Xia, 2003); facilitates heme insertion (Ghosh et al., 2011).

Soluble guanylyl cyclase (sGC) through its β subunit (Venema et al., 2003; Papapetropoulos et al., 2005). Hsp90 binds heme-free sGC, promotes heme binding and dissociates in response to activation by NO allowing association with sGC-α1 (Ghosh and Stuehr, 2012; Ghosh et al., 2014). Hsp90 M domain interacts with PAS domain of sGCβ1 (Sarkar et al., 2015); more detailed study on sGC determinants and role of Hsp90 in preventing heterodimer formation with sGCα during maturation (Dai et al., 2019).

Hemoglobin α, β, and γ (Hbα/β/γ), in the apo-state to promote insertion of heme and association with Hb partner; heme insertion results in release; in erythroid cells, Hbα is chaperoned by AHSP and not Hsp90; ATPase-defective variant and inhibitors block heme insertion (Ghosh et al., 2018).

Myoglobin in the apo-state along with Hop, Cdc37, Aarsd1, Aha1 and Hsp70 to promote insertion of heme, blocked by Hsp90 inhibitors (Ghosh et al., 2019).

Reovirus α1 homotrimer, immature form (Gilmore et al., 1998).

Hap1, complex required for heme regulation (Zhang et al., 1998); association enhanced by heme favoring Hap1 activity (Lan et al., 2004).

binds and stabilizes nascent CFTR (Loo et al., 1998; see also Youker et al., 2004). Hsp90 and many co-chaperones including Aha1, p23, and FKBP8 are part of the CFTR interactome (Wang et al., 2006; see also Sun et al., 2008; Okiyoneda et al., 2010). Differential sensitivities of wild-type and mutant CFTR to calpain correlate with different affinities for Hsp90 (Averna et al., 2011). Folding of ΔF508 is stalled in a chaperone trap (Coppinger et al., 2012); its thermal unfolding post-ER is partially suppressed by Hsc70 and Hsp90 (Bagdany et al., 2017).

Telomerase: bound to and required for proper assembly (Holt et al., 1999; Forsythe et al., 2001). A key role of Hsp90 may be to maintain active Akt and TERT phosphorylation, and to prevent its dephosphorylation by PP2A (Haendeler et al., 2003), and/or to promote proper TERT folding and efficient telomere loading (Keppler et al., 2006). In yeast as well: Hsp90 promotes DNA binding of telomerase and through its continued association and processivity (Toogun et al., 2008); it also promotes switch between telomere capping and extension activities (DeZwaan et al., 2009). Disruption of complex promotes nuclear export (Lagadari et al., 2016) and nuclear localization requires FKB52 to promote interaction with dynein (Jeong et al., 2016).

Calcineurin: co-IPs; activity stimulated by Hsp90 in a partially calmodulin-dependent fashion (Somer et al., 1999). Also Cna2 from budding yeast; Hsc82 may compete with calmodulin binding (Imai and Yahara, 2000). Interaction induced by glucocorticoids in INS-1 cells (Ranta et al., 2008). Interaction in Candida albicans (Singh et al., 2009).

stabilizes and binds the yeast eIF2α kinase Gcn2 (Donzé and Picard, 1999).

Facilitates folding of PKR and keeps its activity repressed (Donzé et al., 2001). β-amyloid peptide activates PKR without disrupting the Hsp90 complex (Suen et al., 2003).


stabilizes Cdk9 as a complex with (and via?) Cdc37, before assembly with cyclin T1 (i.e. p-TEFb) (O’Keeffe et al., 2000; see also Pan et al., 2016).

binds and is required for activation of c-Mos (Fisher et al., 2000).
SV40 large T-antigen: probably required for folding (Miyata and Yahara, 2000).

KSR (Kinase suppressor of Ras) is in a multiprotein complex with Hsp90 (Stewart et al., 1999).

Death domain kinase RIP (RIP1 = RIPK1): complex dissociates upon activation by TNFα (Lewis et al., 2000; see also Li et al., 2015; Yang and He, 2016; see also Wu et al., 2019).

RIP3 (RIPK3) (Li et al., 2015; see also Yang and He, 2016).

12(S)-HETE receptor (not cloned yet) (Herbertsson et al., 1999).

Calponin (Bogatcheva et al., 1999; Ma et al., 2000).

Apaf-1: Hsp90 inhibits cyt. c-mediated oligomerization (Pandey et al., 2000). GA-induced apoptosis depends on Apaf-1 (Fortugno et al., 2003). Interaction through Apaf–1 CARD domain and stronger with S226- and S255-phosphorylated form of Hsp90β and only weak with Hsp90α (Kurokawa et al., 2008).

Human DnaJ homolog Hsj1b (Schnaider et al., 2000).

required for assembly of multi-aminocetyl-tRNA synthetase complex (Kang et al., 2000).

Maintains Akt/PKB activity by preventing dephosphorylation by PP2A (Sato et al., 2000). Discrepancy with more recent study that shows that both Hsp90-Cdc37 bound and free Akt is active and dephosphorylated at same rate (Basso et al., 2002). Hsp90α and Hsp90β overexpression increase and reduce Akt activation (Cortés-González et al., 2010).

PDK1: Hsp90 binds and stabilizes it (Fujita et al., 2002), and promotes its association with Sgk3 (Wang et al., 2014).

ErbB2 (HER2): through its kinase domain; both nascent (shared with EGF receptor) and mature protein Hsp90-dependent (Xu et al., 2001; Xu et al., 2002b). A short region in the hinge that differs from the EGF receptor may be the recognition site (Tikhomirov and Carpenter, 2003). Further mapping to loop in kinase domain and demonstration that Hsp90 restrains ErbB2 from interacting with other ErbB’s in absence of ligand (Citri et al., 2004a). See also Xu et al., 2005. Introducing a negative charge into this surface as present in ErbB1 (EGF receptor) destroys interaction (Citri et al., 2006). Loss of interaction activates in Src-dependent fashion (Xu et al., 2007b). Only the active conformation of ErbB2 interacts and can be targeted with Hsp90 inhibitors (Kancha et al., 2013). Low levels of HER2 need primarily Hsp90α for membrane-targeting, high levels need additionally Hsp90β, and for maintenance at the membrane also Grp94 (Patel et al., 2013). Interaction is impaired when ATM is knocked down or inhibited (Stagni et al., 2015).

Nascent mutant EGF receptor (Lavictoire et al., 2003). Wild-type receptor binds inhibitor-bound Hsp90 (Caldas-Lopes et al., 2009). Mutant EGFR is stabilized by Hsp90 and PKM2 (Yang et al., 2015).

Also mature wild-type EGF receptor (Ahsan et al., 2012). A peptide representing the region responsible for the differential dependence on Hsp90 between EGFR and ErbB2 interferes with Hsp90 binding and promotes degradation (Ahsan et al., 2013).

ErbB3 (HER3), transiently during maturation (Gerbin and Landgraf, 2010; Liu and Landgraf, 2015).

Pim-1: required for accumulation and kinase activity (Mizuno et al., 2001).

ANP receptor: Hsp90 and Cdc37 associated through kinase homology domain (Kumar et al., 2001).

Mik1: required for stability / activity, co-IP (Goes and Martin, 2001).

MOK: associated through kinase domain, along with Cdc37 and Hsc/Hsp70 (Miyata et al., 2001).
MOK relatives *MAK* and *MRK*, but not Erk, p38 nor JNK (Miyata et al., 2001). For JNK and p38, however, see below.

For MAPK (Erk's) there is mostly evidence against (e.g. Miyata et al., 2001; our own unpublished data) Hsp90 complexes, but also some for (Setalo et al., 2002; Caldas-Lopes et al., 2009).

**Polo-like kinase 1 (Plk):** C-terminal and not kinase domain is required for interaction; some disease-associated point mutations abolish it (Simizu and Osada, 2000). Also interacts with *Drosophila* Polo kinase (de Cárcer et al., 2001; see also de Cárcer, 2004), and function depends on Sgt1 (Martins et al., 2009).

**Polo-like kinase 3 (Plk3):** (Ou et al., 2019). DNA polymerase $\alpha$, inactive form, perhaps through Dpit47 (Crevel et al., 2001).

**ApoB:** Hsp90 promotes its degradation after ubiquitination (Gusarova et al., 2001).

**Thrombin receptor (PAR-1):** (Pai et al., 2001).

**Argonaute-1 (= Ago1)** (Iwasaki et al., 2010). In plants, with Hsp90.2, Hsp90.3 and Hsp90.4 during maturation in the nucleus before export to cytoplasm (Bologna et al., 2018). *hsp90.2-3* mutation promotes its membrane association (Sjögren et al., 2018).

**Argonaute-2 (= Ago2 = GERp95), along with p23, Hop, and Hdj2; transiently en route to Golgi** (Tahbaz et al., 2001).

**Argonaute-4 (Ago4):** binds and is required for loading of heterochromatic siRNAs in the cytoplasm in plants (Ye et al., 2012).

**Macrophage scavenger receptor** (Nakamura et al., 2002).

**IkB kinases $\alpha$, $\beta$ (Chen et al., 2002), $\gamma$ and $\epsilon$ (Bouwmeester et al., 2004)** (see also Broemer et al., 2004; Lee et al., 2010; Natarajan et al., 2015). Cdc37 recruits Hsp90 to *de novo* IKK, notably IKK$\alpha$, for maturation to IKK complex, and Hsp90-Cdc37 also required to generate activated state of mature IKK holocomplex following T-loop phosphorylation (Hinz et al., 2007). Interaction with IKK/Cdc37 may be reduced by HBV polymerase (Liu et al., 2014a).

**Vaccinia core protein 4a:** Hsp90 associates transiently with immature viral particles and is required for replication (Hung et al., 2002).

**Ctf13/Skp1:** interact and are dependent for heterodimer formation and in vivo activity (Stemmann et al., 2002). Also needs the Hsp90 co-chaperone Sgt1 (Bansal et al., 2004; Lingelbach and Kaplan, 2004).

**SKP2 complexes contain Hsp90$\beta$ along with SKP1, SGT1, and other proteins** (Lyapina et al., 2001).

**Aurora B:** along with Cdc37 (Lange et al., 2002).

**Cytoplasmic domains of Ire1$\alpha$ and Perk** (Marcu et al., 2002). For Ire1$\alpha$ interaction with Hsp90 and Cdc37, see also Ota and Wang, 2012; Zhao et al., 2019.

In membrane rafts in complexes with caveolin-1 and Stat3; GA blocks IL-6 signaling (Shah et al., 2002), and Hsp90 co-IPs with Stat3 (Sato et al., 2003; Chong et al., 2019), stimulated by LIF (Setati et al., 2010).

**RNA polymerase subunits PB1 and PB2 of Influenza A virus; Hsp90$\alpha$ and $\beta$ interacts as required host factor through N-terminal and middle domain to promote assembly with PA in the nucleus** (Momose et al., 2002; Naito et al., 2007; see also Jirakanwisal et al., 2015).

**Rab-GDI:** a chaperone complex with Hsp90 (possibly the Rab recycling factor) is associated with synaptic vesicle, and required for Rab recycling and Ca$_{2+}$-induced neurotransmitter release (Sakisaka et al., 2002; Chen et al., 2005b), and ER-Golgi traffic (Chen and Balch, 2006).

**Tom70-dependent mitochondrial precursor proteins** (Young et al., 2003; Fan et al., 2006; Zara et al., 2009), along with Tom34, Hsp70, Hop and Cdc37 (Faou and Hoogenraad, 2006).
2012), and Toc64-dependent chloroplast precursor proteins (Qbadou et al., 2006; Fellerer et al., 2011), the latter along with Hop and FKBP73 (Fellerer et al., 2011).

- Mitochondrially targeted proteins with a chimeric signal can be directly directed to TOM40 as ternary complex with Hsp70 and Hsp90 (Anandatheerthavarada et al., 2008), or for some to TOM70 first in a TOM20/22 bypass mechanism (Anandatheerthavarada et al., 2009). New study shows that TOM20 competes with chaperone binding to TOM70 thereby facilitating preprotein release (Fan et al., 2011).

- Aggregation-prone Tau protein (Dou et al., 2003; Luo et al., 2007). Interaction facilitates conformational change leading to phosphorylation and aggregation (Tortosa et al., 2009).

- Oncoprotein MTG8 (Komori et al., 1999).

- Neurotrophin receptor trkB: Hsp90 may be involved in axonal transport in retinal ganglion cells (Bernstein et al., 2001).

- TrkA splice variants I and III; Hsp90 also colocalizes with TrkAI at the cell surface and is required for TrkAI localization there (Farina et al., 2009).

- Knob complexes in the membrane of Plasmodium-infected erythrocytes (Banumathy et al., 2002).

- Tumor suppressor kinase Lkb1 (Boudeau et al., 2003; Nony et al., 2003; Gaude et al., 2012).

- VEGFR1 (Park et al., 2008).

- VEGFR2 (Flk-1/KDR): interaction possibly stimulated by VEGF (Masson-Gadais et al., 2003). Promotes Y300 phosphorylation of Hsp90β by Src (Duval et al., 2007; see also Park et al., 2008).

- Diphtheria toxin A for translocation into cells (Ratts et al., 2003; Dmochewitz et al., 2011); along with Hsp70/Hsc70, Cyp40, FKBP51/52 (Schuster et al., 2017).

- Histones H1, H2A, H2B, H3 and H4 (Schnaider et al., 1999). NASP (tNASP) may be a co-chaperone for the takeover from Hsp70 and assembly of the H3.1 (with K9me1) - unacetylated H4 dimer (Campos et al., 2010). Newly synthesized and unacetylated H4 binds Hsp90 along with PP32 and SET (Saabendra et al., 2017).

- ether-a-go-go-related cardiac potassium channel (ERG = HERG = KCNH2) (Ficker et al., 2003), possibly during trafficking (Walker et al., 2007). Only binds and is dependent on Hsp90α (Peterson et al., 2012). Hsp90 facilitates maturation by preventing interaction with CHIP (Iwai et al., 2013).

- KS type of glutathione S-transferase (GST) subunit 3 (Mayama et al., 2003).

- Thiopurine S-methyltransferase: GA promotes association and enhanced binding correlates with degradation (Wang et al., 2003).

- Purinergic receptor P2X7: complexed with tyrosine phosphorylated Hsp90, which may be inhibitory (Kim et al., 2001; Adinolfi et al., 2003). Hsp90 required for large pore formation and autophagic cell death (Young et al., 2015). Hsp90 may work through cysteine-rich cytoplasmic domain (Migita et al., 2016).

- Plant disease resistance proteins: NB-LRR proteins RPM1 and RPS2 (Hubert et al., 2003; see also Holt III et al., 2005), and RPP4 (Bao et al., 2014).

- LRR protein I-2 (de la Fuente van Bentem et al., 2005).

- NB-LRR proteins in animals: Nod1 (Hahn, 2005; da Silva Correia et al., 2007; Mayor et al., 2007). Also the Nod-like receptors (NLRs) Nod2, NALP2, NALP3 (= NLRP3), NALP4, NALP12 and IPAF; binding to NACHT domain and with SGT1 to LRR domain (Mayor et al., 2007). Monarch-1 (Arthur et al., 2007).

- Inhibitor of apoptosis protein survivin through survivin baculovirus IAP repeat (Fortugno et al., 2003).

- Neuropeptide Y (NPY), although not clear whether this would happen physiologically (Ishiwatari-Hayasaka et al., 2003).
G protein coupled receptor kinases GRK2 (Luo and Benovic, 2003) and GRK6 (Tiedemann et al., 2010). MAPK phosphorylation of GRK2 enhances interaction and promotes GRK2 targeting to mitochondria (Chen et al., 2013a).

- Mal63 of S. cerevisiae (Bali et al., 2003; Ran et al., 2008), and MalR of Aspergillus oryzae (Konno et al., 2018).
- Bid (Zhao and Wang, 2004).
- NFκB-inducing kinase (NIK) (Bouwmeester et al., 2004; Citri et al., 2006).
- TAK1 (Bouwmeester et al., 2004; Liu et al., 2008b).
- TBK1 (Bouwmeester et al., 2004; Yang et al., 2006a).
- Chk1 (Arlander et al., 2003; Arlander et al., 2006; see also Cheng et al., 2017; Oh et al., 2017).
- Flt3 (Yao et al., 2003; Kancha et al., 2013).
- MMP2, interacts with extracellular Hsp90α (Eustace et al., 2004; Yang et al., 2008; Baker-Williams et al., 2019).
- Proenzymes and active forms of MMP2 and MMP9 interact with both isoforms (Stellas et al., 2010; see also Tukaj et al., 2015).
- MMP3 interacts with extracellular Hsp90β (Correia et al., 2013).
- Toll-like receptor 4 (TLR4): Hsp70 and Hsp90 form a cluster with TLR4 and the adaptor molecule MD-2 within lipid microdomains following LPS stimulation, and are targeted to Golgi (Triantafilou and Triantafilou, 2004).
- TLR7 and TLR9 (Saito et al., 2015).
- RET/PTC1 chimeric oncoprotein (Marsee et al., 2004).
- RET (Alfano et al., 2010).
- Annexin II (Annexin A2) (Lei et al., 2004; Díaz-Díaz et al., 2020).
- Na⁺-K⁺-Cl⁻ cotransporter 1 during early biogenesis (Simard et al., 2004).
- c-Kit (Nakatani et al., 2005; Martins et al., 2008) and Kit mutants (Mariño-Enríquez et al., 2013).
- S. pombe UCS protein Rng3, TPR-less relative of UNC-45 (Mishra et al., 2005).
- Cdk11 (Mikolajczyk and Nelson, 2004).
- Dengue virus (Reyes-del Valle et al., 2005), specifically proteins E, NS1, NS2B, NS3, NS4B, NS5 (Srisutthisamphan et al., 2018).
- Histone methyltransferases SMYD1b (Tan et al., 2006; Li et al., 2013a), SMYD2 (Abu-Farha et al., 2008; Abu-Farha et al., 2011; Donlin et al., 2012; Hamamoto et al., 2014), and SMYD3 (Hamamoto et al., 2004; Abu-Farha et al., 2011; Brown et al., 2015). Associate with and are stimulated by Hsp90α. Substrate specificity of SMYD2 modified by Hsp90α (Abu-Farha et al., 2008).
- Histone arginine methyltransferase PRMT5 (Maloney et al., 2007).
- Interleukin-1 receptor-associated kinase 1 (IRAK-1), along with Cdc37 (De Nardo et al., 2005).
- The minimal kinase SSTK (= Tssk6) (Spiridonov et al., 2005), and TSSK4 (Jha et al., 2013).
- Integrin-linked kinase (Aoyagi et al., 2005), stabilizing it and facilitating interaction with α-parvin (Radovanac et al., 2013).
- Active, dually phosphorylated MAPK Slt2 (Millson et al., 2005) and ERK5 (Piper et al., 2006; Truman et al., 2006). In contrast, Hsp90-Cdc37 is released upon activation and autophosphorylation of ERK5, and Cdc37 overexpression dissociates ERK5 inducing its nuclear localization and transcriptional but not kinase activity (Erazo et al., 2013).
- ASK1 forms ternary complex with Akt and Hsp90, both bind middle domain of Hsp90 (Zhang et al., 2005b).
- N-WASP: binds through middle domain and promotes phosphorylation by c-src and actin polymerization activity (Park et al., 2005). Through this interaction, Hsp90 bundles branched actin filaments (Park et al., 2007).
- Hsp90 interacts with and is regulated by HDAC6 (Bali et al., 2005; Kovacs et al., 2005), and HDAC1 (Zhang et al., 2013a), and HDAC6 is a substrate (Rao et al., 2008).
- Interacts with SIR2 (SIR2RP1) in Leishmania (Adriano et al., 2007).
- SIRT1 (Nguyen et al., 2018).
- SIRT2 (Min et al., 2018).
- misfolded VHL (McClellan et al., 2005).
- MUC1: its phosphorylation by c-Src stimulates interaction and Hsp90-dependent targeting to mitochondria (Ren et al., 2006).
- free ribosomal proteins S3 and S6 (Kim et al., 2006).
- Membrane-bound P450 CYP2E1 (Morishima et al., 2005).

- Membrane-bound P450 CYP2E1 (Morishima et al., 2005).
- Binds and protects vimentin from caspase cleavage (Zhang et al., 2006; see also Chen et al., 2009b).
- CLC-1 chloride channel: transiently only with Hsp90β, which promotes its degradation through cullin 4 (CUL4) (Peng et al., 2016b).
- CLC-2 chloride channel (Hinzpeter et al., 2006).
- JAK1 interacts with Hsp90 and Cdc37, required for interferone signaling (Shang and Tomasi, 2006).
- α-synuclein, in Lewy bodies and neurites and glial cell inclusions (Uryu et al., 2006). In the absence and presence of ATP Hsp90 favors soluble oligomeric and fibrillar states, respectively (Falsone et al., 2009). Multiple domains of Hsp90 are able to prevent aggregation and its toxicity by interacting with the soluble oligomeric form (Daturpalli et al., 2013). Interaction with Hsp90 is through N-terminus of α-synuclein, which is disrupted by c-Abl phosphorylation of a tyrosine within it; Hsp90 contributes to preventing targeting to mitochondrial membranes and aggregation (Burmann et al., 2020).
- Mg2+-dependent phosphatidate phosphohydrolase (Siess and Hofstetter, 2005).
- Bcl-2 (Cohen-Saidon et al., 2006). Stimulated by VEGF through KDR (Dias et al., 2002). CpG oligodeoxynucleotide signaling leads to increased expression of Hsp90β and association with Bcl-2 (Kuo et al., 2007). In a ternary complex with Hsp90β, not α, and HIF-1α to mediate hypoxia-induced stabilization (Trisciuoglio et al., 2010). IP/MS of Bcl-2 pulls out Hsp90β (Li et al., 2017b).
- Interferon regulatory factor 3 (IRF3): Hsp90 acts as scaffold to bring the kinase TBK1 to IRF3 (Yang et al., 2006a). In the case of IRF-1, it may be indirectly through Hsp70 (Narayan et al., 2009).
- DNA helicase Ssl2 (Flom et al., 2005).
- Death-associated protein kinases DAPK, DAPK2/ZIPK, and DAPK3/Drp1 (Citri et al., 2006).
- Kinases that are Hsp90 substrates are typically signaling hubs except for the PI3K-Akt pathway (Citri et al., 2006).
- Perilipin (Yamaguchi et al., 2006).
- Tyrosine kinase receptor Ron (Germano et al., 2006).
- Atypical PKCδ as part of a larger complex (Brajenovic et al., 2004).
- All PKCs bind along with Cdc37: required for phosphorylation-dependent maturation and for stability in cell type-dependent fashion (Gould et al., 2009; see also Lu et al., 2014). Required for interaction of PKCδ with importin-α (Adwan et al., 2011).
- TonEBP/OREBP: Hsp90 associated with protein on DNA and required for increased expression and for activity (Chen et al., 2007).
MRE11/Rad50/NBS1 (MRN) complex involved in DNA damage response (Dote et al., 2006); critically dependent on phosphorylation of S164 of Hsp90α by Cdc7-Dbf4 for ATM/ATR signaling (Cheng et al., 2017).

Prolactin receptor in newts (Saribek et al., 2006).

Fused (Kise et al., 2006).

GSK3β: Hsp90 required for autophosphorylation at a tyrosine in activation loop (Lochhead et al., 2006), stability and function (Banz et al., 2009). Another study finds that only a kinase-dead mutant but not wt interacts (Jin et al., 2016). Hsp90-Hop act as scaffold for GSK3β-mediated phosphorylation of LSD1 (Tsai et al., 2018).

Capsid precursor protein P1 of picornaviruses (Geller et al., 2007).

ZAP-70: possibly specifically with Hsp90 from leukemic cells as a "conditional Hsp90 substrate" (Castro et al., 2005; Bartis et al., 2007).

platelet-derived growth factor receptor α (Matei et al., 2007).

Msps (other orthologs: XMAP215, ch-TOG); Hsp90 is required (perhaps indirectly) to recruit Msps to centrosomes and the mitotic spindle (Basto et al., 2007).

Cdk5 activator p35 (Luo et al., 2007).

conserved oligomeric Golgi (COG) complex components COG5, -7, -9 (McClellan et al., 2007).

FLICE-like inhibitory proteins FLIPs and FLIPl; required for recruitment of these and RIP to DISC (Panner et al., 2007).

CB2 cannabinoid receptor; may function as scaffold for interaction with G protein (He et al., 2007; He et al., 2012).

mitochondrial cyclophilin D; Hsp90 and Trap1 prevent cyclophilin D from promoting mitochondrial permeability transition (Kang et al., 2007).

JNK: Hsp90 recruited to JNK in lipid rafts in edelfosine-treated cells (Nieto-Miguel et al., 2008). Additional evidence for Hsp90 requirement for JNK-1 (Wang et al., 2009a).

Pih1 (=Nop17) and R2TP complex (including RUVBL1): directly (Te et al., 2007)? or indirectly through Tah1 (Zhao et al., 2005; Zhao et al., 2008; Pal et al., 2014; Rivera-Calzada et al., 2017). See also Eckert et al., 2010; Izumi et al., 2012; Benbahouche et al., 2014. Also URI complex, either directly or through Pih1 and Tah1 (Izumi et al., 2012). Evidence for several R2TP-like complexes including R2SP, R2SD and others through RPAP-3-like protein Spag1 and through DYX1C1 (Maurizy et al., 2018).

IP6K2: Hsp90 inhibits its activity and thereby protects against apoptosis (Chakraborty et al., 2008).

Rac/Rop GTPase Rac1 of rice (Thao et al., 2007).

Rac1, at least with Hsp90β (Cha et al., 2010).

ATP-sensitive K+ channel Kir6.2: Hsp90 promotes mitochondrial targeting (Jiao et al., 2008).

MAP kinase kinase kinase Tpl2 = Cot (Wu and Wilmouth, 2008).

snoRNP complexes, possibly through R2TP complex (Boulon et al., 2008; Zhao et al., 2008), and Hsp90 is required for accumulation of a series of small RNAs and ribosomal biogenesis.

U5 snoRNP during assembly through interaction with PRPF8, SNRNP200 and maybe other components (Malinová et al., 2017).

Pink1 binds Hsp90 along with Cdc37; binding slightly affects isoform ratio and subcellular localization of Pink1 (Weihofen et al., 2008).

polysomal ribonuclease 1 (PMR1) (Peng et al., 2008).

Leucine-rich repeat kinase 2 (LRRK2) (Gloeckner et al., 2006; Wang et al., 2008); Hsp90 recruits CHIP to substrate (Ko et al., 2009).
c-IAP1: only Hsp90β, complex moves from nucleus to cytoplasm upon differentiation (Didelot et al., 2008).

Tyrosine hydroxylase: stabilizing interaction induced by ethanol via cAMP-PKA pathway and antagonized by GDNF (He and Ron, 2008).

Ure2: Hsp82 interacts with globular Ure2 complexes and prevents formation of \{URE3\} prion fibrils (Savistchenko et al., 2008). Others find no genetic requirement (Kumar et al., 2015).

Extracellular Hsp90α can interact with the receptor CD91 (=LRP-1) (Basu et al., 2001; Cheng et al., 2008; Chen et al., 2010a); stabilized by Hsp90β binding to its cytosolic tail (Jayaprakash et al., 2015).

SGK-1 (Belova et al., 2008).

p300 (Yang et al., 2008).

TGFβ receptors I and II (Wrighton et al., 2008; Datta et al., 2015). Extracellular Hsp90 with TGFβRI (García et al., 2016).

Uroporphyrinogen decarboxylase (HemE) in cyanobacteria (Watanabe et al., 2007; Saito et al., 2008).

DNMT1 (Zhou et al., 2008).

LAMP-2A associated with Hsp90 on the luminal side of lysosomes (Bandyopadhyay et al., 2008).

UCH-L1, along with LAMP-2A (Kabuta et al., 2008).

Chronophin: Hsp90 inhibits phosphatase activity in presence of ATP (Huang et al., 2008).

Transcription factor Sp1 (Hung et al., 2005) for JNK-1-dependent maintenance (Wang et al., 2009a).

Ricin catalytic A chain (Spoon et al., 2008).

Trithorax and its mammalian ortholog "mixed-lineage leukemia" (MLL) (Tariq et al., 2009).

SRPK1, most likely through Aha1, and released by stress and GA (Zhong et al., 2009).

RIG-I (Matsumiya et al., 2009).

Rab11a; involved in regulating recycling of extracellular α-synuclein (Liu et al., 2009b).

Cdc25c (García-Morales et al., 2007) and Cdc25a (Giessrigl et al., 2012).

Cup (Pisa et al., 2009).

Mitochondrial Hsp60 (Liu et al., 2009c).

Tyrosine kinase Fer (Hikri et al., 2009).

Hepatitis C virus nonstructural protein NS3 (Ujino et al., 2009).

Inositol 1,4,5-trisphosphate receptor 3 (IP3R-3); Hsp90 inhibits activity and insulin further augments inhibition and interaction (Nguyen et al., 2009).

Ryk, along with Cdc37 through kinase domain (Lyu et al., 2009).

TOM40 (Anandatheerthavarada et al., 2009).

Cdc13; Hsp82 promotes its dissociation from telomeric DNA (DeZwaan et al., 2009).

Bcl-xL (Caldas-Lopes et al., 2009).

HER3 (Caldas-Lopes et al., 2009).

p90RSK (Caldas-Lopes et al., 2009).

Tyk2 (Caldas-Lopes et al., 2009).

Tab2/3 (Caldas-Lopes et al., 2009).

BLM helicase in the context of alternative lengthening of telomere (ALT) pathway; Hsp90 colocalizes at ALT-associated PML bodies and represses BLM activity (Bhattacharyya et al., 2009).

N-myc downstream-regulated gene 1 (NRDG1) (Banz et al., 2009).
- Importin β1 (KPNB1) and Nup62, promoting the interaction of the latter with GR (Echeverría et al., 2009).
- Importin 4 (IPO4), along with Aha1 (Echeverría et al., 2011a).
- Importin-α6 (KPNA5), along with Aha1 (Echeverría et al., 2011a).
- EphA2 through kinase domain (Annamalai et al., 2009).
- Raptor (Ohji et al., 2006; Delgoffe et al., 2009).
- Cullin 5 (Ehrlich et al., 2009; Samant et al., 2014).
- DNA polymerase η; Hsp90 allows proper folding and interaction with monoubiquitinated PCNA, and thereby translesion repair of UV-damaged DNA (Sekimoto et al., 2010).
- BCL-6, including at BCL-6 target promoters (Cerchietti et al., 2009).
- DEDD (Kurabe et al., 2010).
- Type I lissencephaly gene product LIS1 (Yang et al., 2010; Zhu et al., 2010), stimulated by NudCL2 (Yang et al., 2010).
- PAMP receptor OsCERK1 in rice along with Hop/Sti1; interact at endoplasmic reticulum and required for transport to membrane (Chen et al., 2010b).
- AF9/MLLT3: Hsp90 required for nuclear localization and chromatin recruitment (Lin and Hemenway, 2010).
- p38 mitogen-activated protein kinase is inhibited by Hsp90-Cdc37 complex; interaction favored in presence of Cdc37 (Ota et al., 2010).
- Breast cancer metastasis suppressor 1 (BRMS1) along with HDACs (Hurst et al., 2006).
- Hepatitis E virus capsid protein (Zheng et al., 2010).
- SUR1 subunit of β-cell ATP-sensitive potassium channel (Yan et al., 2010a).
- K1 protein of Kaposi sarcoma-associated herpesvirus (KSHV) (Wen and Damania, 2010).
- Dsn1 and Nsl1 subunits of Mis12 complex involved in assembly of kinetochores; strongly stabilized by Sgt1 (Davies and Kaplan, 2010).
- Peptide-loaded extracellular Hsp90 binds Scavenger receptor expressed by endothelial cells-I (SREC-I) (Murshid et al., 2010; Murshid et al., 2014).
- Tissue plasminogen activator (tPA) interacts with Hsp90α secreted through exosomes (McCreary et al., 2010).
- Latency-associated peptide (LAP) (Suzuki and Kulkarni, 2010).
- PKCε, interacts with and needs Hsp90 for its mitochondrial import (Budas et al., 2010).
- Unassembled RNA polymerase II subunit Rpb1 in the cytoplasm, possibly delivered to it by Spaghetti (Boulon et al., 2010; Villanyi et al., 2014).
- Cholera toxin A1 subunit (CTA1 = CtxA1); required for ratchet-like dislocation from endoplasmic reticulum to cytosol (Taylor et al., 2010), coupled to ATP hydrolysis-dependent refolding (Burress et al., 2014), following ATP-dependent binding to the N-terminal sequence motif RPPDEI (Kellner et al., 2019). Also Pertussis toxin (Ptx) and Salmonella enterica serovar Typhimurium (ArtAB), which contain very similar motifs (Kellner et al., 2019). For CTA1, Hsc70 and Hsp90 independently play complementary roles, independently of Hop (Burress et al., 2019).
- Prostanoid pathway proteins prostacyclin synthase and thromboxane synthase (Fike et al., 2010).
- Tel2 and Tel2-Tti1-Tti2 (TTT) complex; required with Hsp90 for maturation of ATM, ATR and mTOR complexes (Horejsi et al., 2010; Takai et al., 2010; Izumi et al., 2012; see also Pal et al., 2014).
- mTOR (Moulick et al., 2011).
- E. coli ribosomal protein L2 in its native unfolded state binds htpG and activates its ATPase (Motojima-Miyazaki et al., 2010).
- Triosephosphate isomerase (TPI) (Hrizo and Palladino, 2010).
Wilms tumor 1 (WT1) (Bansal et al., 2010).

LATS1 and LATS2 (Hunton et al., 2010; see also Nokin et al., 2016).

Sumo protease 3 (SENP3): in response to oxidative stress Hsp90 protects it from CHIP-mediated degradation but in a CHIP-dependent way and by blocking the CHIP E3 ligase activity (Yan et al., 2010b).

Activation-induced deaminase (AID): Hsp90 inhibition reduces AID-induced antibody-diversification, class switching and off-target mutation (Orthwein et al., 2010).

APOBEC-3B, -3C, and -3G (Chen et al., 2017c).

Eml4-Alk (Chen et al., 2010c; Richards et al., 2014) and NPM-Alk (Kancha et al., 2013; see also Kuravi et al., 2019) fusion proteins.

Piwi in Drosophila (Gangaraju et al., 2011). PIWI protein Ago3 colocalizes with Hsp83 to cytoplasmic foci and its RNA loading may be promoted by Hsp83 with the FKBP36 ortholog Shutdown (Olivieri et al., 2012). Alternatively, Hsp90-Shutdown may help to eject inhibitory RNAs from Ago3 (Xiol et al., 2012).

PIWIL2 (= HILI) interacts and in doing so reduces stabilizing interactions of TGFβ receptors with Hsp90 (Zhang et al., 2012b).

Cineole synthase 1 from sage (SfCinS1); co-overexpressed with Hsp90 in yeast leads to increased cineole production (Ignea et al., 2011).

PIDD; interaction with Hsp90, along with p23, in the cytoplasm is required for autoproteolytic cleavage and PIDDosome function following Hsp90 release (Tinel et al., 2011).

DNA-activated protein kinase (= DNA-PK=PRKDC) (Lees-Miller and Anderson, 1989a; Falsone et al., 2005; Quanz et al., 2012; Solier et al., 2012).

α2C adrenergic receptor: Hsp90 binds it and prevents surface expression at 37°C and less so at 30°C (Filipeanu et al., 2011).

Rapsyn: interaction stabilizes it and through Rapsyn promotes acetylcholin receptor clustering; apparently only Hsp90β (Luo et al., 2008).

Phosphatidylinositol 4-kinase type IIβ (PI4KIIβ): Hsp90 stabilizes cytosolic form and keeps it inactive until stimulus induces dissociation and recruitment to membranes (Jung et al., 2011).

Pnck (Deb et al., 2011).

NADPH oxidases 1, 2, 3, and 5 (Nox1-3, Nox5) through their C-termini for stability and superoxide formation (Chen et al., 2011; Chen et al., 2015a).

F1F0-ATP synthase, suggested as co-chaperone (Papathanassiu et al., 2006); see also global proteome analysis (Krogh et al., 2006) and genetic analysis of assembly (Francis and Thorsness, 2011) for supporting evidence.

Rotavirus nonstructural protein 3 (NSP3) for dimerization (Dutta et al., 2011).

FGFR3 and FGFR4 (Laederich et al., 2011). Influence of disease-relevant mutations on interaction with Cdc37 and Hsp90 (Bunney et al., 2018).

FOP2-FGFR1 (Jin et al., 2011).

Non-structural protein NS1 of influenza A virus (Zhang et al., 2011).

PCNA (Wang et al., 2010).

Kinase SSCMK1 of the fungus Sporothrix schenckii, possibly promoting thermotolerance through this interaction (Rodriguez-Caban et al., 2011).

Beclin 1; required for TLR-mediated autophagy (Xu et al., 2011).

Y-family polymerase REV1 for its folding and interaction with PCNA in translesion DNA synthesis (Mayca Pozo et al., 2011).

Ulk1 along with Cdc37 for regulation of mitophagy (Joo et al., 2011).

Exportin-1 (XPO1=CRM1), with both Hsp90 isoforms and along with Aha1 (Echeverría et al., 2011a; see also Falsone et al., 2005).
- IRS-2 (Fukushima et al., 2011).
- Bruton agammaglobulinemia tyrosine kinase (BTK) (Moulick et al., 2011; Guo et al., 2017a).
- CARM1 (Moulick et al., 2011).
- PRKD2 (Moulick et al., 2011; see also Azoitei et al., 2014).
- Stat5, notably phosphorylated form (Moulick et al., 2011).
- Adhesin A from Neisseria meningitidis (NadA) (Cecchini et al., 2011; Montanari et al., 2012).
- Clostridium toxins CDT and iota, which need Hsp90 as membrane translocator (Kaiser et al., 2011).
- Campylobacter jejuni protein JlpA (Jin et al., 2003).
- F box protein ZEITLUPE (ZTL) of circadian clock in plants (Kim et al., 2011; see also Noren et al., 2016) in ternary complex with putative Hsp90 co-chaperone GIGANTEA (Cha et al., 2017).
- XPORT (Rosenbaum et al., 2011).
- TRIM8 with Hsp90β, α not looked at (Okumura et al., 2011).
- PARK7 (DJ-1) (Knobbe et al., 2011).
- E protein of Japanese encephalitis virus; specifically only with Hsp90β isoform, which gets co-secreted with viral particles (Hung et al., 2011); whole viral particles, too (Wang et al., 2017b).
- GTPase Bms1 in yeast (Franzosa et al., 2011).
- Phosphorylated β-catenin and axin 1 (Cooper et al., 2011).
- AMPK subunits α and γ (Zhang et al., 2012c; see also Park et al., 2017b).
- ALK1 and ALK5 (Antonov et al., 2012).
- Smyd2-methylated Hsp90 in complex with titin (Donlin et al., 2012).
- E3 ubiquitin ligase Hectd1 via a central domain (Sarkar and Zohn, 2012).
- Huntingtin (Baldo et al., 2012; He et al., 2017).
- BRCA1 (Stecklein et al., 2012); in particular BRCT domain mutants (Johnson et al., 2013).
- BRCA2 (Noguchi et al., 2006).
- WASF3 (Teng et al., 2012).
- NELF-E (=RDBP in human) (Sawarkar et al., 2012).
- DDR1 (Wu et al., 2012b).
- Adenylate cyclase Cyr1 in yeast (Flom et al., 2012).
- O-linked β-N-acetylglucosamine transferase (OGT) (Zhang et al., 2012a; Fierro-Monti et al., 2013a; Frank et al., 2014).
- Nanog (Bradley et al., 2012).
- Oct4 (Bradley et al., 2012).
- RNA-dependent RNA polymerase and 3'UTR of Bamboo mosaic virus (Huang et al., 2012).
- TDP-43 (Jinwal et al., 2012). Hsp90 prevents assembly and promotes disassembly of soluble TDP-43 filaments (Carlomagno et al., 2014).
- PTK6 (Kang et al., 2012).
- p27 replicase component of Red clover necrotic mosaic virus (RCNMV) (Ahsan et al., 2012).
- Calmodulin methyltransferase (CAMKMT) (Magen et al., 2012).
- LANA of Kaposi sarcoma-associated HSV (Chen et al., 2012b).
- Adaptor protein Act1 (=TRAF3IP2); point-mutant variant linked to psoriasis-susceptibility fails to interact (Wang et al., 2013a; see also Wu et al., 2014).
Transcription factors ATP3, BBX, C20orf194, CEBPE, CXXC1, DLX6, DMRTA1, FOXD4L6, FOXM1, FOXP2, GTF2IRD2, HMGAl, HP1BP3, IRF2, ISX, MAFG, MAX, MKX, NFIC, NFRKB, NR1H3, NR1H2, PCGF6, POGK, PRDM1, PREB, SETDB1, SIM2, SLFN11, SREBF1, STAT2, TADA2A, TBX22, TCF25, TEAD2, TFPD3, THAP4, TRIM32, ZBED4, ZBTTB17, ZBTTB20, ZC3H7B, ZNF215, ZNF509, ZNF74 (Taipale et al., 2012).

Kinases ACVR1B, ACVR1C, ACVR2B, AKT2, ALK, ALPK1, AMHR2, AURKC, AXL, BLK, BMPR1A, BMX, CAMK1G, CAMK2A, CAMK2B, CAMK2D, CAMK2G, CAMK4, CAMKK1, CAMKK2, CAMKV, CDK11B, CDK14, CDK15, CDK18, CDK3, CLK2, CLK3, CSF1R, CSNK1A1, DCLK2, DDR2, DMPK, DYRK1B, DYRK2, DYRK4, EPHA1, EPHA4, EBHB1, EBHB6 (see also Allonby et al., 2014), ERBB4, FASTK, FGFR1, FLT4, FRK, FYN, GRK4, GRK7, GSK3A, HCK, HIPK4, ICK, INSRR, IRAK2, IRAK3, ITK, LCK, LIMK1, LIMK2, LYN, MAP2K5, MAP2K7, MAP3K12, MAP3K15, MAP3K2, MAP3K6, MAP3K9, MAP4K1, MAP4K2, MAP4K4, MAPK15, MAPK4, MAPK7, MAST2, MATK, MERTK, MINK1, MUSK, MYLK2, MYLK3, MYLK4, NEK11, NEK8, NEK9, NPR2, NTRK1, NTRK2, NTRK3, NUAK2, PAK6, PASK, PDGFRB, PIDK1L, PIM2, PIM3, PKN1, PKN2, PRKAA2, PRKACB, PRKCA, PRKCB, PRKCG, PRKCH, PRKCI, PRKCC, PRKCZ, PRKD1, PRKG2, PRKX, PRKY, PSKH1, PSKH2, PTK2, PTK2B, PTK6, ROR2, RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA5, RPS6KA6, RPS6KB1, RPS6KC1, RPS6KL1, SGK2, SGK23, SGK3, SRPK3, STK32B, STK32C, STK38, STK38L, STYK1, TAOK3, TESK1, TESK2, TIE1, TNK1, TNK2 (see also Mahendrarajah et al., 2017), TNNI3K, TP53RK, TSSK1B, TSSK2, TSSK3, TYRO3, WK4N (Taipale et al., 2012).

Miscellaneous proteins: ARMC5, ASB17, ASB2, ASB3, ASB4, ASB6, DET1, ENC1, KAT5, KSR1, KSR2, LARP4B, MYO3B, RAG1, RGS11, RGS6, RGS7, RGS9 (Taipale et al., 2012), and CCDC117 (Taipale et al., 2014).

E3 ligases and related proteins ANAPC2, BTRC, CUL1, CUL2, CUL3, CUL4A, CUL4B, DTX4, FBXL12, FBXL13, FBXL14, FBXL15, FBXL18, FBXL2, FBXL3, FBXL8, FBXO10, FBXO17, FBXO18, FBXO24, FBXO25, FBXO27, FBXO28, FBXO3, FBXO34, FBXO38, FBXO4, FBXO40, FBXO6, FBXO9, FBXW11, FBXW2, FBXW5, FBXW7, G2E3, GAN, HECTD3, HERC4, HERC6, KBTBD4, KBTBD7, KCNA5, KCNA6, KCNG1, KCNS3, KCTD8, KIAA0317, KLHL1, KLHL10, KLHL13, KLHL14, KLHL22, KLHL23, KLHL25, KLHL26, KLHL27, KLHL32, KLHL34, KLHL36, KLHL38, KLHL6, LGALS3BP, LNX1, LOC440248, LRSAM1, MARCH9, MDM4, NHLRC1, PARK2, PCDGF1, PCDGF3, PRPF19, RAB40A, RCBTB1, RCBTB2, RFWD3, RHOBTB1 (see also Prince et al., 2015), RNF10, RNF111, RNF19B, RNF40, SF3B3, SH3RF2, SKP2, SOCS6, SPSB1, SPSB3, TNFAIP3, TRIM10, TRIM17, TRIM2, TRIM36, TRIM37, TRIM41, TRIM49, TRIM56, TRIM7, TRIM73, TRIM74, VPS18, VPS41, WSB2, WWP1 (Taipale et al., 2012).

E3 ligase KEAP1 (Prince et al., 2015).

KCNO4 potassium channel: Knock-down and overexpression of Hsp90β reduces and overexpression augments levels and the converse is true for Hsp90α indicating a particular case of isoform selectivity (Gao et al., 2013).

Formylglycinamidase synthetase (FGAMS) and the entire purinosome (French et al., 2013; Pedley et al., 2018).

Phosphoribosylpyrophosphate amidotransferase (PPAT) of the purinosome (Pedley et al., 2018).

HAX-1 (Lam et al., 2013).

PLN (Lam et al., 2013).

SERCA2a (Lam et al., 2013).

Sicily (fly ortholog of human NDUFAF6): cytoplasmic preprotein interacts in the cytoplasm to stabilize preprotein subunits of complex I (Zhang et al., 2013b).
Flagellar motor protein FliN and FliI in *E. coli* (Li and Sourjik, 2011).

p23 recruits PHD2 to Hsp90-HIF1α (Song et al., 2013).

p53 family member TP73 (Zhang et al., 2013a).

*Arabidopsis* transcription factors BES1 (Lachowiec et al., 2013; Shigeta et al., 2014) and BZR1 (Shigeta et al., 2015). BES1 complex is all over the cell, but accumulates in cytoplasm upon brassinosteroid signaling (Samakovli et al., 2020).

*Arabidopsis* brassinosteroid signaling factor BIN2 (Samakovli et al., 2014).

Cla4: interacts genetically (McClellan et al., 2007) and biochemically (Hsieh et al., 2013) in yeast.

Histone demethylases KDM4B/JMJD2B (Ipenberg et al., 2013) and KDM3A/JMJD1A (Kasioulis et al., 2014).

thiazide-sensitive NaCl cotransporter NCC (=SLC12A3) (Donnelly et al., 2013).

EBV DNA polymerase catalytic subunit BALF5, probably facilitating interaction with BMFR1 for nuclear transport (Kawashima et al., 2013).

Flagellar motor protein FliN with htpG in *E. coli* (Press et al., 2013).

Phosphatase CheZ with htpG in *E. coli* (Press et al., 2013).

Chemoreceptor histidine kinase CheA with htpG in *E. coli* (Press et al., 2013).

Chloroquine resistance transporter (PICRT) of *Plasmodium* (Shahinas et al., 2013).

USP1 and Met1 in insect cells in response to ecdysone and juvenile hormone, respectively, in a mutually exclusive way (Liu et al., 2013). Hsp83 promotes juvenile hormone-induced nuclear localization and chromatin binding of Met (He et al., 2014).

EBAX-1 of *C. elegans* interacts genetically and by yeast 2-hybrid (Wang et al., 2013e).

Adenosine A2A receptor, but exclusively with Hsp90α (Bergmayer et al., 2013).

Ura2 (Zuehlke et al., 2013).

BRAT1 (Fierro-Monti et al., 2013a).

vFLIP of KSHV (Nayar et al., 2013).

Tax of HTLV-1 (Gao and Harhaj, 2013).

Aldo-keto reductase 1B10 (AKR1B10); Hsp90α promotes its non-classical secretion through lysosomes (Luo et al., 2013).

Wild-type and mutant glucocerebrosidase (GBA) (Lu et al., 2011; Yang et al., 2014a; Yang et al., 2015a); as part of a complex with Hop and Cdc37 that recruits Hsp27 for targeting GBA to degradation (Yang et al., 2015a).

Fibronectin (Hunter et al., 2014).

DBC2/RhoBTB2; Hsp90 promotes GTP binding and assembly of DBC2-Cul3-COP9 complex (Manjarrez et al., 2014).

Utp21 (Tenge et al., 2014).

HSV-1 capsid protein ICP5 (Zhong et al., 2014) and VP16 (Wang et al., 2018).

Precursor of Lysyl oxidase-like 2 protein (LOXL2) with extracellular Hsp90α (McCready et al., 2014).

Legumain (= LGMN = asparaginyl endopeptidase) precursor associates with Hsp90α in a TRAF6-mediated ubiquitination-dependent way (Lin et al., 2014).

nsP3 and nsP4 of Chikungunya virus (Rathore et al., 2014).

Urokinase plasminogen activator (uPA) (Donet et al., 2014).

ANKMY2 (Taipale et al., 2014).

Broad-Complex-Tramtrack-Bric-a-brac (BTB) domain containing proteins BrZZ and mod(mdg4) of insects (Cai et al., 2014).

XRCC1, not bound to DNA Pol β, interacts with DNA-PK-phosphorylated Hsp90α (Fang et al., 2014).

PGK1 (Chen et al., 2015b; Zhou et al., 2019b).
◆ Serotonin transporter (SERT), only with Hsp90β isoform, along with Hsp70, Hop, p23 and CHIP (El-Kasaby et al., 2014).
◆ Ribonucleotide reductase subunit Bnr4 (Truman et al., 2015).
◆ Macrophage migration inhibitory factor (MIE), but only with Hsp90α (Schulz et al., 2012).
◆ Calpain-1, even in its active state, but not calpain-2 (Averna et al., 2015).
◆ Hsp27 (Yang et al., 2015a).
◆ L-protein (polymerase) of human respiratory syncytial virus (Munday et al., 2015).
◆ HPV splice isoform E6^E7 (Ajiro and Zheng, 2015).
◆ Human and mouse norovirus capsid proteins VP1 (Vashist et al., 2015).
◆ Rad51 and Rad52 (Suhane et al., 2015; see also Gavin et al., 2002; Zhao et al., 2005).
◆ VirE2 interacting protein 1 (VIP1) (Park et al., 2014).
◆ DNA polymerase λ of Arabidopsis (Roy et al., 2015).
◆ DYRK1A mutants, but not wt, in luciferase interaction assay (Sonamoto et al., 2015).
◆ SDF2 (Siragusa et al., 2015).
◆ Tup1 in Candida (Diezmant et al., 2015).
◆ ANP32C and ANP32D (Yuzefovsky et al., 2015).
◆ BPIFB4, notably a longevity-associated variant, in a Perk and 14-3-3 dependent way (Villa et al., 2015).
◆ DnaA with overexpressed htpG (Grudniak et al., 2015).
◆ Auxin co-receptor TIR1 (Wang et al., 2016b; Watanabe et al., 2016).
◆ HMGA2 (Kao et al., 2016).
◆ Pyruvate kinase M2 (PKM2) along with Hop and p23; as dimer stabilizes mutant EGFR (Yang et al., 2015b). Complex with Hsp90 promotes its stabilizing phosphorylation by GSK3β (Xu et al., 2017).
◆ MLKL, promoting necroptosis (Bigenzahn et al., 2016; Zhao et al., 2016; see also Yang and He, 2016).
◆ Lectin-like oxidized LDL receptor-1 (LOX1=OLR1) as membrane receptor for membrane-bound Hsp90 (Zhu et al., 2016a).
◆ Hsp90α interacts with VP2 of IBDV (Hu et al., 2015).
◆ Kinase BGLF4 of EBV by split renilla assay (Wang et al., 2016a).
◆ Yeast cytochrome c peroxidase Ccp1 (Kathiresan and English, 2016).
◆ Multidrug resistance-associated protein 1 (MRP1) (Roundhill et al., 2016).
◆ Yeast galactokinase Gal1; when Hsp90 function is compromised, Gal1 and several other Gal proteins aggregate and galactose utilization is slightly less efficient (Gopinath and Leu, 2016; see also Gopinath and Leu, 2017).
◆ Hsp90 interacts with NMNAT2 to stimulate its ATPase and foldase activities (Ali et al., 2016).
◆ Phosphoprotein (P) of rabies virus, along with Cdc37 (Xu et al., 2016).
◆ Rab3GAP1 with Hsp90α, perhaps through Aha1, colocalized at secretory vesicles (Ghosh et al., 2015).
◆ Integrin α2 and integrin αL (Ghosh et al., 2016).
◆ Checkpoint kinase Mps1; interaction stabilized by phosphorylation of Hsp90 by Mps1 itself and destabilized by dephosphorylation by Cdc14 (Woodford et al., 2016c).
◆ Cdc14, preferentially with (T101) non-phosphorylated Hsp82 (Woodford et al., 2016c).
◆ Tumor suppressor folliculin (FLCN) (Woodford et al., 2016a).
◆ Proteins encoded by flowering genes Leafy (LFY), SOC1, AGL24, and SUP in Arabidopsis (Margaritopoulou et al., 2016).
◆ UHRF1; Hsp90 inhibitor-induced degradation is not mediated by CHIP or CUL5 (Ding et al., 2016).
◆ Tyrosine kinase receptor MET (Prince et al., 2015).
Transferrin receptor 1 (TFR1) (Shapiro et al., 2016).

NHE1 (Amith et al., 2017; Odunewu-Aderibigbe and Fliegel, 2017).

REB-ERβ; this interaction somehow antagonizes interaction of Hsp90 with GR (Okabe et al., 2016).

N-acetyltransferase ARD1; not clear whether it is through androgen receptor (AR) (DePaolo et al., 2016).

ATM phosphorylates nuclear Hsp90α (Elaimy et al., 2016).

UCS protein and Unc45 relative She4 in yeast by 2-hybrid (Millson et al., 2004); heat increase affected by phosphorylation of She4 (Gomez-Escalante et al., 2017).

p14ARF of INK4a gene; Hsp90 with CHIP induces lysosomal degradation of p14ARF, thereby preventing senescence of tumor cells (Han et al., 2017).

Glutamate transporter 1 (GLT-1); Hsp90β promotes its degradation by the proteasome and epileptic seizures in mouse model, countered by GA (Sha et al., 2017).

Spleen tyrosine kinase (SYK) (Guo et al., 2017a; Walter et al., 2017).

SOD1 point mutant linked to severe ALS (Karras et al., 2017).

FANCA, both wild-type (Oda et al., 2007) and mild disease mutants (Karras et al., 2017).

Thioredoxin reductase (TrxR), thioredoxin (Trx1) and Rab3a on the cytosolic face of synaptic vesicles (Azarnia Tehran et al., 2017; see also Pirazzini et al., 2018).

KAP1 (Hummel et al., 2017).

EZH2 in complex with CDK1 to promote its phosphorylation and degradation (Göllner et al., 2017).

Hsp90 is required for maturation of L protein of mumps virus (Katoh et al., 2017), together with R2TP complex and blocking RNA synthesis of mumps and measles viruses (Katoh et al., 2019).

SREBP1, SREBP2, and SCAP (Kuan et al., 2017).

TilS in Shewanella oneidensis (Honoré et al., 2017).

misfolded transthyretin (TTR) monomer, in vitro (Oroz et al., 2017).

MTA1, Hsp90 required for hypoxia-induced nuclear-cytoplasmic translocation (Marzook et al., 2017).

LYN (Taipale et al., 2012; see also Guo et al., 2017a).

Intracellular domain (ICN1) of Notch1 (Wang et al., 2017d).

Zyogen pro-Dcp1 in Drosophila (Choutka et al., 2017).

Nibrin (NBN) (Pennisi et al., 2017).

HNF4A (Jing et al., 2017).

Tsc2 in a Tsc1-dependent way (Woodford et al., 2017).

RanBP9 (Woo et al., 2017).

STK33 (Azoitei et al., 2012; Liu et al., 2017).

GREB1 (Savitski et al., 2018).

Cholin acetyltransferase (ChAT), notably mutants (Morey et al., 2017).

LSD1, stabilization also requires Hop (Tsai et al., 2018; see also Bennesch et al., 2016).

PRDM14 (Moriya et al., 2018).

mtHsp70/Grp75/mortalin (Rozenberg et al., 2018).

Complement C9 (Rozenberg et al., 2018).

Humanin (Gong et al., 2018).

Tobamovirus resistance protein Tm-2 of tomato (Qian et al., 2018).

Caspase-8, protecting it against degradation (Gupta et al., 2018).

Lamin A/C; knock-down of Hsp90 reduces levels and affects morphology and migration of dermal papilla cells (Thanomkitti et al., 2018).

Chl1 component of sister chromatid cohesion complex in yeast (Khurana et al., 2018).

HSV-1 protein Us11, disrupts Hsp90-TBK1 interaction (Liu et al., 2018).
Mature interleukin-1β (IL-1β), promoting its secretion by translocation into a vesicle intermediate to formation of autophagosomes (Zhang et al., 2015b; see also Zhang et al., 2018b); stimulated by starvation (Zhang et al., 2015b) or infection by Mycoplasma hyopneumoniae (Zhang et al., 2018b).

SOX11, with Hsp90α (Elzakra et al., 2017).

ER membrane complex component Emc2 in yeast in TPR-independent mode (Kudze et al., 2018).

WTAP (Bansal et al., 2014; Kuai et al., 2018).

Twist1 (Meng et al., 2019).

Glutamine synthetase Gln1 in stressed yeast cells (O’Connell et al., 2014).

Dual leucine zipper kinase (DLK), required for axon injury signaling (Karney-Grobe et al., 2018).

Effectors NleH1 and NleH2 of type III secretion system of pathogenic bacteria upon injection into mammalian cells (Wu and Hardwidge, 2018).

Capping enzyme RNGTT (Trotman et al., 2018).

HMG-CoA reductase (HMGCR) (Dong et al., 2019).

α4 integrin but not β2 integrin (Lin et al., 2019).

Clusterin, which appears to behave like a (intracellular) co-chaperone (Xiong et al., 2019a). See also interaction with eHsp90α (Tian et al., 2019).

Neuraminidase of influenza virus A; Hsp90 overexpression further stabilizes it (Kumar et al., 2019).

LRP5 with Hsp90β (Wang et al., 2019a).

Cytosolic catalytic domain of type III CD38 (Wu et al., 2019c).

Cwt1 in C. albicans (Guan et al., 2019).

Nck-associated protein 1 (NAP1) (Xiong et al., 2019b).

GluR1 subunit of AMPA receptors; association with FKBP51 promotes disposal of internalized receptors (Blair et al., 2019a).

E. coli tubulin homolog FtsZ: holds it and prevents its polymerization in ATPase-independent manner (Balasubramanian et al., 2019).

The metalloprotease toxin AIP56 from Photobacterium damselae, upon translocation from endosomes to cytosol (Rodrigues et al., 2019).

Pellino protein Peli1, directly through its RING domain to regulate Ire1-Hsp90 interaction and Ire1 phosphorylation (Zhao et al., 2019).

F-box protein COL1 in Arabidopsis (Zhang et al., 2015c).

REST (Orozco-Díaz et al., 2019).

TSG101 (Giordano et al., 2019).

SLC6A14 interacts and depends on it for trafficking to cell surface (Rogala-Koziarska et al., 2019).

MAP1B (Wu et al., 2019d).

Kinase Pbs2 of Hog1 pathway in C. albicans (O’Meara et al., 2019).

Sumo deconjugating enzyme Ulp1 of C. albicans; Hsp90 impairment leads to hypersumoylation of Rvb1 (O’Meara et al., 2019).

S. aureus protein Lpl1; interaction on cell surface triggers F-actin formation (Tribelli et al., 2019).

HopBF1 family of bacterial effectors both as clients and Hsp90 kinases, independently of Cdc37 (Lopez et al., 2019).

MAST1 (Pan et al., 2019).

Bluetongue viral proteins (Mohl and Roy, 2019).

Nuclear pool of HCFC1; Hsp90 inhibition affects its levels and function in regulating cell cycle genes (Antonova et al., 2019).
Rubella virus non-structural protein p150 (Sakata et al., 2019).

Tumor suppressor NDRG2; in its absence PRMT5 methylation of Hsp90 is required to maintain Hsp90 activity (Ichikawa et al., 2020).

Bacillus thuringiensis Cry toxins are protected from proteases and their interaction with the cadherin receptor is enhanced (García-Gómez et al., 2019).

E3 ligase Hakai (Díaz-Díaz et al., 2020).

c-Myc (Lee et al., 2018).

Other in vivo analyses (other than genetic in the narrow sense):

Subcellular localization: mostly cytoplasmic, some nuclear (see e.g. van Bergen en Henegouwen et al., 1987; Berbers et al., 1988; Akner et al., 1992; Perdew et al., 1993). Slightly increased nuclear accumulation upon heat stress (van Bergen en Henegouwen et al., 1987; Berbers et al., 1988) and hypoxic shock (Katschinski et al., 2002). Associated with lysosomal membranes (Agarraberes and Dice, 2001; Bandyopadhyay et al., 2008; see also Luo et al., 2013; Gong et al., 2018). It binds the nuclear envelope of permeabilized cells (Schlatter et al., 2002). A GFP fusion gives same pattern and shows an increase in periplasmic and intranuclear staining after heat-shock (Langer et al., 2003). Evidence for Hsp90 at the cell surface (Ferrarinì et al., 1992; see also below, paragraph "Unusual stuff"). Golgi targeting upon LPS stimulation (Triantafillou and Triantafillou, 2004). Shift to more nuclear localization is developmentally regulated in Toxoplasma gondii (Echeverría et al., 2005). Age- and estradiol-dependent shift to more cytoplasmic localization in fish (Rendell and Currie, 2005). Present in secreted exosomes (Hegmans et al., 2004; Clayton et al., 2005; Chen et al., 2006b; Yu et al., 2006; McCready et al., 2010; Lv et al., 2012; Takeuchi et al., 2015; Cruz et al., 2017; Ono et al., 2018; Saha et al., 2018) and on exosome membranes (Yang et al., 2014b) (however, see Jeppesen et al., 2019). Hsp90 can be found in mitochondria (intermembrane space and matrix), notably of tumor cells (Kang et al., 2007; see also Barksdale and Bijur, 2009), and possibly in budding yeast (Francis and Thorsness, 2011). Stress and pulmonary arterial hypertension promotes mitochondrial localization of Hsp90 in pulmonary arterial smooth muscle cells, thereby preserving mitochondrial functions and promoting diseased state (Boucherat et al., 2018). PDGF stimulation recruits Hsp90 to membrane ruffles and macropinosomes (Gao et al., 2007). Recruited to stress granules along with several co-chaperones (Pare et al., 2009). Becomes nuclear in quiescent budding yeast along with Sba1 and Ydj1 (Tapia and Morano, 2010), and in Aspergillus after heat stress (Lamoth et al., 2012). Helicobacter pylori infection leads to membrane recruitment of Hsp90β and association with Rac1 (Cha et al., 2010). A Hsp90-FKBP52-p23 complex forms an intranuclear perinuclear ring in undifferentiated neurons that redistributes during differentiation (Quintà et al., 2010); both differentiation and disassembly are triggered by FK506 (Quintà and Galigniana, 2012). Relocalizes to nucleus in cells infected with influenza (Naito et al., 2007) and HSV-1 (Zhong et al., 2014). Concentrated at neuromuscular junctions (Luo et al., 2008). Ecdysone or juvenile hormone induce nuclear localization in insect cells (Liu et al., 2013). Overexpression of E3 SUMO ligase PIAS1 induces nuclear localization in astrocytes (Soares et al., 2013). HSP90.1 and HSP90.3 accumulate in nucleus in Arabidopsis, and geldanamycin or brassinosteroid signaling reversed that (Samakovli et al., 2014). Associated with and required for integrity of centrosome (Lange et al., 2000; see also Wigley et al., 1999), possibly through Polo (see there). Hsp90α phosphorylated on T5/7 appears to form a ring at the neck of the primary cilium (Wang et al., 2015). Associated with secretory vesicles along with Aha1 and survivin at the leading edge of migrating cells (Ghosh et
Hsp90β along with Unc45a more nuclear in transformed breast epithelial cells (Eisa et al., 2019).

- by overexpression of mutants: interaction with ERα (Kang et al., 1994; Meng et al., 1996), GR (Cadepont et al., 1993; Kang et al., 1999).
- Antibody injections: reduces insulin-induced mitogenesis (Takata et al., 1997) and proteasome-mediated degradation of insulin receptor mutants (Imamura et al., 1998).
- Hsp90 added to medium stimulates neurite outgrowth (Ishimoto et al., 1998).
- Overexpressed Hsp90 with a NLS slightly inhibits GR function in vivo and DNA binding in vitro (Kang et al., 1999).
- Degradation of Hsp90 in budding yeast: both Hsp82 and Hsp90 from C. albicans are degraded to large C-terminal fragments upon shifting from fermentative to respiratory media (Panaretou et al., 1999).
- Hsp90 is cleaved upon treatment of cells with H2O2 (Pantano et al., 2003). Cleavage in tissue culture cells treated with mimosine or H2O2 (Panopoulos et al., 2005). Oxidative stress leads to cleavage of Hsp90β and degradation of Hsp90α, but only in tumor cells (Beck et al., 2009). Free radicals cleave Hsp90 isoforms at conserved site in ATPase domain in an ADP and ionic iron-dependent reaction (blocked by ATP and Hsp90 inhibitors) both in vivo and in vitro (Beck et al., 2012). Taxotere (docetaxel) induces ubiquitination and degradation (Murtagh et al., 2006). Hsp90 degradation accelerated in NOS-3/β-actin complex thus temporally limiting NOS-3 activity (Ji et al., 2007). Extracellular Hsp90α is a cleavage substrate of MMP-2 (Dean and Overall, 2007) and MMP-14 (Butler et al., 2008). UV induces Hsp90β cleavage by caspase-10, and cleavage mutants are protective (Chen et al., 2009a). Hsp90β is far more rapidly degraded by MMP-2 than Hsp90α (Song et al., 2010b). The diterpenoid andrographolide induces a ROS-dependent cleavage in the middle domain (Liu et al., 2014b). HDAC inhibitor SAHA also induces ROS and caspase-10 mediated cleavage (Park et al., 2015). The tricyclic pyrano-orthonaphthoquinone β-lapachone induces a NQO1- and ROS-dependent cleavage (Wu et al., 2016). Cleavage induced by proteasome inhibitors in leukemia cells through ROS and caspase 10 (Park et al., 2017a). Oxidative stress-induced cleavage product promotes co-aggregation with accumulating oxidized actin (Castro et al., 2019). Cold physical plasma induces ROS-mediated cleavage (Bekeschus et al., 2019).

- Overexpression and antibody injections in Xenopus oocytes: anti-Hsp90 (and anti-p23) activates HSF1, and anti-Hsp90, -Hip, -Hop, -p23, or anti-FKBP delay attenuation; attenuation accelerated by Hsp90 (and Hsp70, Hip, or Hop; delayed by immunophilins) overexpression (Ali et al., 1998; Bharadwaj et al., 1999).
- Overexpression of Hsp90 in NIH 3T3 cells retards cell cycle, blocks Hsf1 (Zhao et al., 2002) and TNFα-induced apoptosis by preventing cleavage of Bid (Zhao and Wang, 2004). Opposite result to the latter in U937 cells (Galea-Lauri et al., 1996b). Also opposite effects of Hsp90α overexpression on survival in HC11 versus SkBr3 cells (Perotti et al., 2008).
- Antisense oligos and constructs: inhibits proliferation and TNFα-induced apoptosis, and affects macrophage phenotype of monoblastoid U937 cells (Galea-Lauri et al., 1996a; Galea-Lauri et al., 1996b). In contrast, another study says that Hsp90α knock-down sensitzizes cells to TRAIL-induced apoptosis because of a failure to promote the recruitment of FLIPs and RIP to DISC (Panner et al., 2007). Effect on oxidative protection of proteasome (Conconi et al., 1998) and telomerase activity (Chang et al., 2002).
- CHIP overexpression displaces Hop and p23 from Hsp90, promotes ubiquitination of substrate and targets it to proteasome for degradation (Connell et al., 2001).
- Hsp90 facilitates nuclear export of 60S ribosomal subunits in Xenopus oocytes (Schlatter et al., 2002).
Role in disassembly of transcriptional complexes: Hsp90 and p23 are recruited to chromatin-bound glucocorticoid receptor (GR); promoter-tethered p23 and to varying extents Hsp90 inhibit adjacent GR, TR, NFkB, an AP-1 (Freeman and Yamamoto, 2002).

Associates genome-wide with chromatin in Drosophila, notably with a large fraction of promoters containing paused RNA polymerases; helps to maintain the elongation factor NELF-E and to enable proper inducibility of genes in response to environmental and physiological stimuli (Sawarkar et al., 2012).

Hsp90 ChIP-seq in BT474 cells shows strong overlap with NELF-A in promoters and gene bodies (Greer et al., 2015).

Hsp90 is recruited to activated ERα complexes and can be found at ERα binding sites on chromatin; it is required for activation and possibly acts as a scaffold or chaperone for the assembly of transactivation complexes (Bennesch et al., 2016).

Associates with hTERT promoter and required for its activity (Kim et al., 2008). Recruited to 12(S)-lipoxygenase promoter through Sp1 and required for activity (Hung et al., 2005). Recruited to a regulatory element of the MMP-13 promoter with inhibitory (Fan et al., 2009), or perhaps stimulatory (Boehm et al., 2007) effects. With BCL-6 at target promoters (Cerchietti et al., 2009). With AF9/MLLT3 at a target promoter (Lin and Hemenway, 2010). Heat further increases colocalization with actively transcribing HIV-1 provirus (Roesch et al., 2012). In Drosophila, associates genome-wide with chromatin (Sawarkar et al., 2012) and with Met at juvenile hormone response element (He et al., 2014).

Found in polyglutamine aggregates; Hsp90 overexpression reduces rate of aggregate formation and improves cell survival (Mitsui et al., 2002). Multiple chaperones including Hsp90 associate with polyglutamine proteins during aggregation (Walter et al., 2011).

Overexpression and underexpression (with siRNA) correlates with increased and decreased solubility and microtubule binding of tau protein (Dou et al., 2003; see also Dickey et al., 2007), respectively. Hsp90 complexes promoting folding (with p23) and degradation (in presence of Hsp90 inhibitor and/or with CHIP) compete with each other for phospho-tau folding versus degradation based on RNAi experiments (Dickey et al., 2007; see also Kundrat and Regan, 2010a). Knock-down of FKBP51 also dramatically reduces tau levels although FKBP51 can interact with tau in Hsp90-independent way and promote tau-Hsp90 interaction (Jinwal et al., 2010). See also pharmacological approach to tauopathies (Luo et al., 2007). Hsp90 and Hsp70 coordinate control tau clearance with Hsp90 promoting it (Thompson et al., 2012). FKBP51 with Hsp90 promotes accumulation of neurotoxic tau species and FKBP51 levels increase with AD progression (Blair et al., 2013). Decreasing Hsp90 levels or function impairs the foldase activity of NMNAT2 required to neutralize the proteotoxic burden of Tau (Ali et al., 2016; see comment by Shorter, 2017). RanBP9 levels correlate with Hsp90 levels in Tau complexes and sensitivity of Tau to Hsp90 inhibitors (Woo et al., 2017). Gets sequestered to tau aggregates in cells (Yu et al., 2019).

Acanthamoeba variants with lower levels of Hsp90 or wild-type treated with Hsp90 inhibitors are partially defective for phagocytosis of and killing pathogenic bacteria (Yan et al., 2004).

ATP depletion, like geldanamycin, triggers rapid dissociation from ErbB2 and degradation -> Hsp90 may function as ATP sensor and thereby modulate growth factor responsiveness (Peng et al., 2005).

Pharmacological and genetic (RNA interference) inhibition of Hsp90 in human tumor cells induces telomere shortening by promoting NOS-mediated production of oxygen radicals (Compton et al., 2006).

Hsp90 knock-down or inhibition interferes with processing to antigenic peptides; Hsp90α but not Hsp90β is associated with large precursor peptides (Kunisawa and Shastri, 2004).
2006). Hsp90 associates with N-terminally extended antigenic peptides and loading into MHC-I depends on Hsp90 function (Callahan et al., 2008). Hsp90 required for generation of a pool of crosspriming viral peptide (Lev et al., 2008). Hsp90α/β associates with some MHC class II antigens and is required for their presentation (Houlihan et al., 2009; see also Tsuji et al., 2012). Hsp90α required for antigen cross-presentation, possibly by promoting antigen translocation from endosomes to cytosol (Ichiyanagi et al., 2010; Imai et al., 2011). Hsp90 interacts with ovalbumin added as extracellular antigen, presumably acting as cytosolic translocator (Imai et al., 2011).

- Hsp90 knock-down and glucocorticoids disrupt T-cell receptor signaling complex containing also Lck, Fyn, and glucocorticoid receptor (Löwenberg et al., 2006).
- Hsp90 α required for antigen cross-presentation, possibly by promoting antigen translocation from endosomes to cytosol (Ichiyanagi et al., 2010; Imai et al., 2011).
- Hsp90 interacts with ovalbumin added as extracellular antigen, presumably acting as cytosolic translocator (Imai et al., 2011).
- FRAP analyses: intracellular mobility suggests bulk of Hsp90 is in a variety of complexes both with and without geldanamycin (Picard et al., 2006). Hsp90β overall mobility not affected by geldanamycin (Lev et al., 2008).
- Protects against amyloid β stress upon overexpression in cells (Veereshwarayya et al., 2006). Aβ reduces Hsp90 expression in cerebral endothelial cells and, possibly as a result, Hsp90 client levels (Chiu et al., 2011).
- Role in antigen presentation for extracellular Hsp90-peptide complexes: bind surface receptor, transit to early endosomes where precursor peptides can be processed and transferred to MHC class I (Kurotaki et al., 2007; Oura et al., 2011). Through an alternate route, proteins can be internalized and get to the cytosol through the ERAD pathway for refolding by Hsp90 (Giodini and Cresswell, 2008); inhibited by Hsp90 inhibitors (Lu et al., 2018).
- Hsp90α1 appears to be specifically required for myofibrillogenesis in zebra fish along with Unc-45b (Krone et al., 2003; Etard et al., 2007; Du et al., 2008; Hawkins et al., 2008), and this involves Smyd1b (Li et al., 2013a), and exogenous Hsp90α2 can only partially rescue (Du et al., 2008; Hawkins et al., 2008). The Z line of striated muscle may serve as a highly dynamic reservoir for Hsp90 (and Unc-45b) (Etard et al., 2008). Hsp90 may be important for proteins other than myosin in myofibrillogenesis (Codina et al., 2010). Complementation of Hsp90α1 knock-down with point mutants abolishing ATP binding or affecting putative PTM sites interfere with thick filament organization (He et al., 2015). In C. elegans, Hsp90 associates dynamically with I and M-bands (Gaiser et al., 2011). Smyd2-methylated Hsp90 associates with and stabilizes the I-band in skeletal (Donlin et al., 2012) and cardiac muscle (Voelkel et al., 2013). Hsp90 translocates to titin springs in myofibrillar myopathy (Unger et al., 2017).
- Inhibition of Hsp90 in cells by designed TPR modules that bind with higher affinity and specificity (Cortajarena et al., 2008).
- Hsp90α knock-down or inhibition compromises VDR signaling (Angelo et al., 2008).
- p23/Sba1 expression protects yeast and mammalian cells against Hsp90 inhibitors (Forafonov et al., 2008).
- Use of split Renilla luciferase assay to track p23/Hsp90 interaction in cells and mice, minus and plus Hsp90 inhibitors (Chan et al., 2008). Split firefly luciferase for Hsp90-RAR1/SGT1 interactions in plants (Chen et al., 2008a). Split Renilla for Hsp90-PP5 interaction (Connarn et al., 2014).
- Hsp90 knock-down relieves inhibition of FKBP38 (e.g. catalytic activity and inhibitory interaction with Bcl-2) and thus promotes apoptosis (Edlich et al., 2007; Erdmann et al., 2007). FKBP38's role in promoting CFTR folding is also inhibited by Hsp90 (Banasavadi-Siddegowda et al., 2011).
Trafficking in Golgi is dependent on TPR1-mediated interaction with VAP-33 (Lotz et al., 2008).

Knock-down of both Hsc70 and Hsp72 inhibits Hsp90 and renders cells GA hypersensitive (Powers et al., 2008). Similarly, knock-down of Cdc37 reduces client kinases, but not Cdc37-independent clients, and increases sensitivity of cells to Hsp90 inhibitors (Smith et al., 2009) and ATP-competitive kinase inhibitors (Polier et al., 2013).

Knock down of Hsp90 inhibits HBV viral production (Liu et al., 2009c). Hsp90-dependent capsid assembly is promoted by ROS (Kim et al., 2015).

GA blocks intranuclear cyclical GR activation (Stavreva et al., 2009; Conway-Campbell et al., 2011).

Hsp90α inhibits caspase-2 activation directly or indirectly, possibly by interacting with the PIDDosome (Bouchier-Hayes et al., 2009).

Knock-down/inhibition of the Hsp90 kinase Wee1 sensitizes cancer cells to Hsp90 inhibitors (Mollapour et al., 2010).

Hsp90 inhibition or Hsp90α knock-down induce contraction of CAG repeats in a model gene (Mittelman et al., 2010).

Hsp90 inhibition or Hsp90 knock-down impair maturation of respiratory syncytial virus: Hsp90 associated with viral filaments and inclusion bodies (Radhakrishnan et al., 2010). Hsp90 along with Hop interacts with large polymerase protein (L) and is required for stability and function (Munday et al., 2015). Also impair HIV-1 replication (Vozzolo et al., 2010), including in hyperthermic cells (Roesch et al., 2012). Ritonavir-resistant HIV is hypersensitive to Hsp90 inhibition and Hsp90β overexpression can rescue their infectivity defect (Joshi and Stoddard, 2011). Hsp90β in HIV virions and CA mutants are hypersensitive to Hsp90 inhibition (Joshi et al., 2013). Ensures reactivation of HIV-1 from latency by maintaining IKK (Anderson et al., 2014) and p-TEFb (Pan et al., 2016). Inhibition prevents HIV rebound viremia (Joshi et al., 2016).

Hsp90α expression levels correlate with freezability of boar semen (Casas et al., 2010).

Overexpression in some cells favors switch from apoptosis to autophagocytosis (Jiang et al., 2011). Hsp90-Cdc37 is required for Ulk1-mediated mitophagy (Joo et al., 2011).

Analysis in yeast of effects of deleting p23 (Δsba1) or inhibiting Hsp90 pharmacologically on gene expression patterns (Echeverría et al., 2011b).

EBV: found in EBV particles (Johannsen et al., 2004) and required for EBNA1 accumulation and EBV transformation (Sun et al., 2010), and for nuclear localization of BALF5 and replication (Kawashima et al., 2013).

Knock-down or inhibition in Arabidopsis lenghtens circadian cycle (Kim et al., 2011) through defective entrainment via the morning loop (Davis et al., 2018).

Hsp90α KD or inhibitor sensitizes cells to DNA damage, since Hsp90α accumulates in repair foci and is required for their maintenance (Quanz et al., 2012). Hsp90α KD but not Hsp90β KD or inhibitors decreases TRAIL-induced nuclear apoptotic effects, possibly in part by reducing DNA-PK (Solier et al., 2012). Accumulation at DSBs not seen by others (Pennisi et al., 2017).

Hsp90 is required for embryonic stem cell pluripotency; the effect of a miRNA-mediated Hsp90 knock-down can be suppressed by Hsp90β overexpression (Bradley et al., 2012).
- KD or inhibition of Hsp90 in tobacco blocks early stages of replication of genomic RNA of Bamboo mosaic virus (Huang et al., 2012).
- Hsp90 knock-down in tobacco impairs replication of Red clover necrotic mosaic virus (RCNMV) (Ahsan et al., 2012).
- KD and overexpression of Hsp90β destabilizes and stabilizes Akt, respectively, in Caco-2 cells (Zhang et al., 2013c).
- Colocalizes with and is required for the assembly of the purinosome (French et al., 2013).
- Transduced nitrated Hsp90 kills neuronal cells (Franco et al., 2013).
- Low levels of Hsp90 correlate with longer survival in non-small cell lung cancer patients (Gallegos Ruiz et al., 2008). High levels correlate with poor prognosis in acute myeloid leukemia cells (Flandrin et al., 2008), and gastric cancer (Wang et al., 2013b).
- KD and overexpression of Hsp90α in ovarian cancer cell line inhibit proliferation/viability and increase resistance to cisplatin, respectively (Chu et al., 2013).
- GA and siRNA specifically against Hsp90β, not α, blocks cellular entry and replication of enterovirus 71; extracellular Hsp90β interacts with virions and added recombinant Hsp90 blocks cell entry; Hsp90 also required for stabilization of capsid protein and intracellular assembly (Tsou et al., 2013; Wang et al., 2013c).
- 17-AAG or Aha1-targeted morpholinos partially correct severe phenotype of a Gata3 mutation (Sheehan-Rooney et al., 2013).
- Hsp90 inhibitors and proteotoxic stress impair PPARγ-mediated adipogenic differentiation in culture (Nguyen et al., 2013).
- KD or pharmacological inhibition blocks HTLV-1 replication and function (Gao and Harhaj, 2013).
- Hsp90 protects Smad3 against CHIP-mediated degradation and thereby promotes TGFβ signaling (Shang et al., 2014). 17AAG or transfection of Hsp90 C-terminal truncation blocks nuclear localization and functions of Smads, possibly by affecting accumulation of importin-β1 (Lee et al., 2016a).
- Novobiocin blocks LPS-induced preconditioning of mice involving increase in Hsp90 and Hsp70 (Kaucsár et al., 2014).
- KD of Hsp90α impairs stability and secretion of precursor of asparaginyl endoproteptidase (Lin et al., 2014).
- Associated with Rift Valley Fever Virus virions and KD or inhibition impair early stages of replication/transcription (Nuss et al., 2014).
- KD or inhibition impair replication of Chikungunya virus (Das et al., 2014; Rathore et al., 2014).
- Coexpression of Hsp90α and UNC45b improves yield of soluble and functional unconventional myosin 15 in baculovirus system (Bird et al., 2014).
- Knock-down of either Hsp90α or Hsp90β reduces VEGF-induced activation of eNOS (Natarajan et al., 2015).
- Knock-down of either Hsp90α or Hsp90β reduces leukocyte migration (Ye et al., 2015).
- Hsp90 is recruited to MG132-induced aggresomes and required for proteasome remodeling and aggresome clearance (Nanduri et al., 2015).
- γ-synuclein protects Hsp90 clients Akt and mTOR against Hsp90 inhibitor-induced degradation (Liang et al., 2015).
- KD or inhibition impair, overexpression promotes replication of norovirus, at least in part through Hsp90 binding genomic RNA and stabilizing capsid protein VP1 (Vashist et al., 2015).
- Anticancer immune response induced by hyperthermic chemotherapy may be mediated by exposed Hsp90, since it can be blocked by antibodies and inhibitors (Zunino et al., 2015).
Hsf1 KD leads to disruption of Hsp90 complex and hyperacetylation (Ganguly et al., 2015).

Hsp90 siRNA or geldanamycin facilitate the liver metamorphosis of sea lamprey (Chung-Davidson et al., 2015).

Synthetic peptide derived from telomerase, which binds extracellular Hsp90, is delivered into cells by LRP1-mediated endocytosis and inhibits HCV replication by blocking Hsp90 interaction with FKBP8, and ROS production (Lee et al., 2016b); also inhibits HIV-1 reactivation through Hsp90 (Kim et al., 2016).

Hsp90α expression is reduced by ischemia/reperfusion through direct targeting of its mRNA by miR-1 (Zhu et al., 2016).

In C. albicans, Hsp90 depletion leads to increased nucleosome density at Hsf1 targets, possibly by affecting the SAGA complex (Leach et al., 2016).

Hsp90α is downregulated in differentiating mouse myoblasts and absence from adult muscle; maintaining expression interferes with differentiation (Echeverría et al., 2016).

Knock-down or pharmacological inhibition interferes with folding of enzymatic L component of the polymerases and replication of measles, VSV and Nipah viruses (Bloyet et al., 2016; see also Katoh et al., 2017).

Knock-down or pharmacological inhibition reduces replication of porcine circovirus type 2 (Liu et al., 2016).

Epichaperome disruption in certain types of cancers by Hsp90α/β KD or inhibition or KD of Hop or Aha1 renders cells more resistant to Hsp90 inhibitors (Rodina et al., 2016; see also Wang et al., 2016).

In rat model, 17DMAG or Hsp90β knockdown alleviate high-salt-diet-induced proteinuria and renal damage (Yan et al., 2016).

Inhibition or knock-down blocks rabies virus (Xu et al., 2016).

Knock-down of Hsp90 in cardiomyocytes in the rat impairs signaling crosstalk to fibroblasts and reduces collagen synthesis (Datta et al., 2017).

Hsp90 overexpression or inhibition affect human endothelial cells by affecting expression of VEGFRs and CD31 (Meng et al., 2017).

Tomato yellow leaf curl virus (TYLCV) infection alleviates effects of Hsp90 inhibition, induces Hsp90/Hsp70 aggregation with the viral protein CP, and is increased (!) when Hsp90 is inhibited (Moshe et al., 2016; Gorovits and Czosnek, 2017).

Inhibition or knockdown leads to CLL cell death (Guo et al., 2017a).

Hsp90 overexpression, and inhibition or knockdown boosts or repress deaminase and mutational activities of APOBEC-3B/-3C/-3G on HBD DNA in vitro and in vivo (Chen et al., 2017c).

HSP90AB1 (Hsp90β) KO in iPS-derived endodermal progenitor cells prevents hepatic differentiation, possibly because of increased turnover of HNF4A (Jing et al., 2017).
Conditional Tsc1 KO increases Hsp90 ATPase activity, overexpression reduces client levels (Woodford et al., 2017).
- KD of either both Hsp90 isoforms or SGT1 prevents recognition of centromere-specific histone H3 variant CENP-A by CUL4A-COPS8 E3 ligase, and CENP-A centromere deposition (Niikura et al., 2017).
- KD of Hsp90α in head and neck cancer cells, which overexpress it, reduces proliferation (Elzakra et al., 2017).
- Overexpression of Hsp90α S164A mutant impairs ATM/ATR signaling and DNA repair by homologous recombination (Cheng et al., 2017).
- KD of Hsp90α in mice and in human skeletal muscle myoblasts increases glucose tolerance and metabolism, respectively (Jing et al., 2018).
- Hsf1-dependent cell-to-cell variations of Hsp90 levels affect cell-specific resistance to fluconazole in S. cerevisiae (Zheng et al., 2018).
- Involved in chaperone-mediated autophagy (CMA) (Majeski and Dice, 2004; Kaushik and Cuervo, 2012), in part for oligomerization and stability of LAMP2A (Bandyopadhyay et al., 2008; Kabuta et al., 2008). Humanin promotes interaction of Hsp90 with substrates of CMA on the cytosolic side of lysosomes (Gong et al., 2018). For some substrates such as IL-1β, it may be independent of LAPM2A (Zhang et al., 2015b).
- Knock-down inhibits necroptosis and ferroptosis (Wu et al., 2019e).
- Diff. proteotoxic stressors differentially compromise Hsp90 "availability" in yeast; there are distinct Hsp90- and Hsp70-dependent pathways for the activation of the heat-shock response (HSR) (Alford and Brandman, 2018).
- KD of both isoforms in HEK293T cells reduces adhesion of calcium oxalate crystals (Manissorn et al., 2018).
- KD of Hsp90α but not β blocks HSV-1 VP16-activated transcription (Wang et al., 2018).
- High fever promotes adhesion and transmigration of T-lymphocytes by stimulating expression and interaction of Hsp90 with cytoplasmic tail of α4 integrin; this Hsp90 ATPase- and dimerization-independent activity, which can be obtained by constitutive Hsp90 overexpression, promotes α4 clustering and activation; disruption of this interaction impairs fever-induced T-cell action (Lin et al., 2019).
- Knock-down inhibits necroptosis and ferroptosis (Wu et al., 2019e).
- KD of Hsp90β inhibits, and overexpression of Hsp90β promotes growth of gastric cancer cells through interaction with LRP5 (Wang et al., 2019a).
- KD of either Hsp90α or Hsp90β destabilizes type III CD38 (Wu et al., 2019c).
- Hsp90-stimulated MMP9 activation, invasion and metastasis of NSCLC cells requires NAP1 Xiong et al., 2019b.
- Hsp90 inhibitor or KD increase mitochondrial metabolism in iPSC-derived cardiomyocytes (Ebert et al., 2019).
- Hsp90 is in baculovirus virions, is required for viral replication, and nuclear egress of virions, probably by somehow supporting the accumulation of the P40/ARPC1...
component of the Arp2/3 complex and nuclear actin polymerization (Li et al., 2019b; see also Lyupina et al., 2011).

- KD in *Arabidopsis* impairs jasmonate signaling (Zhang et al., 2015c).
- KD or inhibition alleviates effect of mutant huntingtin on REST resulting in a neuroprotective effect (Orozco-Díaz et al., 2019).
- KD, inhibition or antibodies added to medium of host cells reduces invasion and pathogenicity of *S. aureus* (Tribelli et al., 2019).
- KD of Hsp90β (not α) or inhibition and levels of wild-type p53 (and p53-mediated senescence) are anti-correlated in myoblasts and muscle, and Hsp90β promotes Mdm2-dependent degradation of wild-type p53 (He et al., 2019).
- Bacterial effectors of the HopBF1 family of kinases mimic a client to phosphorylate and to block Hsp90 in yeast, human cells and plants (Lopez et al., 2019).
- MAST1 is destabilized and cancer cells sensitized to cisplatin by Hsp90 KD or inhibition (Pan et al., 2019).
- KD or inhibition impair accumulation of bluetongue viral proteins and viral replication (Mohl and Roy, 2019).
- KD or inhibition impair processing and integrity of Rubella non-structural protein p150 and viral replication (Sakata et al., 2019).
- KD or inhibition impair cAMP-induced differentiation of Schwann cells (Han et al., 2019).
- Hsp90α-specific inhibition or CRISPR/Cas9 KD of Hsp90α, p23 or Cdc37 in the brain blocks opioid anti-nociception by preventing MAPK activation through the mu opioid receptor (Lei et al., 2019).

**Pharmacology:**

- *in vivo* analyses with *geldanamycin* (GA) and similar compounds, of Raf (Schulte et al., 1995; Schulte et al., 1996; Schulte et al., 1997; Stancato et al., 1997; Grammatikakis et al., 1999), glucocorticoid receptor (Whitesell and Cook, 1996; Czar et al., 1997), progesterone receptor (Smith et al., 1995), p53 mutants (Blagosklonny et al., 1995; Blagosklonny et al., 1996; see also Whitesell et al., 1998), pp60v-src (Whitesell et al., 1994), reverse transcriptase of duck hepatitis B virus (HBV) (Hu and Seeger, 1996; Hu et al., 1997), receptor tyrosine kinases (Sepp-Lorenzino et al., 1995). Reduction of hormone binding of androgen and estrogen (Segnitz and Gehring, 1997), glucocorticoid (Whitesell and Cook, 1996; Czar et al., 1997; Segnitz and Gehring, 1997), progesterone (Smith et al., 1995; Segnitz and Gehring, 1997) and mineralocorticoid (Bamberger et al., 1997) receptors, and Xenopus HSF (Ali et al., 1998). Glucocorticoid receptor levels reduced (Whitesell and Cook, 1996; Czar et al., 1997; Segnitz and Gehring, 1997). Glucocorticoid and progesterone receptors still in large complex with Hsp90 (Smith et al., 1995; Czar et al., 1997; Segnitz and Gehring, 1997). GA and herbimycin A induce degradation of Raf, receptor tyrosine kinases (Sepp-Lorenzino et al., 1995; Schulte et al., 1997), CFTR (Loo et al., 1998) through proteasome, and transfected nNOS (Bender et al., 1999). Blocks "assembly" of active telomerase (Holt et al., 1999). Macbecin I, the most potent in budding yeast, inhibits v-src and steroid receptors (Bohen, 1998) or only slightly (Fang et al., 1998). Blocks induction of ec dysone receptor in fly cells (Arbeitman and Hogness, 2000). Inhibits accumulation of the Src family kinases c-Src, Lck, and Lyn indicating a requirement for Hsp90 very early during their synthesis, before membrane association (Bijlmakers and Marsh, 2000). Within a few minutes, GA transiently activates PKR and MAPK (Donzé et al., 2001), c-Src (Koga et al., 2006) and the ensuing osteoclast differentiation (Yano et al., 2008), PI4KIIβ (Jung et al., 2011), Ire1α (Ota and Wang, 2012) and LKB1 (Gaude et al., 2012). GA/radicicol induce the differentiation of
Leishmania promastigotes into amastigotes (Wiesgigl and Clos, 2001). Drugs block morphogenetic movements during early development of ascidian and sea urchin embryos (Bishop et al., 2002). Induction of ER-stress response by GA is mediated by its effects on Grp94 (Marcu et al., 2002). GA transiently reduces translation (Marcu et al., 2002). GA and novobiocin inhibit Tom70-dependent import into mammalian mitochondria (Young et al., 2003; Fan et al., 2006; Barksdale and Bijur, 2009) and Toc64-dependent import into chloroplasts (Qbadou et al., 2006). GA blocks priming of HDAC3 by TRiC (Guenther et al., 2002). Induces complete loss of Processing Bodies (PBs) (Pare et al., 2009). Analyses of proteome- or kinome-wide changes in response to GA or other inhibitors (Haupt et al., 2012; Sharma et al., 2012; Wu et al., 2012b; Fierro-Monti et al., 2013a; Marrugal et al., 2019). GA induces a remodeling of the Hsp90 chaperone machine itself, in part by a combinatorial increase of both synthesis and degradation rates (Fierro-Monti et al., 2013a; Fierro-Monti et al., 2013b). GA also leads to increased levels of some oncoproteins and decrease of some tumor suppressors (Fierro-Monti et al., 2013a). Hsp90 inhibitor induced changes partially resemble those due to aneuploidy (Donnelly et al., 2014). GA-induced ubiquitinome (Quadroni et al., 2015). Meta-analysis of multiple pharmacoproteomic studies shows specific signatures (Echeverría and Picard, 2014). Proteome-wide analysis of synthesis and degradation rates upon Hsp90 inhibition indicates that more stably associated clients have lower thermal stability and that most clients may only require Hsp90 during synthesis (Savitski et al., 2018). Slightly promotes (!) Dengue virus replication (Srisutthisamphan et al., 2018). Inhibits foot-and-mouth disease virus replication through blocking capsid precursor processing (Newman et al., 2018). Comparative proteomic analysis of impact of different Hsp90 inhibitors shows specific signatures (Echeverria et al., 2019). And many more.....

- Hsp90 inhibitor induces dissociation of most Hsp90::kinase complexes, leading to degradation or aggregation dependent on client; interaction strength correlates poorly with subsequent degradation (Taipale et al., 2012).
- Specificity of standard Hsp90 inhibitors ("off-target effects"): the specificity of GA (Dikalov et al., 2002; McCollum et al., 2006; Clark et al., 2009; Samuni et al., 2010; Mlejnek and Dolezel, 2014) and radicicol (Ki et al., 2000; Tuganova et al., 2001; Besant et al., 2002b; Kato et al., 2007) may not be perfect, and some sources of GA contain a component with a different biological activity (Barzilay et al., 2004). At high concentrations, GA induces production of ROS and scavengers can prevent cytotoxicity (Clark et al., 2009; Samuni et al., 2010); it affects glutathione (GSH) levels (McCollum et al., 2006; Mlejnek and Dolezel, 2014). GA/17-AAG target VDAC (outer mitochondrial membrane) resulting in membrane depolarization of mitochondria and increased intracellular Ca^{2+} (Xie et al., 2011). Radicicol but not GA inhibits the archaeal DNA topoisomerase type IIIB (Gadelle et al., 2005) and binds its ATPase domain in equivalent manner (Corbett and Berger, 2006). Radicicol also inhibits mammalian branched-chain α-keto acid dehydrogenase kinase and at high concentrations yeast Sln1 histidine kinase (Besant et al., 2002a), and PDHKs (Tuganova et al., 2001; Kato et al., 2007). Dual inhibitors of Hsp90 and PDHK can be developed (Meng et al., 2014). Radicicol inhibits the GHKL ATPase Smchd1 (Chen et al., 2016).
- Blood-brain/testis barrier: 17-DMAG does not cross it (Glaze et al., 2005) whereas 17-AAG (Sha et al., 2017) and pochoxime (Grad et al., 2010) do.
- Budding yeast living on human Hsp90β is hypersensitive to Hsp90 inhibitors (Piper et al., 2003b).
- C. elegans Hsp90 does not bind GA, is not inhibited by it and does not confer GA resistance to mammalian cells (David et al., 2003). However, yeast with C. elegans Hsp90 is sensitive to high doses of GA (Piper et al., 2003b). Analysis of Hsp90s from other nematodes also suggest a complex mechanism of GA sensitivity (Him et al., 2009).
*Humicola fuscoatra* produces radicicol and has an Hsp90 with low binding affinity for it (Prodromou et al., 2009). *Streptomyces hygroscopicus* produces GA and its htpG does not bind it at all (Millson et al., 2011).

- Reports on synergistic effects of adding both radicicol and GA (Rosenhagen et al., 2001; Ratts et al., 2003).
- Role of CHIP or other E3 ligases in degradation of Hsp90 clients induced by Hsp90 inhibitors: GA stimulates association of CHIP with client (erbB2) and facilitates degradation (Xu et al., 2002a; Zhou et al., 2003); U-box mutant of CHIP blocks GA effect (Zhou et al., 2003), but GA still works in CHIP-negative cells (Xu et al., 2002a; Morishima et al., 2008), and CHIP is replaced by other E3 ligases such as parkin at least for some substrates (Morishima et al., 2008). GA-induced degradation of ERα (Fan et al., 2005) and Akt (Dickey et al., 2008) depend on CHIP, and, conversely, Akt regulates Hsp90/CHIP-mediated degradation of phospho-tau (Dickey et al., 2008). Cullin5-RING E3 ubiquitin ligase complex is recruited to Hsp90 for CHIP-independent degradation of some substrates (Ehrlich et al., 2009; see also Samant et al., 2014). CHIP can also be required to stabilize the Hsp90 client SENP3 in response to oxidative stress (Yan et al., 2010b). In yeast, this involves the ubiquitin ligases Ubr1 and Ubr2 (Nillegoda et al., 2010); levels of Hsc82 itself are increased in Δubr1 (Oh et al., 2017). In mammalian cells, Ubr1 contributes as well and its absence induces Hsp90 and renders cells more resistant to GA (Sultana et al., 2012). Inhibitor-induced OGT degradation is independent of CHIP (Zhang et al., 2012a). In addition to promoting the GA-induced degradation of kinases, Ubr1 promotes the degradation of GR and AR but not ERα (Sultana et al., 2013). KD of Cullin-5 or its partner RBX2 reduces inhibitor-induced degradation, delays co-chaperone release, and renders cells more resistant; moreover, Cullin-5 neddylation is required for client degradation, but not for loss of client activity (Samant et al., 2014). Global analysis shows that CHIP is primarily connected to Hsp70 system (Taipale et al., 2014). E3 ligase HECTD3 is recruited to Hsp90-Cdc37-kinase complexes (notably c-Raf) in the presence of Hsp90 inhibitors and contributes to client degradation (also: CUL5 but not CHIP) (Li et al., 2017c). CHIP mediates Hsp90 inhibitor-induced degradation of ICN1 (Notch1) (Wang et al., 2017d).

- *Plasmodium falciparum*: GA blocks primarily transition from Ring to trophozoite stages (Banumathy et al., 2003). Hsp90 inhibition effectively blocks growth of *P. berghei* and *Trypanosoma evansi* (Pallavi et al., 2010), *P. yoelii* (Mout et al., 2012) and *T. brucei* (Meyer and Shapiro, 2013) in a mouse model.
- GA induced degradation of Hsp90 clients suppressed by overexpression of CAIR-1/BAG-3 (Doong et al., 2003).
- Substrates that are NOT degraded in presence of Hsp90 inhibitors (or in Hsp90 mutants): list includes P2X7 (Adinolfi et al., 2003; Migita et al., 2016), PPARα (Sumanasekera et al., 2003a), IRF3 (Yang et al., 2006a), αGDI (Chen and Balch, 2006), cyclin B and Msps (Basto et al., 2007), CB2 cannabinoid receptor (He et al., 2007), Cup (Pisa et al., 2009), NDRG1 (Banz et al., 2009), p38 (Ota et al., 2010), a mutant form of TP1 {even stabilized} (Hrizo and Palladino, 2010), Piwi (Gangaraju et al., 2011), mutant glucocerebrosidase (Lu et al., 2011; Yang et al., 2014a; Yang et al., 2015a), CLC-1 (Peng et al., 2016b), GLT-1 (Sha et al., 2017).
- GA stabilizes Hsp90 degradation substrates (Gusarova et al., 2001; McClellan et al., 2005; Hrizo and Palladino, 2010; Hahn et al., 2011; Sha et al., 2017).
- GA selectively targets tumor cells because of a 100-fold higher affinity of their Hsp90 complexes (Kamal et al., 2003). Contradicted in a more recent study that shows equal time-dependent binding of GA to Hsp90 from different sources; GA binding occurs in two steps with a µM Kd for the initial encounter complex to a nM Kd for the tight complex after 24 hours (Gooljarsingh et al., 2006). Along the same lines, though, as Kamal et al.,
Hsp90 in extract from Alzheimer disease brain has 1000-fold higher binding affinity for Hsp90 inhibitor (Dickey et al., 2007), but lower levels (Thompson et al., 2012). Systems biology analysis of such differences shows effects on critical clients (Vali et al., 2010). Normal blood cells have few-fold higher affinity for PU-H71 than leukemia cells and this correlates with killing potential of the inhibitor (Moulick et al., 2011). Increased sumoylation of Hsp90 in transformed cells may explain both increased ATPase and affinity for inhibitors (Mollapour et al., 2014). Hyperactivated signaling pathways in AML cells renders them more sensitive and vulnerable to Hsp90 inhibition; sensitivity correlates with gradual activation (and addiction) (Zong et al., 2015). Cancer types with epichaperome (integrated chaperome units) are more sensitive to Hsp90 inhibition than those with insular chaperomes (e.g. Hsp90 chaperome), and PU-H71 pulls out a different set of chaperome complexes; epichaperome, not Hsp90 abundance correlates with Hsp90 inhibitor sensitivity (Rodina et al., 2016; see also Wang et al., 2016c; Joshi et al., 2018; see also Pillarsetty et al., 2019). Hsp90 inhibitor sensitivity is determined by equilibrium between cellular quiescence and activity, and can be pushed towards less sensitivity in oncogenically transformed cells and more sensitivity in normal cells (Echeverria et al., 2019).

- Tissue-specific effects of GA on Zebra fish development (Lele et al., 1999). Selective sensitizing effects on mutant phenotypes of inhibition with GA or isoform-specific morpholinos (Pei et al., 2007; Yeyati et al., 2007; Pei and Feldman, 2009).
- GA and RNAi against Hsp90 block replication of alphaherpesvirus Flock House virus (Kampmueller and Miller, 2005). GA blocks replication of HSV-1 and cytoplasmic relocalization of its DNA polymerase (Burch and Weller, 2005; see also Zhong et al., 2014; Wang et al., 2018). GA inhibits replication of hepatitis C virus, possibly by disrupting Hsp90-FKBP8-NS5A complex (Okamoto et al., 2006); Hsp90 KD also decreases HCV replication (Braga et al., 2017). Also destabilizes core protein and its toxic effects expressed in yeast (Kubota et al., 2012). GA blocks replication of RNA viruses of the picornavirus family (poliovirus, rhinovirus, coxsackievirus) by blocking folding and maturation of the capsid precursor protein P1 (Geller et al., 2007); see also impact of Hsp90 inhibition on balanced evolution of P1 protein stability and aggregation (Geller et al., 2018). GA blocks replication of hepatitis E virus, potentially by blocking the transport of capsid protein (Shim et al., 2011; see also Seo et al., 2018). Also of HBV by affecting capsid formation (Shim et al., 2011; see also Seo et al., 2018). Inhibits infectivity but not replication of Japanese encephalitis virus (Hung et al., 2011; see also Wang et al., 2017b). GA and siRNA specifically against Hsp90β blocks cellular entry and replication of enterovirus 71 (Tsou et al., 2013). Inhibitors block paramyxoviruses such as mumps and measles (Katoh et al., 2017).
- Peptidomimetic inhibitor shepherdin binds ATP pocket and when introduced into cells as fusion with carrier proteins inhibits Hsp90 functions (Plescia et al., 2005).
- GA or SGT1 knock-down blocks formation of inflamasome and NLR-mediated gene activation and gout (Mayor et al., 2007; see also Piippo et al., 2018).
- Small-cell lung cancer cells, unlike many other cancer types, go into apoptosis upon inhibition of Hsp90; protective effect of Hsp90 depends on Akt and blocking Apaf-1 (Rodina et al., 2007; see comments in Workman and Powers, 2007). See also effect of inhibitors on non-small cell lung cancer (NSCLC) cell lines (Gallegos Ruiz et al., 2008). KRAS mutations predict increased Hsp90 inhibitor sensitivity of NSCLC (Sos et al., 2009).
- Pharmacoproteomics with anaplastic large cell lymphoma cells (Schumacher et al., 2007).
GA does not reach mitochondrial Hsp90 isoforms (Kang et al., 2007).
Hsp90 inhibitors reduce turnover of mitochondrial proteins pointing to a role of Hsp90 and the proteasome in degradation of mitochondrial proteins (Margineantu et al., 2007).
Discovery of novel Hsp90 inhibitors, the natural triterpenoids celastrol and gedunin, by chemical genomics (Hieronymus et al., 2006; Lamb et al., 2006).
Celastrol disrupts interaction with Cdc37 and function without blocking ATP binding (Zhang et al., 2008b; Zhang et al., 2009). Celastrol acts through C-terminal domain of Hsp90 to disrupt interaction with Cdc37 allosterically (Zhang et al., 2009). Also binds directly to p23 and disrupts complexes (Chadli et al., 2010). Effects on transcription factors (Zhang et al., 2010b) or not at all (Olesen et al., 2015). Celastrol induces oligomerization, possibly through C-terminal domain, and yet has no effect on anti-aggregation activity or interaction with TPR co-chaperone (Zanphorlin et al., 2014). Modelling and mutagenesis indicates that residues at dimer interface between middle and C-terminal domains may be involved (also required for Cdc37 binding) (Peng et al., 2016a).
Small-molecule inhibitor disrupts Cdc37 binding and specifically affects Cdc37-Hsp90 substrates by binding to the interface next to ATP binding pocket (Wang et al., 2019b).
Male contraceptive agent gamendazole behaves like Hsp90 inhibitor but is not competed by GA or novobiocin (Tash et al., 2008). The specific Hsp90 inhibitor pochoxime A partially phenocopies an hsp90α mutation in the mouse resulting in reduced testis size (Grad et al., 2010).
The withanolide Tubocapsenolid A leads to thiol oxidation and aggregation of Hsp90 (Chen et al., 2008b).
Acute myeloid leukemia cells are more sensitive to 17-AAG than normal CD34-positive cells (Flandrin et al., 2008).
Degradation of B-Raf mutant V600E upon treatment with Hsp90 inhibitors depends also on induction of oxidative stress (e.g. by 17-AAG) (Fukuyo et al., 2008).
GA blocks development of Dictyostelium beyond mound stage (Sawarkar et al., 2008).
Hsp90 inhibitors unveil a prodeath role of Hsp90 in ER stress induced death of calcineurin-defective yeast cells (Dudgeon et al., 2008).
Inhibitors prevent γ-tubulin from being recruited to overduplicated centrosomes (Prosser et al., 2009).
Potential of combination therapies for treating fungal diseases (Cowen et al., 2009; Singh et al., 2009) and preventing endocrine resistance in breast cancer (Whitesell et al., 2014); also in dermatophyte Trichophyton rubrum (Jacob et al., 2015).
Induction of apoptosis by 17-DMAG in a variety of cell lines depends on p53 (Ayraud et al., 2009). Cancer cells with mutant p53 are more sensitive to Hsp90 inhibitors or HDAC inhibitors than cells with wt p53 (Li et al., 2011a; Li et al., 2011b). In irradiated T-cells, Hsp90 stabilizes induced p53 and inhibitors protect cells from apoptosis (Fukumoto and Kiang, 2011).
Inhibitor screens to block interaction between Hop and Hsp90 (Yi et al., 2009). Small molecules (Yi and Regan, 2008) and modified TPR modules (Cortajarena et al., 2008) block it in vitro and in vivo leading to degradation of Hsp90 substrates. Compound that blocks interaction between Hop and Hsp90 but does not induce Hsp70 (Pimienta et al., 2011).
Tamoxifen (OHT) binds at or near the ATP binding pocket and stimulates ATPase (Zhao et al., 2010).
GA disrupts P-bodies (Pare et al., 2009; Suzuki et al., 2009; Johnston et al., 2010).
Hsp90 inhibition or Hsp90α knock-down induces contraction of CAG repeats in a model gene (Mittelman et al., 2010).
Inhibitor occupancy is a better predictor of client protein degradation (pharmacodynamics) and tumor growth inhibition than plasma or tumor pharmacokinetics (Tillotson et al., 2010).

Cell-permeable hybrid TPR peptide specifically inhibits interaction with Hop and affects Hsp90 clients and cell growth of cancer cells (Horibe et al., 2011; Horibe et al., 2012), in particular in the presence of an Hsp70-targeted peptide (Horibe et al., 2014). Short peptides which bind and block Hsp90 through MEEVD region (Buckton et al., 2016).

Cyclic lipopeptide antibiotics block chaperone function but not ATPase of htpG, possibly by increasing surface hydrophobicity and oligomerization of the N-terminal domain (Minagawa et al., 2011).

Cell-permeable hybrid TPR peptide specifically inhibits interaction with Hop and affects Hsp90 clients and cell growth of cancer cells (Horibe et al., 2011; Horibe et al., 2012), in particular in the presence of an Hsp70-targeted peptide (Horibe et al., 2014). Short peptides which bind and block Hsp90 through MEEVD region (Buckton et al., 2016).

Peptides from Cdc37 to disrupt interaction (D’Annessa et al., 2020).

Hsp90 or HDAC6 inhibition augments the activity of T-regulatory cells (Teg) (de Zoeten et al., 2011). It also protects islet cells against glucocorticoid toxicity (Zhu et al., 2020).

Purine-based inhibitors block growth of filarial worm *Brugia pahangi* and can be selective for pathogen Hsp90 (Taldone et al., 2010). Other types of inhibitors work, too (Gillan et al., 2014).

Gene expression profiling of mammalian cells (Maloney et al., 2007) and budding yeast (Echeverría et al., 2011b) treated with Hsp90 inhibitors. In yeast, radicicol induces a stress response through the Msn2/Msn4 pathway (Echeverría et al., 2011b). Network analysis of changes in lung cancer cells reveals ErbB as a key target pathway (Pham et al., 2011).

Novel inhibitor that blocks FKBP52-stimulated AR function by preventing hormone-induced dissociation of the AR-Hsp90-FKB52 complex (De Leon et al., 2011).

In silico systems biology analysis of effects of Hsp90 inhibition on protein homeostasis (Proctor and Lorimer, 2011).

Aneuploid cells are more sensitive to 17-AAG than euploid cells (Tang et al., 2011). And conversely, pharmacological, heat-induced or genetic inhibition of Hsp90 in yeast induces aneuploidy fueling rapid adaptation (Chen et al., 2012a).

Hsp90 inhibition transiently releases paused RNA polymerases and thus results in gene activation (Sawarkar et al., 2012).

A peptide matching the middle domain can block the interaction with LPS and its signaling, and in a cell-permeable form affects clients (Wu et al., 2012a).

GA induces degradation of client PCNA and Hsp90 in extracts (Wang et al., 2010).

Co-chaperones are usually not degraded upon treatment with Hsp90 inhibitors, but their may be exceptions, for example in endothelial cells (Zhang et al., 2012a).

PU-H71 blocks *Plasmodium falciparum* and synergizes with chloroquine (Shahinas et al., 2013).

Species-selective inhibitors: Differential sensitivities of *Plasmodium falciparum* and human Hsp90 to Hsp90 inhibitors in yeast system (Wider et al., 2009). The alkaloid harmine is selective for *Plasmodium* Hsp90 and this depends on the pathogen-specific Arg98 (Shahinas et al., 2010; Shahinas et al., 2012). Purine-based inhibitors block growth of filarial worm *Brugia pahangi* and can be selective for pathogen Hsp90 (Taldone et al., 2010). Selective inhibitors for *T. brucei* Hsp90 (Pizarro et al., 2013). Specific inhibitors against *E. histolytica* and *Giardia* (Debnath et al., 2014). 7-azaindole derivatives are selective for *Plasmodium* Hsp90 (Wang et al., 2014a). Aminoalcohol-carbazoles that bind Hsp90 are more likely to inhibit *Plasmodium falciparum* proliferation (Wang et al., 2016d).

Potentially Grp94-specific inhibitor (Duerfeldt et al., 2012).

Screen with split Renilla luciferase p23/Hsp90 interaction assay for new inhibitors, including isoform-selective compounds (Chan et al., 2012).
Hsp90 inhibitors block BRCA1-dependent DSB repair, and BRCA1-deficient cells are hypersensitive (Stecklein et al., 2012).

Protoporphyrin/hemin affects Hsp90 clients and may directly inhibit Hsp90 (Lee et al., 2012b; Lee et al., 2013).

Dimer-monomer shift as assay to distinguish mode of action of Hsp90 inhibitors (Cruz et al., 2013).

Inhibition affects the ILK-FAK pathway and impairs fibroblast migration and the fibrotic response (Radovanac et al., 2013).

Probe for fluorescence polarization assay allowing comprehensive analysis of paralog-selectivity and affinity of inhibitors; several with poor affinity for Grp94 and Trap1 (Taldone et al., 2013).

ATP acyl phosphate derivative as probe for paralog conformations and inhibitor binding (Nordin et al., 2015).

Several compounds with about 5-fold selectivity for Hsp90α over β, and selectivity for one or several Hsp90 paralogs (Patel et al., 2013). Compounds with over 1000x α/β-selectivity relative to Grp94 and Trap1 (Ernst et al., 2014).

Novel drug binding between N and M domains blocks interaction with TPR co-chaperones, induces degradation of GR, without inducing heat-shock response (McConnell et al., 2014).

Acute Hsp90 inhibition can rescue some rhodopsin mutants (Aguilà et al., 2014).

17-AAG inhibits growth of Entamoeba histolytica (Singh et al., 2014), but promotes encystation (Singh et al., 2015). New specific inhibitors against E. histolytica and Giardia (Debnath et al., 2014).

High-throughput screen based on luciferase refolding yields many new candidates (Davenport et al., 2014).

mTOR inhibitors block Hsf1 activation and thereby potentiate inhibitory effects of Hsp90 inhibitors (Acquaviva et al., 2014).

FITC-GA is not cell-permeable (Bozza et al., 2014).

Compounds that accelerate Hsp90 ATPase, promote interaction with GR LBD but reduce its activity (Zierer et al., 2014).

C-terminally targeted compounds such as novobiocin and silibilin induce the degradation of Cdc2 but not GR, which is released in mature form in the presence of glucocorticoids (Riebold et al., 2015). Novel compounds may block Hsp90 without inducing a heat-shock response (Wang and McAlpine, 2015c; Wang and McAlpine, 2015a; Wang and McAlpine, 2015b).

Overexpression in tomato protoplasts reduces cytosolic accumulation of some chloroplast precursor proteins suggesting a role in quality control (Tillmann et al., 2015).

Computational modeling and in silico screen for inhibitors against specific Hsp90-target combinations (Anighoro et al., 2015).

Goniothalamin enhances ATPase but inhibits chaperone activity in collaboration with Hsp70 system (Yokoyama et al., 2015).

Vibsanin B may be an Hsp90β-selective inhibitor (Ye et al., 2015).

Gambogic acid is Hsp90β-specific, not compatible with Hop and p23 binding, induces client degradation but not Hsp70 induction, and appears to bind middle domain (Yim et al., 2016). Obly binds htpG in presence of ATP (Yue et al., 2018).

C-terminal inhibitor KU675 displays some Hsp90α-selectivity (Liu et al., 2015).

Mild heat-shock and isothermal geldanamycin yield similar proteomic changes (Finka et al., 2015).

Capsaicin inhibits PR assembly in vitro and may be an inhibitor of the Hsp90 machine (at high concentrations) (Patwardhan et al., 2015).
Inhibition of c-Abl sensitizes cancer cells to Hsp90 inhibitors because of its impact on Aha1 (Dunn et al., 2015).

Allosteric activators of ATPase and their impact on co-chaperone and client interactions (Sattin et al., 2015), and on dynamic properties of the closed state (Vettoretti et al., 2016).

Repression of transcription elongation by HDAC inhibitors requires Hsp90, presumably through NELF; both HDAC inhibitors and geldanamycin inhibit the production of eRNAs. (Greer et al., 2015).

Hsp90 inhibition compromises temperature-dependent and auxin-stimulated growth in Arabidopsis, most likely by affecting TIR1 (Wang et al., 2016b); see also more direct evidence for interaction with TIR1 (Watanabe et al., 2016).

Kongensin A inhibits Hsp90 by a covalent attachment to C420, resulting in the release of Cdc37, downregulation of client kinases and inhibition of necroptosis (Li et al., 2016).

Consider combination therapies with Hsp90 inhibitors to target oncogene addiction (Mandato et al., 2016).

Renal cell carcinoma overexpress the Hsp90 regulatory kinase Mps1 resulting in higher affinity and intracellular accumulation of Hsp90 inhibitors (Woodford et al., 2016c).

High levels of FNIP1/2 increase Hsp90 drug binding and sensitize cancer cells to Hsp90 inhibitors (Woodford et al., 2016a).

PP5 overexpression or knock-down increases inhibitor binding to Hsp90 (Oberoi et al., 2016).

HER2 expression may be a biomarker for sensitivity to Hsp90 inhibitors in treated breast cancer patients (Jhaveri et al., 2016).

Calpain KD sensitizes cells to geldanamycins by affecting the levels of ABC transporters (Grieve et al., 2016).

Geldanamycins are both inhibitors and substrates of some ABC transporters such as Pgp and MRP1 (Huang et al., 2007; Pham et al., 2009).

Gyrase B inhibitors such as coumermycin A1 inhibit dimer formation through C-terminus (Vezzola et al., 2010; Cele et al., 2016).

Hsp90 inhibitors block Sendai virus-induced prion-like aggregation of MAVS (Hou et al., 2011) and of prion-like luminidependens in Arabidopsis (Chakrabortee et al., 2016b).

Some prion-like heritable traits induced by overexpression of intrinsically disordered proteins in yeast are lost upon inhibition of Hsp90 (Chakrabortee et al., 2016a; see comment by Tuite, 2016).

Some disparities between in vivo effects, IC50s, and in vitro affinities between N- and C-terminal inhibitors and effects of Hsp90α knock-down (Wang et al., 2017a).

1,4-naphthoquinone forms adducts on C412 and C564 of Hsp90 and disrupts complexes with Hsf1 (Abiko et al., 2017).

The kinase Ulk1, by phosphorylating Cdc37 on S339, compromises client recruitment, a Cdc37 C339E mutant sensitizes cells to Hsp90 inhibitors, and an Ulk1 knock-down renders them more resistant (Li et al., 2017a).
Single-cell proteomics with some GFP fusion proteins show bimodal effects of an Hsp90 inhibitor (Zimmer et al., 2017).

Toxicity of single-walled carbon nanotubes may in part be mediated by inhibiting Hsp90 function and can be suppressed by overexpression of Hsp90β (Ong et al., 2017).

DYRK1B mutants are more vulnerable to Hsp90 inhibition and display increased interaction with Cdc37 (Abu Jhaisha et al., 2017).

Pathogenic fungus Cryptococcus neoformans is hypersensitive to Hsp90 inhibitors at elevated temperature (Chatterjee and Tatu, 2017).

Hsp90 inhibitors have senolytic activity, i.e. preferentially kill senescent cells, possibly by inhibiting the PI3K/Akt pathway, and could be repurposed as anti-aging drugs (Fuhrmann-Stroissnigg et al., 2017).

Hsp90 inhibitor restricts influenza virus evolution (Phillips et al., 2017).

Compound that binds N-terminal domain at a transient interaction site with Aha1 prevents stimulation by Aha1 (Stiegler et al., 2017).

The tetrapeptide NFGK from bovine hemoglobin may affect eHsp90α levels by binding N-terminal domain (Wang et al., 2017c).

Highly Hsp90β-selective inhibitor affects certain clients more than others and does not induce Hsp90 expression (Khandelwal et al., 2018).

High levels of miR-21 correlate with resistance to Hsp90 inhibitors of cholangiocarcinoma, possibly mediated by targeting DnaJB5 expression (Lampis et al., 2018).

Hsp90 inhibition impairs chromosome segregation in budding yeast (Khurana et al., 2018).

Parkinson’s disease-related cellular phenotypes can be reverted with PU-H71 (Kishinevsky et al., 2018).

Hsp90 inhibitor sensitivity correlates with basal Hsf1 activity and inversely with magnitude of activation of Hsf1 (Pastorek et al., 2018).

The cyclic sesquiterpene zerumbone stimulates ATPase and inhibits Hsp90 function by covalently coupling to several cysteine residues (Nakamoto et al., 2018).

Hsp90 inhibitors block axon injury signaling (Karney-Grobe et al., 2018).

Bentropine mesylate removes inhibitory FKBP51 from GR-Hsp90 complex (Sabbagh et al., 2018).

GA destabilizes the capping enzyme and reduces levels of cytoplasmic capped RNAs (Trotman et al., 2018).

Hsp90 inhibition or heat shock induce the expression of LINE-1 and ALU transposable elements in samples of systemic lupus erythematosus patients (Kelly et al., 2018).

Transformation of NIH-3T3 cells with the oncogene Ras renders them hypersensitive to Hsp90 inhibitors; inhibitors affect a substantial portion of oncogenic program (Echeverria et al., 2019). Hsp90 inhibitor sensitivity is determined by equilibrium between cellular quiescence and activity, and can be pushed towards less sensitivity in oncogenically transformed cells and more sensitivity in normal cells (Echeverria et al., 2019).

Selection for Hsp90 inhibitor resistance yields cell clones with activated JAK-STAT pathway and sensitivity to combined inhibition of this pathway and Hsp90 (Mumin et al., 2019).

GA treatment leads to reduced levels of cohesin subunits and defective sister chromatid cohesion (Yang et al., 2018).

Similarly to heat shock, Hsp90 inhibition induces transient high SUMO2/3 conjugation (Liebelt et al., 2019).

Radicicol derivatives with high selectivity for C. albicans Hsp90 over human Hsp90 (Whitesell et al., 2019).
Didier Picard – 02/2020

- Hsp90 inhibitors extend lifespan in *C. elegans* through activation of Hsf1 (Janssens et al., 2019).
- Induction of nuclear localization of HSFA1 proteins in *Arabidopsis* is insufficient to induce robust transcriptional response (Yoshida et al., 2011).
- Novobiocin analog KU-32 stimulates partial N-terminal closure and ATPase activity, and antagonizes GA binding and effects (Chatterjee et al., 2019).
- Binds artemisinin at high concentrations, possibly through K58 (Hsp90β), resulting in disruption of Hsp90-iNOS complex (Wu et al., 2019a).
- Loss of tumor suppressor Tsc1, as in bladder cancer, reduces sensitivity and binding to Hsp90 inhibitors (Woodford et al., 2019).
- Chronic low dose Hsp90 inhibition increases MHC I expression and antigenicity of cancer cells whereas high dose treatment reduces it (Jaeger et al., 2019; see also comments in Srivastava and Callahan, 2019).
- Destabilizing effects of Hsp90 inhibitors can be counteracted for some clients by specific ligands, which can be exploited as a drug screening tool (Taipale et al., 2013; see also Cho et al., 2020).
- Hsp90 inhibitors promote T-cell-mediated anti-tumor responses (immunotherapy) (Mbofung et al., 2017).

Biochemistry:

- homodimer, α/α and β/β (Radanyi et al., 1989; Minami et al., 1991), some β monomer (Minami et al., 1991; see also Cortés-González et al., 2010). Evidence that some heterodimers exist as well (Perdew et al., 1993; Miao et al., 2008), but mass spec analysis reveals no α-β heterodimers (Garnier et al., 2001) and sepharose-immobilized Hsp90β pulls out only β (Tsaytler et al., 2009). Also evidence for higher oligomers of both isoforms (Nemoto and Sato, 1998). Oligomerization inhibited by ATP binding to C-terminal site (Garnier et al., 2002b). ATP, ADP, CTP and NAD inhibit oligomerization of Neurospora Hsp90 (Ouimet and Kapoor, 1999). Dimerization constant for wild-type yeast Hsp90 is 60 nM (Richter et al., 2001). Poor dimer formation of human Hsp90β can be mapped to two amino acid differences compared to α (Kobayakawa et al., 2008). Yeast Hsp90 isoforms readily form heterodimers both in vitro and in vivo (Girstmair et al., 2019), but this is disfavored in humans (Richter et al., 2008).
- forms higher oligomers at elevated temperature (Lanks, 1989; Minami et al., 1993; Yonehara et al., 1996); cut-off temperature is 50°C and oligomerization is primarily due to self-association of dimers; it is inhibited by ATP and GA and promoted by molybdate, vanadate and NP-40 (Chadli et al., 1999). Oligomerization correlates with activity in aggregation assay (Nemoto et al., 2001b). Also promoted by divalent cations, not inhibitable by GA (Garnier et al., 2002a). Mg2+ and heat induce similar oligomers, notably tetramers, hexamers and double hexamers, with the circular hexamer containing a 50 Å central chamber (Moullintraffort et al., 2010). N-terminally truncated human Hsp90α exists as dimers, tetramers and hexamers (Lee et al., 2011). Biochemical characterization of *Arabidopsis* Hsp90 isoforms 1 and 3 shows that higher oligomeric state of isoform 3 correlates with higher holdase and ATPase activities (Cha et al., 2013). Maximum stoichiometry of Aha1-Hsp90 interaction is 4 Aha1 per Hsp90 dimer, including in higher order oligomers, which have higher Aha1 affinity than Hsp90 dimer (Lepvrier et al., 2015a). In contrast, p23 has higher affinity for dimer and promotes a shift of the oligomer-dimer equilibrium towards dimer (Lepvrier et al., 2015b).
- Oxidative stress can lead to disulfide bond formation (Cumming et al., 2004). Dimerization is antiparallel through C-terminal domain and high temperature or ATP induce transition to O-ring shaped structure (Maruya et al., 1999).
- Phosphorylation: P-Ser (Lees-Miller and Anderson, 1989b), in vitro by CKII (Lees-Miller and Anderson, 1989b; Shi et al., 1994), and Hsp90α but not β by dsDNA-activated protein kinase (DNA-PK) on T5/T7 (Lees-Miller and Anderson, 1989a; see also Quanz et al., 2012; Solier et al., 2012; Park et al., 2017b). Hsp90 phosphorylation, restored by CKII, is essential for stimulation of HRI (Szsyszka et al., 1989), and correlates with release from the substrate protein αC1 (Zhao et al., 2001). In cells, phosphorylation of Hsp90 may trigger release of pp60v-src (Mimnaugh et al., 1995). Statins induce tyrosine phosphorylation of Hsp90 in endothelial cells (Brouet et al., 2001). Hsp90 is tyrosine phosphorylated in an inhibitory complex with the purinergic receptor P2X7, and GA reduces it and increases P2X7 activity (Adinolfi et al., 2003). Di-phosphorylated form is the most abundant (in pig brain) (Garnier et al., 2001). Capacitation of sperm induces tyrosine phosphorylation (Ecroyd et al., 2003). Hsp90α/β in AhR complexes have inhibitory (for assembly and AhR function) phosphorylations in charged domain (Ogiso et al., 2004). Ppt1 binds, specifically dephosphorylates Hsp90 and ameliorates function of several Hsp90 substrates in yeast (Wandinger et al., 2006). Substrate ofAkt (Barati et al., 2006). Phosphorylation of Hsp90α T90 by PKA promotes secretion (Lei et al., 2007; Wang et al., 2009b) and this may be directly reversed by PP5 (Wang et al., 2009b). T90 phosphorylation decreases ATP and client binding, and differentially affects co-chaperone binding (Wang et al., 2012). 5-fluorocytosine treatment of cells induces phosphorylation on S254 (Negroni et al., 2007). VEGF signaling leads to Y300 phosphorylation of VEGFR-2 associated Hsp90β by Src and this is essential for eNOS association with Hsp90 and activity (Duval et al., 2007) and stimulates association with Aha1 (Desjardins et al., 2012). Phosphorylation of S226 and S255 of human Hsp90β stimulates strong interaction with Apaf-1 and this is reduced in transformed cells; not controlled by PP5 in this case (Kurokawa et al., 2008). p23, C-terminally truncated by caspases, reduces Hsp90 phosphorylation (at S231 and S263 of Hsp90α) and activity, for example for telomerase, possibly by recruiting more PP5 and thus reducing Hsp90 phosphorylation (Woo et al., 2009). Swe1/Wee1 modulates Hsp90 activity by phosphorylation of Y24 of yeast Hsp82 (Y38 of human); this constitutes a signal for ubiquitination and nuclear export, and non-phosphorylatable mutants are defective for supporting some client proteins and for interaction with some co-chaperones (notably Aha1 and p23) (Mollapour et al., 2010, commented on by Mayer, 2010). Phosphorylation sites identified in phosphoproteome analysis of Leishmania (Morales et al., 2010). Casein kinase II (CK2) phosphorylates Hsp90 on T22 (in yeast), altering ATPase and chaperone function, reducing interaction with Aha1 and Cdc37, and affecting inhibitor sensitivity (Mollapour et al., 2011a; Mollapour et al., 2011b). Pnck overexpression leads to hyperphosphorylation of T89 (T90) and T616 of both Hsp90α and β and S391 of α (Deb et al., 2011). Ten sites identified in yeast Hsp90, two of which are Ppt1-regulated and some affect chaperone function (Soroka et al., 2012). Hsp90α is phosphorylated by DNA-dependent protein kinase (DNA-PK) (and other PIKKs) on T7 upon induction of DNA stress (Quanz et al., 2012). DNA-PK also phosphorylates Hsp90α in response to apoptotic signals and recruits it to nuclear apoptotic rings (Solier et al., 2012). Yes promotes phosphorylation of Y197, Y313 and Y627 (human Hsp90α) (Xu et al., 2012a; see also Desjardins et al., 2012). In humans, Y627 phosphorylation, instead of Hch1 interaction in yeast, impairs interaction with clients, impairs formation of closed state and corresponding co-chaperone interactions (Zuehlke et al., 2017). c-Src mediates LPS-induced phosphorylation of Y309/Y300 (Hsp90α/β) and increased function towards Hsp90 clients (Barabutis et al., 2013). Phosphorylation of serine just N-terminal of MEEVD reduces and favors binding to CHIP and HOP, respectively, tilting the balance between degradation and chaperoning; mimicked by point mutations (Muller et al., 2013). PKCγ phosphorylates T115 (would be T101 in yeast Hsp82), T425 and T603 of...
human Hsp90\(\alpha\); phosphorylation of the first two sites affects ATPase activity and of all three differentially affects co-chaperone binding, triggering the release of PKC\(\gamma\) itself (Lu et al., 2014). CK2-phosphorylated Hsp90-Cdc37 complexes are exquisitely sensitive to disruption by ADP (Olesen et al., 2015). CK2 phosphorylates Hsp90\(\beta\) on Ser 225/254 and promotes interaction with PXR (Kim et al., 2015b). Phosphorylation of Aha1 by c-Abl is essential to promote interaction with Hsp90 and chaperoning (Dunn et al., 2015). Yeast checkpoint kinase Mps1 phosphorylates T101, with T22 the only other P-site in the N-terminal domain, inhibiting ATPase activity, p23 binding, activating and repressing kinase and non-kinase clients, respectively; human Mps1 phosphorylates Hsp90\(\alpha\) at T115 (Woodford et al., 2016c). Cdc14 dephosphorylates T101 promoting inactivation of Mps1 and mitotic exit (Woodford et al., 2016c). PP5 overexpression or knock-down increases inhibitor binding to Hsp90 (Oberoi et al., 2016). ATM phosphorylates Hsp90\(\alpha\) on T5/T7 in response to ionizing radiation (Elaimy et al., 2016). Phosphorylation of Y197 by BCR signaling in Burkitt lymphoma cells is specifically essential for interaction with SYK (Walter et al., 2017). S365 is an Hsp90\(\beta\)-selective phosphorylation site; can be phosphorylated \textit{in vitro} by CK2: mutants have some effects on growth and client activity in yeast, and affect conformational dynamics and interaction with Cdc37 (Nguyen et al., 2017). T5/T7 phosphorylation of Hsp90\(\alpha\) by DNA-PK increases with age in some tissues, notably muscle, and triggers release of clients (Park et al., 2017b). MAPK1 of \textit{Leishmania donovani} phosphorylates Hsp90 and regulates its protein levels (Kaur et al., 2017). Hsp90\(\alpha\) S164 is a key target of Cdc7-Dbf4 for recovery from DNA replication stress and DNA repair by homologous recombination (Cheng et al., 2017). T5/T7 phosphorylation stimulated by low electric treatment of cells (Hasan et al., 2019). Testosterone stimulates T89 phosphorylation by PKA in AR-positive cells and promotes release of Hsp90 from AR (Dagar et al., 2019). Y313 phosphorylation (of human Hsp90\(\alpha\)) promotes asymmetric association with Aha1, and reduced Hop binding, through long-range conformational effects throughout Hsp90 (Xu et al., 2019). Bacterial HopBF1 specifically phosphorylates eukaryotic Hsp90 on the serine of the lid (e.g, S108 of human Hsp90\(\beta\)) that contacts the \(\beta\)-phosphate of ATP, resulting in ATPase inhibition (Lopez et al., 2019).

\*\textbf{Acetylation}: Acetylation sites mapped to K294 and K287 in Hsp90\(\alpha\) and \(\beta\), respectively (Scroggins et al., 2007). Seven different sites mapped in Hsp90\(\alpha\) by Bhalla and colleagues (Yang et al., 2008); and there are a number of other ones (Krämer et al., 2014). HDAC inhibitors induce hyperacetylation of Hsp90 and block binding to substrates (Yu et al., 2002; Nimmanapalli et al., 2003). HDAC inhibitor reduces binding to ATP sepharose (Nimmanapalli et al., 2003; Murphy et al., 2005). HDAC6 is the regulator (Bali et al., 2005; Kovacs et al., 2005) and its inhibition leads to substrate degradation (Bali et al., 2005; Fiskus et al., 2007), dissociation of p23, and compromised GR (Kovacs et al., 2005; see also Zhu et al., 2020) and ER\(\alpha\) (Fiskus et al., 2007) functions and assembly (Murphy et al., 2005) (reviewed in Krämer et al., 2014). \(\Delta\)hdac6 MEFs have hyperacetylated Hsp90 and compromised GR function (Zhang et al., 2008c). Mutants mimicking acetylation have reduced interactions with co-chaperones and clients but still support viability and src function in yeast (Scroggins et al., 2007). Inhibition of HDAC6 or HDAC10 leads to degradation of Hsp90 substrates VEGFR1 and VEGFR2 (Park et al., 2008). Acetylation-resistant mutant (Hsp90\(\alpha\) K294R) stimulates membrane ruffling (Gao et al., 2007). p300 is one of the acetylases (Yang et al., 2008). Different set of single acetylation-deficient mutants (K to R) show hardly any effects on ATP, co-chaperone and substrate binding whereas some of the acetylation-mimetics (K to Q) are modified (Yang et al., 2008). Acetylation correlates with GA binding, promotes secretion of Hsp90\(\alpha\), interaction with MMP2 and cell invasion (mimicked by some acetylation mutants) (Yang et al., 2008). HDAC1 can deacetylate Hsp90 in the nucleus (Zhou et al., 2008; see also Zhang et al., 2013a). 17-AAG reduces HDAC6 binding and leads to
hyperacetylation, and conversely, hyperacetylation increases 17-AAG binding (Rao et al., 2008). Response of androgen receptor is regulated by HDAC6-regulated Hsp90 acetylation (Ai et al., 2009). Dramatically reduced HDAC6 expression in JNK1-negative cells leads to lower Hsp90 levels and defective HIF-1α stabilization (Zhang et al., 2010a). Sites in Plasmodium falciparum Hsp90 are different from those in human but may also interfere with Aha1 and p23 binding (Pallavi et al., 2010). Yeast Hsc82 is acetylated on K27 and K270, and acetylation is regulated by Hda1 and Rpd3 (Robbins et al., 2012). Human Hsp90α on K191 (Mollapour et al., 2014). Acetylation of K27 and K271 (equivalent to human K294) of A. fumigatus Hsp90 compromises function (Lamothe et al., 2014). Promoted by Hsf1 knock-down (Ganguly et al., 2015). HDAC6-reversible Hsp90 acetylation affects interaction with MR and subcellular localization of apo-MR but not transcriptional response (unlike GR) (Jiménez-Canino et al., 2016). Deacetylation by SIRT2 triggers Hsp90 ubiquitination and degradation leading to reduced actin polymerization (Min et al., 2018). Tsc1 promotes acetylation of Hsp90α on K407/K419, which is essential for drug sensitivity (Woodford et al., 2019).

- **Nitrosylation**: Hsp90 becomes S-nitrosylated (Gao et al., 2005; Martínez-Ruiz et al., 2005; Zhang et al., 2005c), including htpG in M. tuberculosis exposed to NO (Rhee et al., 2005). S-nitrosylation on C597 (human Hsp90α) results in reduced ATPase and NOS stimulation (Martínez-Ruiz et al., 2005). This conserved cysteine acts as a switch point affecting N- and C-terminal association and therefore ATPase activity (Retzlaff et al., 2009; discussed in Scroggins and Neckers, 2009).

- **Nitrination of tyrosines**: several tyrosine residues can be nitrated of which Y33 or Y56 in Hsp90β are sufficient to inhibit ATPase and to display a dominant toxic gain-of-function; nitrated Hsp90 binds and activates P2X7 thereby eliciting apoptosis, for example in motoneurons (Franco et al., 2013). A fraction of Hsp90β with nitrated Y33 localizes to outer mitochondrial membrane and down-regulates mitochondrial membrane potential and therefore metabolic activity in a manner dependent on non-nitrated Hsp90 (Franco et al., 2015).

- **Methylation**: Human Hsp90α is methylated by SMYD2 on K209 and K615 (616 in mouse), which is inhibited by Hop, and K615 is demethylated by LSD1 (Abu-Farha et al., 2011). K616 methylation is not affected by KDM3A (Kasioulis et al., 2014). Hsp90β also methylated by Smyd2, on lysine equivalent to K607 in human (Donlin et al., 2012). Smyd2 may methylate human Hsp90β on K531 and K574 thereby promoting dimerization and interaction with Hop and Cdc37 (Hamamoto et al., 2014). Methylation of R345 and R386 of Hsp90α required to maintain Hsp90 activity in tumors with low NDRG2 (Ichikawa et al., 2020).

- **O-glycosylation (O-GlcNAc)** sites in middle domain (Overath et al., 2012; see also Frank et al., 2014).

- **Sumoylation**: K178 and K191 of yeast Hsp82 and human Hsp90α, respectively, promoting the asymmetric interaction with Aha1; sumoylated Hsp90 has higher affinity for inhibitors, which increase sumoylation, compete with Aha1, and displace ATP prior to lid closure (Mollapour et al., 2014). K559-sumoylated Hsp90 present in blood, and antibodies against it, correlates with certain BCR-driven diseases (Preuss et al., 2015). Sumoylation of K178C in vitro does not affect ATPase (Wolmarans et al., 2019).

- **Ubiquitination**: Long-term treatment of cells with the pH lowering drug hypericin induces monoubiquitination (primarily) but not degradation) of Hsp90, release of Cdc37, and degradation of clients (Blank et al., 2003). Taxotere (docetaxel) induces ubiquitination and degradation (Murtagh et al., 2006). CHIP can mediate polyubiquitination of Hsp90 in vitro (Morales and Perdew, 2007; Kundrat and Regan, 2010b; Kundrat and Regan, 2010a). Hectd1 polyubiquitinates Hsp90α via K63 linkages, which prevents its secretion
(Sarkar and Zohn, 2012). Human Hsp90α on K191 (Mollapour et al., 2014). Deacetylation by SIRT2 triggers its ubiquitination and degradation (Min et al., 2018).

- **Glycation**: by methylglyoxal on many residues across protein resulting in inhibition of activity (Nokin et al., 2016).

- **N-terminal ATP binding domain, ATPase cycle** (see also Hsp90 cycle):
  - binds ATP in presence of Ca^{2+} or Mn^{2+} (Csermely and Kahn, 1991).
  - ATPase activity in some species (e.g. Trypanosomes) (Nadeau et al., 1992; Nadeau et al., 1993; Nardai et al., 1996), maybe even GTPase (Nardai et al., 1996). Yeast Hsp82 and *E. coli* HtpG have ATPase activity, roughly like Hsp70; mutations in pocket destroy selectively ATP binding or hydrolysis, and abolish complementation *in vivo* (Obermann et al., 1998; Panaretou et al., 1998). A hydrolysis mutant can still bind p23 and has reduced affinity for Hop, but both binding and hydrolysis required for full luciferase refolding and assembly of mature PR complex (Grenert et al., 1999). ATP binding by both subunits but only ATP hydrolysis by one protomer are required for complementation in yeast (Mishra and Bolon, 2014).
  - low autophosphorylation activity (Csermely and Kahn, 1991; see also Park et al., 1998), blocked by novobiocin (Langer et al., 2002).
  - ATP induces conformational change (Csermely et al., 1993); contradicted by other authors (Shi et al., 1994; Jakob et al., 1996).
  - ATP binds with adenosine toward bottom of pocket (Grenert et al., 1997; Prodromou et al., 1997a).
  - higher affinity for ADP than ATP (Grenert et al., 1997; Prodromou et al., 1997a), but note that there is much more ATP in the cell than ADP (about 100x).
  - ATP and GA-binding domain (N-terminal 200 AA) (Grenert et al., 1997; Prodromou et al., 1997a; Stebbins et al., 1997). N-terminal domain alone only binds ATP but has low ATPase activity (Obermann et al., 1998; Weikl et al., 2000). "Lid" closure upon ATP binding promotes N-terminal dimerization and closure of a molecular clamp which in turn stimulates ATPase activity (Prodromou et al., 2000; Vaughan et al., 2009). More C-terminal sequences (N451) are required for commitment to ATP hydrolysis and even more for high level ATP hydrolysis (Weikl et al., 2000; see also Owen et al., 2002; Ratzke et al., 2012a). N-terminal dimerization required for ATPase allowing coupling of hydrolysis and opening-closing movements of Hsp90 (Richter et al., 2001). AA 8-24 of yeast Hsp82 are necessary for ATP hydrolysis, not binding; ∆16 can still stimulate ATPase of a wild-type subunit (Richter et al., 2002). γ-phosphate may "touch" middle domain (Sóti et al., 2002). Crystal structure and mutagenesis reveal a loop around AA 380 (yeast) that may contact the γ-phosphate (Meyer et al., 2003), and is released by interaction with Aha1 (Meyer et al., 2004). Middle domain required for trapping ATP and efficient ATPase, and N-terminal dimerization per se is not sufficient (Wegele et al., 2003). Conformationally coupled ATPase mechanism is common to yeast and human (Vaughan et al., 2009). R380 does not directly participate in catalysis, but helps to stabilize the proper conformation (Cunningham et al., 2012).
  - McLaughlin et al. find no evidence of N-terminal coupling or of a requirement for N-terminal dimerization for ATPase for human Hsp90 -> open ring model (McLaughlin et al., 2004).
  - Sti1 (yeast Hop) binds N-terminal domain, blocks access to ATP (but see also below), and displaces GA; antagonized by Cpr6 (Prodromou et al., 1999), which binds preferentially in presence of AMP-PNP (Johnson et al., 2007). If Hop is also
bound to Hsp70, it does not inhibit ATP binding (Hernández et al., 2002b). Cdc37 also blocks ATPase without displacing GA or nucleotides (Siligardi et al., 2002; Roe et al., 2004; Gaiser et al., 2010), but does not bind ATP-bound Hsp90 (Zhang et al., 2009; however, also see Olesen et al., 2015). TPR domain of Cpr6 can stimulate ATPase activity 2-fold (Panaretou et al., 2002). Sti1 blocks ATPase of yeast Hsp90 but not nucleotide binding, probably by blocking N-terminal dimerization of Hsp90 (Richter et al., 2003). Sti1 blocks early conformational changes (including lid closure) in ATPase cycle (Hessling et al., 2009). ATPase activity of human Hsp90 not blocked by Hop (McLaughlin et al., 2002). Sba1 inhibits ATPase (Panaretou et al., 2002; Cox and Miller III, 2004). p23 increases apparent affinity of human Hsp90 for AMP-PNP and blocks ATPase (McLaughlin et al., 2006).

- Stimulation by substrates (McLaughlin et al., 2002; Falsone et al., 2009; Motojima-Miyazaki et al., 2010; Hagn et al., 2011; Street et al., 2011). Opposite effect seen with the GR HBD under slightly different conditions (Lorenz et al., 2014).
- The even stronger stimulation by Aha1 and Hch1 (without an increase in affinity for ATP) is inhabitable by Sti1 and Sba1, but slightly stimulated by Cpr6 (Panaretou et al., 2002). At lower ratios, only Aha1 not Hch1 stimulates (Lotz et al., 2003; see also Horvat et al., 2014; Wolmarans et al., 2016). ATPase and stimulation by Aha1 inhibited by GCUNC-45 (Chadli et al., 2006). Aha1 remodels Hsp90 even in absence of nucleotide to promote N-terminal dimerization (Hessling et al., 2009). One Aha1 molecule can bridge the two Hsp90 subunits and stimulate the ATPase (Koulou et al., 2010; Retzlaff et al., 2010) either in cis or trans, potentially allowing a substrate molecule to be bound to the other subunit; although affinities are low, p23 and Sti1/Hop can form ternary complexes with Hsp90 and Aha1 (Retzlaff et al., 2010). See also detailed analysis of Hsp90-cochaperone complexes in the C. elegans system (Gaiser et al., 2010). E. histolytica contains only the C-terminal domain and yet it can stimulate Hsp90 from various species (Singh et al., 2014). Aha1 and Hch1 regulate Hsp90 function through catalytic loop but in vivo functions of Hch1 may not be linked to its ability to stimulate the ATPase (Horvat et al., 2014).
- NASP stimulates ATPase (Alekseev et al., 2005).
- ATP hydrolysis required for substrate release and its stimulation by p23 (Young and Hartl, 2000).
- nucleotide binding specificity: prefers adenosine nucleotides; NAD and diadenosine polyphosphate alarmones are specific for N-terminal ATP binding domain (Söti et al., 2003).
- Hsp90 multichaperone complexes from tumor cells have higher ATPase activity (Kamal et al., 2003). Systems biology analysis of such differences shows effects on critical clients (Vali et al., 2010).
- The lid both inhibits dimerization in the absence of ATP and promotes the ATPase together with N-terminus of other subunit after closure (Richter et al., 2006).
- weakly stimulated by a large excess of Tah1 (Millson et al., 2008; Eckert et al., 2010) and Drosophila Spag (Benbahouche et al., 2014), but repressed by a Pih1-Tah1 heterodimer (Eckert et al., 2010).
- in-depth comparison of conserved conformational changes in ATPase cycle (Richter et al., 2008). For lack of cooperativity, see also comments in Elnatan et al., 2017.
- intradomain and interdomain interactions stabilize active conformation (Cunningham et al., 2008).
- NudC inhibits ATPase (Zhu et al., 2010). NudCL2 as well (Yang et al., 2018).
- Enforced N-terminal dimerization stimulates ATPase for both human and yeast Hsp90 (human still weaker) and is viable in yeast suggesting that the large transitions between open and closed conformations may not be physiologically relevant (Pullen and Bolon, 2011).

- EM analysis shows that the TPR1 domain of a single Hop molecule can sterically block Hsp90 N-terminal dimerization by being situated between the Hsp90 monomers and interacting with the adjacent N-terminal/middle domains; nevertheless, the TPR1 domain remains available for Hsp70 (Southworth and Agard, 2011).

- there is a negative cooperativity for binding ATP to the two monomers; one monomer "only" required for activation of the other ATP-bound one (Ratzke et al., 2012a).

- in E. coli, ATPase activities of interacting htpG and DnaK are synergistic (Genest et al., 2015).

- ATPase activity is stimulated by crowding (using polymer crowders) by a mechanism different from that used by co-chaperones (Halpin et al., 2016).

- Confirmation by single-molecule analysis by SMACKS that N-terminal conformational dynamics are not coupled to ATP hydrolysis (Schmid et al., 2016) nor affected by inhibitors (Schmid et al., 2018).

- FKBP8 does not inhibit ATPase activity (Blundell et al., 2017).

- N-terminal domain can rotate by 180° relative to Hsp82-Sba1 structure; this is required for ATPase activity, suppressed by Aha1 and not Sba1 in the presence of nucleotide, depends on a minimal length of the charged linker and is required for only some clients in yeast (Daturpalli et al., 2017).

- htpG has a uniquely pH-dependent ATPase (higher at alkaline pH) because an electrostatic interaction between H255 and ATP blocks it in the open inactive conformation (Jin et al., 2017).

- The ATPase of cytosolic Hsp90s but not Grp94 and Trap1 is strongly inhibited by ADP; can be relieved by Aha1 in eukaryotes and DnaK in bacteria; specific residues contribute to stabilizing ATP versus ADP (Halpin and Street, 2017).

- ATP binding and ATPase are stimulated by RanBP9 (Woo et al., 2017).

- ATPase stimulated by Ids2, which is released upon glucose-stimulated phosphorylation by PKA in yeast (Chen et al., 2018b).

- Differential contributions of enthalpy and entropy to thermodynamic characteristics of nucleotide binding of Hsp90s from different species (Minari et al., 2019).

- Analysis with electron resonance techniques shows a more compact N-terminally closed conformation of ADP-bound (posthydrolysis, before opening) Hsp90 than the closed ATP-bound state; vanadate stabilizes this compact state (Giannoulis et al., 2020).

- Second C-terminal ATP binding domain: also binds ATP, apparently through novobiocin-binding domain (Marcu et al., 2000a; Garnier et al., 2002b; Sóti et al., 2002). Has lower affinity, only opens up when N-terminal site is occupied (even by GA → Sóti et al., 2003) except for certain ligands (Sóti et al., 2003); conversely, occupancy by GTP or novobiocin blocks binding to N-terminal site; cisplatin is a specific blocker of the C-terminal site (Sóti et al., 2002; Ishida et al., 2008), but induces a conformational change of the N-terminus (Ishida et al., 2008). Binding specificities of the two binding sites differ; GTP and UTP are specific for C-terminal site (Sóti et al., 2003).

- Neurospora Hsp80 binds CTP and NAD (Freitag et al., 1997)

- binds Ca^{2+} (Kang and Welch, 1991; Minami et al., 1993).
Hsp90 binding drugs: deoxyspergualin (Nadeau et al., 1994) and geldanamycin and relatives (Whitesell et al., 1994). Non-benzoquinone ansamycin antibiotic radicicol works like GA (Schulte et al., 1998; Sharma et al., 1998; Roe et al., 1999). Oxime derivative of radicicol with better pharmacology (Soga et al., 1999). Radicicol has higher affinity for Hsp90 than Grp94, but also binds Trap1 with lower affinity (Schulte et al., 1999; see also Felts et al., 2000). Cisplatin (CDDP) binds, induces conformational change, and inhibits chaperone activity (Itoh et al., 1999; Sóti et al., 2002); specific effects on steroid receptor ligand binding and Hsp90 association while other substrates are not affected (Rosenhagen et al., 2003). Coumarin antibiotics such as novobiocin bind Hsp90 and reduce levels of Hsp90 clients (Marcu et al., 2000a; Marcu et al., 2000b). GA derivative WX514 about 100-fold more specific for Hsp90 than Grp94 (Xu et al., 2001). Molybdate effects: antagonizes some GA effects; inhibits lck biogenesis and luciferase refolding while promoting salt-stable complexes (Hartson et al., 1999). Molybdate and vanadate bind Hsp90 directly (Soti et al., 1998). One TPR acceptor site (composed perhaps of two half-sites with lower affinity) per Hsp90 dimer (at least for FKBP52) (Silverstein et al., 1999). Unlike Hop, FKBP52 can also bind Hsp90 monomer (Ebomb et al., 2011; Ebong et al., 2016). Molybdate effects: antagonizes some GA effects; inhibits lck biogenesis and luciferase refolding while promoting salt-stable complexes (Hartson et al., 1999). Molybdate and vanadate bind Hsp90 directly (Soti et al., 1998). One TPR acceptor site (composed perhaps of two half-sites with lower affinity) per Hsp90 dimer (at least for FKBP52) (Silverstein et al., 1999). Unlike Hop, FKBP52 can also bind Hsp90 monomer (Ebomb et al., 2011; Ebong et al., 2016). May have low level proteolytic activities (Montel et al., 2000). Hsp90 promotes degradation of membrane-bound CYP2E1 by proteasome (Goasduff and Cederbaum, 2000), possibly by promoting membrane release and in ethanol-inhibited manner (Kitam et al., 2012). Also promotes degradation of mutant glucocerebrosidase (Lu et al., 2011; Yang et al., 2014a; Yang et al., 2015a) and oncoproteins ANP32C and ANP32D (Yuzefovsky et al., 2015). Hsp90 - yeast cyclophilin or Sti1 binding constants 14-57 nM; measured with Hsp90 on BiaCore chip (Mayr et al., 2000). Binding constant for Hop is 90 nM (Hernández et al., 2002b). Hsp90 - immunophilin binding constants (55 and 226 nM) and stoichiometry (1:1) (Pirkl and Buchner, 2001). At high immunophilin concentrations, two molecules of FKBP51 or 52 or a mixture thereof can bind per Hsp90 monomer (Ebomb et al., 2016). Two molecules of p23/Sba1 bind a dimer of Hsp90 and trap it in the ATP hydrolysis state (Richter et al., 2004; see also McLaughlin et al., 2006). Cocrystal clearly shows 2 molecules of Sba1 per Hsp90 dimer (Ali et al., 2006).
Facilitates nuclear export of 60S ribosomal subunits in an in vitro assay; ATP helps but is not absolutely required (Schlatter et al., 2002).

Strongly stimulates PP5 phosphatase activity (Ramsey and Chinkers, 2002) by releasing phosphatase domain from an inhibitory interaction with TPR domain (Yang et al., 2005). Additional contacts to M- and C-domains contribute (Haslbeck et al., 2015). MEEVD promotes folding of TPR domain suggesting a coupled folding-binding mechanism (Cliff et al., 2005). Hsp70 IEEVD motif has lower affinity, but stimulates PP5 activity more strongly than MEEVD (Connam et al., 2014).

Hsp90 - Cdc37 binding constants and stoichiometry (dimer : dimer) (Siligardi et al., 2002; Roe et al., 2004). With Cdk4 as client protein the stoichiometry is (Hsp90)2-Cdc37-kinase (Vaughan et al., 2006).

Substrate release stimulated by Tpr2 even without ATP (Brychzy et al., 2003).

Mutation of CK2 phosphorylation site of Cdc37 (S13) blocks its ability to stabilize client-Hsp90-Cdc37 complexes (Shao et al., 2003) and to recruit Hsp90 (Miyata and Nishida, 2005). Complexes contain S13-phosphorylated Cdc37 and localize to membrane ruffles in EGF-stimulated cells (Miyata and Nishida, 2007). P-S13 is specifically dephosphorylated by Hsp90-associated PP5/Ppt1 and cycles of phosphorylation appear important for client activation (Vaughan et al., 2008; Oberoi et al., 2016); dephosphorylation is required for client release (Oberoi et al., 2016).

Some Hsp90 associated with membrane preparations may bind iron (Kovár et al., 2004).

Drosophila Hsp83 identified in in vitro screen for membrane-deforming proteins (Uytterhoeven et al., 2015).

Plant Hsp90 is retained by beads with phosphatidic acid (Testerink et al., 2004). Hsp90 catalyzes trans-cis isomerization of geldanamycin (Lee et al., 2004a), or perhaps not (Onuoha et al., 2007).

Novobiocin induces distinct conformation of C-terminal domain, release of Hsp90 and Cdc37 but not other co-chaperones from substrate HRI; may induce “client-release” conformation (Yun et al., 2004). Inhibits binding of immunophilins, PP5 and Cdc37, chaperone activity and dimer formation (Allan et al., 2006).

Prevents early stages of aggregation of amyloid β peptide in ATPase-dependent fashion in vitro (Evans et al., 2006). Binds tau amyloid structures directly through hexapeptide motif (one Hsp90 homodimer binding about 50) inhibiting both assembly and disassembly (Schirmer et al., 2016). Promotes (!) formation of tau aggregates/fibrils in vitro; ATP-dependent, strongly boosted by Aha1, and blocked by Aha1 inhibitor (Shelton et al., 2017a).

Hydrogen-exchange mass spectrometry used to determine conformational dynamics, long-range interactions and effects of drugs and Cdc37 (Phillips et al., 2007), and orthosteric and allosteric effects of inhibitors in ATPase domain (Chandramohan et al., 2016).

Covalent immobilization of Hsp90 to aminopropyl silica via either end for determination of binding affinities and ATPase activity (Marszall et al., 2008a).

p23/Sba1 inhibits binding of GA to Hsp90 in vitro (Forafonov et al., 2008).

no Hsp90α/Hsp90β-isoform specific interactions with a number of cochaperones (p23, immunophilins, Hip, Hop, Hsp70) and substrates detected (Taherian et al., 2008).

Clients KEAP1, MET, Hsf1, HIF1α and RHOB1 preferentially interact with Hsp90α, some even with ATP-independent mutants, whereas drugs have a preference for Hsp90β (Prince et al., 2015) (for Hsf1, see also Kijima et al., 2018).

GCUNC45 (UNC45A) preferentially binds Hsp90β in vitro (5x), unlike p23 and Hop that have identical affinities (Chadli et al., 2008b). UNC45B apparently does not have isoform specificity (Taipale et al., 2014).
FKBP8 also displays Hsp90β specificity (Taipale et al., 2014) or perhaps not (Blundell et al., 2017).

Hsp90α bound to magnetic beads can fish out proper ligands and proteins (Marszall et al., 2008a; Marszall et al., 2008b).

Hsp90 cycle (see also above and under "Structure"): There are a series of conformational intermediates, some regulated by co-chaperones, and transitions are much slower than ATP hydrolysis (Hessling et al., 2009; comment in Neckers et al., 2009b). Single-molecule assays reveal very rapid stochastic and thermal conformational fluctuations, some of which are accelerated by ATP hydrolysis in a non-directional way (Mickler et al., 2009). Similar experiments reveal ATP-modulated dynamic opening and closing of the C-terminal domain that is anticorrelated with opening of the N-terminal domain (Ratzke et al., 2010). The opening is inhibited by Sti1. With previous results (Owen et al., 2002; Retzlaff et al., 2009), this suggests long-range communication between the N- and C-terminal domains. Mixed Sti/Hop-PPlase-Hsp90 complexes are a favored intermediate and the requirements for ATP and p23 to displace Sti/Hop give directionality to the process (Li et al., 2011c). Cpr6, but not Cpr7, promotes association of Aha1, which in turn drives Hsp90 to a partially closed state; together, Cpr6 and Aha1 displace Sti1, and p23 finally the release of Aha1 (Li et al., 2013b). Thermal fluctuations dominate the cycle and drive conformational changes and nucleotide binding (which on average happens multiple times before hydrolysis takes place); hence, conformational changes per se do not need ATP binding/hydrolysis (Ratzke et al., 2012a). Unlike the thermally driven conformational changes of eukaryotic Hsp90, the ratchet mechanism of the "cochaperone-independent" bacterial htpG is strongly nucleotide-controlled (Ratzke et al., 2012b). With eukaryotic Hsp90, co-chaperones such as p23 can impose directionality, with an asymmetric interaction of the two molecules of p23 with the Hsp90 homodimer and the specifics of the nucleotide turnover (Ratzke et al., 2014). A series of tyrosine phosphorylation on Cdc37 and Hsp90 drive ordered and directional assembly and disassembly, with Y197, Y313 and Y627 promoting dissociation of Cdc37, association of Aha1 and release of client, respectively, at least for human Hsp90α (Xu et al., 2012a). Phosphorylation of Cdc37 by Yes on Y298 leads to partial unfolding of its C-terminus unmasking an SH2-binding motif; this allows a high local concentration of Yes to target the Y197 switch and to promote the release of Cdc37 and specifically kinase substrates (Bachman et al., 2018). Effect of sumoylation (Mollapour et al., 2014). ATP hydrolysis in one protomer may be largely sufficient (Mishra and Bolon, 2014). GR HBD preferentially binds to the partially closed state and decelerates ATPase (Lorenz et al., 2014). Co-chaperones FNIP1/2 decelerate ATPase competing with Aha1, promoting client interaction (Woodford et al., 2016a; see also Sager et al., 2019). Single-molecule analyses of conformational motions reveal two-step mechanism for lid closure (Schulze et al., 2016). Stimulation of ATPase by Aha1 occurs in three steps, from a weak stimulation upon binding the middle domain to a N-terminal conformational rearrangement (Wolmarans et al., 2016). Confirmation by single-molecule analysis by SMACKS that N-terminal conformational dynamics are not coupled to ATP hydrolysis (Schmid et al., 2016). ATPase activity and in vivo activity in yeast do not correlate; what is important is a certain dwell time in the open state (Zierer et al., 2016). 3-color single-molecule FRET shows cooperativity of nucleotide binding of the two protomers and effects of Aha1 (Wortmann et al., 2017). Genetic and biochemical evidence that Sti1 promotes recruitment of client-loaded Hsp70 and client transfer through a conformational change of Hsp90 favoring N-terminal closure (Reidy et al., 2018). Conserved N-terminal NxNNWHW motif of Aha1/Hch1 affects affinity for nucleotides and stimulation of ATPase, and is required for in vivo functions in yeast (Mercier et al., 2019). Kinetic model based on FRET and NMR reveals Hsp90 is a "perfect" enzyme (Lee et al., 2019).
of TIMP2 increases affinity of ATP and inhibitors, but also inhibits ATPase (Baker-Williams et al., 2019).

- C. elegans Cdc37 binds both open and closed Hsp90 conformations, competes with Sti1 and p23, but can form ternary complexes with the phosphatase Php5 and Aha1; nucleotide-induced closing of the Hsp90 N-terminus disrupts the latter ternary complex (Gaiser et al., 2010).

- Purification of Hsp90 complexes with PU-H71-beads selectively enriches for oncoprotein-Hsp90 complexes and complexes with a subset of co-chaperones (Moulick et al., 2011). Other types of inhibitors may not trap anything (Barrott et al., 2013). A fluorescent probe specific for the cytosolic Hsp90 isoforms induces the internalization of eHsp90 into punctate structures specifically in transformed cells (Crowe et al., 2017). Labelling particularly high in aggressive and glycolytic breast tumors (Crouch et al., 2017).

- PU-H71 and GA trap Hsp90 in different N-terminally undimerized conformations, the former being preferentially able to bind the Y197-phosphorylated form as well as Cdc37 and some substrates (Beebe et al., 2013). PU-H71-beads pull out viral proteins, notably vFLIP, of Kaposi sarcoma-associated herpes virus (KSHV) (Nayar et al., 2013).

- A model substrate facilitates a repositioning of the N-terminal versus the middle domain through cross-monomer contacts with both (Street et al., 2012).

- Initiator methionine of both Hsp90α and Hsp90β is removed in cells (Beck et al., 2012).

- Although interaction of Cpr6 and Cpr7 with Hsp90 is normally ATP-dependent (see also Johnson et al., 2007), they interact independently of nucleotide with Hsp90 lacking the charged linker domain, and Cpr6 binds even wt Hsp90 in the absence of Cpr7 suggesting that Cpr7 mediates a conformational signal to relay the nucleotide status to the C-terminal TRP-binding domain (Zuehlke and Johnson, 2012).

- Hsp90 increases efficiency of targeting of tail-anchored proteins to chloroplasts in vitro (Kriechbaumer and Abell, 2012). Binds the chlorophyll biosynthetic intermediate Mg-protoporphyrin IX and mediates this stress signal; inhibited by tetrapyrrole accumulation (Kindgren et al., 2011; Kindgren et al., 2012).

- High affinity interaction of Cdc37 (and by extension Cdc37-Hsp90) inhibits ATP binding to Cdc37-dependent kinases and conversely, ATP-competitive kinase inhibitors prevent interaction with Cdc37-Hsp90 ("chaperone deprivation", primarily of nascent kinases) eventually resulting in degradation (Polier et al., 2013).

- Fission yeast S. pombe Hsp90 is able to refold thermally denatured luciferase in ATP-stimulated manner (Ishida et al., 2013).

- Detailed analysis of the interactions of Toc64, OM64 and AtTPR7 with the Hsp70s and Hsp90s in Arabidopsis shows differences (Schweiger et al., 2013; see also Panigrahi et al., 2013). OM64, whose TPR-mediated interaction with Hsp90 is inhibited by phosphorylation, may replace Tom70 in plants (Nickel et al., 2019).

- Specificity and selectivity of binding of CHIP, Hop, DnaJC7, FKBP51, and FKBP52 to C-terminus is influenced by affinity and possibly phosphorylation N-terminal of MEEVD (Assimon et al., 2015).

- C-terminal sumoylation of FKBP51 stimulates interaction with Hsp90 and repression of GR (Antunica-Noguerol et al., 2016).

- The epichaperome (integrated chaperome units) of certain types of cancers, as defined by what PU-H71 beads can pull down and migration in native gels, is due to chaperome network rewiring by c-Myc activity (Rodina et al., 2016).

- Hsp90 dissociates the chromatin remodeler RSC from DNA, but unlike p23 does not stimulate the completion of nucleosome remodeling; this biochemical activity is mirrored.
by continued RSC activity on chromatin and persistent DNase I hypersensitive sites in vivo with G170D at restrictive temperature (Echtenkamp et al., 2016).

- Yeast Hsp90 required in vivo for stability of a wide range of transcription factors and in vitro for their DNA binding (Gvozdenov et al., 2019a).
- Expression of NOD1 as fusion protein with SGT1 and coexpression with mammalian Hsp90α improves its expression in E. coli (Hong and Hahn, 2016).
- Allosteric regulation points modulate conformational dynamics and ATPase activity (Rehn et al., 2016).
- Protocol for producing human Hsp90β in bacteria (Radli et al., 2017).
- Hsp90 in yeast may be a substrate of the Nα-terminal acetylase NatA, and in its absence of the Arg/N-end rule degradation pathway (Oh et al., 2017).
- Hsp90 binds with high affinity (low nM range) to phospholipids with a preference for negatively charged and unsaturated ones; this reduces the fluidity and increases the transition temperature of membranes (Zhang et al., 2018a). Hsp90α penetrates deep into phospholipid membrane through its C-terminal domain, loses part of its α-helical core, and overexpression in E. coli improves membrane integrity upon heat treatment (Li et al., 2019a).
- Interaction with AIPL1 is stimulated by ATP and depends both on the FKBP-like and TPR domains of AIPL1 (Sacristan-Reviriego et al., 2017).
- p23 binds Hsp90α with 3x stronger affinity than Hsp90β and this is mediated by stronger dimer closure due to Hsp90α-specific middle domain (Synoradzki et al., 2018).
- Hsp90β preferentially binds Ni-NTA over Co-NTA and Ni²⁺ promotes release of HIF-1α (Asakawa et al., 2018).
- Evolutionary conserved W300 of yeast Hsp82 (and equivalent of human Hsp90β) functions as a conformational switch point relaying "information" about client binding from the middle to the N-terminal domains through a cation-π interaction with a neighboring lysine (Rutz et al., 2018).
- Upon binding lncRNA GALNT5 uARNA in gastric cancer, some clients such as AKT and IKK are further stabilized (Guo et al., 2018).
- Dimeric Hsp90, in open conformation, independently of ATP binding and hydrolysis, binds and deforms membranes through an amphipathic α-helix in the M domain; required for exosome release from multivesicular bodies (Lauwers et al., 2018).
- Hsp90-associated proteins are bound less tightly as pluripotent stem cells differentiate into dopaminergic neurons and this is counteracted by genetic or pharmacological stress (Kishinevsky et al., 2018).
- Hsp90 acts as a dynamic scaffold to bring together the PPlase of FKBP51 and Tau (Oroz et al., 2018).
- Single-molecule analyses reveal two dissociation rates for C-terminal dimerization, which is dependent on ATP (Tych et al., 2018).
- Single-molecule analyses show conformational dynamics on the time scale from seconds to hours (Ye et al., 2018).
- Interaction with Cns1 is through its TPR domain and not modulated by nucleotides (Schopf et al., 2019).
- Complex of Hsp90-Cns1-Hgh1, possibly with Cpr7, chaperones eEF2 (Schopf et al., 2019).
- Comprehensive comparison of the two S. cerevisiae isoforms: Hsp82 is more heat-stable than Hsc82, the latter has faster N-terminal closing and slightly higher ATPase activity, but co-chaperone binding is similar (Girstmair et al., 2019).
- Purification protocols for portions of recombinant human Hsp90α (Aluksanasuwan et al., 2020).
Structure:

- Crystal structure of N-terminal domain (AA 9-232) of human Hsp90α containing geldanamycin binding pocket (Stebbins et al., 1997) and AA 1-220 of yeast Hsp82 with adenine nucleotide binding site (Prodromou et al., 1997a; Prodromou et al., 1997b; revised view in Prodromou et al., 2000). Reviewed by Joachimiak, 1997. Structure of N-terminal domain of human Hsp90 with ATPγS (Obermann et al., 1998). Radicicol and geldanamycin co-crystals (Roe et al., 1999). Cocrystal with GA derivative (Jez et al., 2003). Comparative structures of N-terminal domain of human Hsp90α without ligand and with ATP and AMPPCP (Li et al., 2012b). N-terminal domain of rice Hsp90 (Raman and Suguna, 2015).

- By NMR, p53 core domain bound to Hsp90 is predominantly unstructured (Rüdiger et al., 2002). p53 DBD adopts loosened molten globule-like state upon interaction primarily with the Hsp90 N and M domains (Park et al., 2011a; see also Park et al., 2011b). Others find no evidence of conformational changes, p53 being bound in a native-like state based on shape and charge (Hagn et al., 2011). p53 DBD is positioned near middle domain (Quintana-Gallardo et al., 2019).

- Backbone assignments of ATPase domain by NMR (Sale et al., 2002); NMR shows conformational changes upon ligand binding (Dehner et al., 2003).

- Crystal structure of middle domain (AA 273-525) of yeast Hsp82 and model of combination with N-terminal domain (Meyer et al., 2003).

- Cocrystal of N-terminal domain with Cdc37 (Roe et al., 2004); solution structure analysis of complex (Zhang et al., 2004b). Crystal structure and NMR analysis of interacting domains (Sreeramulu et al., 2009). Detailed mutational analysis of interface by split renilla assay (Jiang et al., 2010). In C. elegans, the N- and C-terminal domains of Cdc37 interact with the M-domain of Hsp90 and kinases, respectively, promoting cooperative binding (Eckl et al., 2015).

- Cocrystal of middle domain with N-terminal domain of Aha1 (Meyer et al., 2004).

- Structure of C-terminal domain and model of entire htpG (Harris et al., 2004).

- N- through middle domains of htpG without nucleotide and with ADP (Huai et al., 2005; and comments in Bracher and Hartl, 2005). Shows (i) eukaryotic charged linker may be looped out from N-domain, (ii) nucleotide binding domain is made up from both N- and middle domains, (iii) ADP induces conformational changes.

- Structure of C-terminal TPR binding tail with Hop (Scheufler et al., 2000), PP5 (Cliff et al., 2005; Cliff et al., 2006; see also Haslbeck et al., 2015), CHIP (Zhang et al., 2005a; see also Quintana-Gallardo et al., 2019 and there for additional contacts with Hsp90 middle domain), and Plasmodium FKBP35 (Alag et al., 2009).

- Cryo-EM structure of p53 DBD-Hsp90-CHIP complex shows the client between Hsp90 and CHIP (Quintana-Gallardo et al., 2019).

- Full-length structure in ATP-bound mode and complex with p23/Sba1 shows intimate contacts in N-terminal domain with closed lid and absence of space for substrate between monomers in the "middle" (Ali et al., 2006).

- NMR analysis of p23-Hsp90 complex; no effect of ATPγS and interactions with middle domain of Hsp90 (Martinez-Yamout et al., 2006). H/D exchange NMR analysis of Aha1-Hsp90 complex (Dyson et al., 2008). Domain details of interaction of Aha1 with Hsp90 studied with NMR (Retzlaff et al., 2010; see also Oroz et al., 2019) and various other techniques (Koulov et al., 2010). Complex with p23 not fully symmetric and p23 also induces conformational changes in Hsp90 (Karagöz et al., 2011).

- EM analysis of Hsp90-Cdc37-Cdk4 complex shows asymmetric ring-like shape with Cdk4 bound to outside of one Hsp90 molecule and bridging N-terminal and middle
domains (Vaughan et al., 2006). More recent cryo-EM structure is different (Verba et al., 2016).

- Crystal structure and EM analysis of full-length htpG reveal several different conformations from open apo-protein to ADP- and ATP-bound protein (Shiau et al., 2006; discussed by Richter and Buchner, 2006). SAXS analysis of htpG structure in solution shows apo-htpG is more extended and AMPPNP-htpG is in equilibrium between open and closed states (Krukenberg et al., 2008); structural analysis of full-length eukaryotic apo-Hsp90 by SAXS and cryo-EM reveals an equilibrium between two open states (Bron et al., 2008) (see discussion in Jackson, 2008). Effects of osmolytes on these transitions (Street et al., 2010). Single particle analysis shows species-dependent equilibrium between extended apo state and more compact/closed nucleotide-favored states, with human being primarily in the open state even in presence of ATP (Southworth and Agard, 2008). HX-MS and fluorescence spectroscopy show progression of ATP-induced conformational changes through htpG that are rate limiting for ATP hydrolysis (Graf et al., 2009). Low pH drives htpG into a Grp94-like closed state that can be modeled with His mutants and has increased chaperone activity (Krukenberg et al., 2009). A model substrate induces partial closure of apo-Hsp90 and accelerates open/closed transition and ATP hydrolysis (Street et al., 2011).

- Comparison with Grp94 structure (Richter et al., 2007b).
- Modeling of C-terminal domain with inhibitors (Sgobba et al., 2008).
- Structure of Hsp90 in complex with CS domain of SGT1 and CHORD-I domain of RAR1 by NMR (Kadota et al., 2008) and with CS by crystal structure analysis (Zhang et al., 2008a). Structure of Hsp90-CS-CHORD ternary complex (Zhang et al., 2010c). CD shows a symmetric complex with 2:2:1 stoichiometry for Sgt1-Hsp90-Rar1 (Siligardi et al., 2017).
- Crystal structure of N-terminal domain of *Dictyostelium* Hsp90 (Sawarkar et al., 2008).
- Modelling of conformational dynamics of N-terminal domain (Colombo et al., 2008) and full-length dimer (Morra et al., 2009). Molecular dynamics simulations of apo and nucleotide-bound htpG, yeast Hsp82 and Grp94 reveal two hinges, including a new one at the end of a 3-helix bundle in the middle domain (Morra et al., 2012). Mechanistic model of Hsp90 dynamics and regulatory interactions (Dixit and Verkhivker, 2012; Blacklock and Verkhivker, 2014b). Molecular dynamics modeling of allostery in htpG (Seifert and Grater, 2012). Molecular dynamics simulations show large conformational changes, with and without nucleotide, apparently guided by electrostatic interactions between subunits (Simunovic and Voth, 2012). Computational study of dynamics and allostery communication in complexes with Aha1 and p23 (Blacklock and Verkhivker, 2013), and of reorganization of lid by cochaperones (Blacklock and Verkhivker, 2014a). More modelling showing communication hubs (Penkler et al., 2018). Novel allosteric regulatory sites and candidate compounds (Penkler and Tastan Bishop, 2019). Domain interactions also influence MC dynamics (Kandzia et al., 2019). Correlating allosteric and functional effects (D’Annessa et al., 2019).

- Comparative structures of N-termini of Grp94 and yeast Hsp82 with different inhibitors reveals significant paralog-specific differences including conformational changes (Immormino et al., 2009).
- Comparative analysis of enthalpic contributions to binding of different ligands to N-terminus (Nilapwar et al., 2009).
- see also Hsp90 cycle.
- Crystal structure of N-terminal domain of Hsp90 of *Plasmodium falciparum* Hsp90 (Corbett and Berger, 2010).
- Dimers of N-terminally truncated human Hsp90α are the building blocks of a hexameric assembly in the crystal (Lee et al., 2011).
EM and cryo-EM structures of Hop-Hsp90α complex (Southworth and Agard, 2011). It shows that one molecule of Hop makes extensive contacts with the Hsp90 dimer to promote an alternate open state that is poised for Hsp70 binding, client loading and ATP hydrolysis. Cryo-EM structure of GR-Hsp90-Hsp70-Hop complex (Kirschke et al., 2014). Several structures indicating substrate (GR LBD) transfer from Hsp70 to Hsp90 machinery, highlighting notably that GR binds Hsp90 dimer opposite of Hop (Alvira et al., 2014).

Structure of UNC-45 reveals formation of chains with a potential for periodic binding of Hsp90 through C-terminus (Gazda et al., 2013).

Solution structure analysis of the Aha1-Hsp90-Hsp70-Hop complex (Kirschke et al., 2014). Several structures indicating substrate (GR LBD) transfer from Hsp70 to Hsp90 machinery, highlighting notably that GR binds Hsp90 dimer opposite of Hop (Alvira et al., 2014).

Crystal structure of NTD of T. brucei Hsp83 with several selective inhibitors (Pizarro et al., 2013).

TRAP1 structure revealed an asymmetry in the closed state because of a helix swap at the middle-C-terminal domain interface that is also present in htpG (Lavery et al., 2014).

NMR/SAXS analysis of Tau-Hsp90 interaction reveals a broad interaction surface with discontinuous contacts, only marginally affected by ATP binding (Karagöz et al., 2014).

NMR/EM/SAXS analysis reveals extended contacts of GR HBD across N- and mostly M-domains, partially overlapping with Aha1 N-domain interactions (Lorenz et al., 2014).

7-azaindole derivatives can exploit differences in conformational dynamics at the base of the lid of Plasmodium Hsp90 relative to human (Wang et al., 2014a).

Prediction by molecular dynamics of the novobiocin-type binding site in the C-terminus based on dynamic fluctuations induced by N-terminally bound ATP (Moroni et al., 2014).

htpG adapts its conformation to a model substrate and in turn remodels the substrate (Street et al., 2014).

Structure of complex with Tah1 and the metazoan Spagh/RPAP3 (Pal et al., 2014); shows how a Tah1 helix-swap allows binding of the five-helix TPR (Morgan et al., 2015). Structure of R2TP complex shows binding mode of the Pih1-Tah1 heterodimer to a Rvb1-Rvb2 hetero-hexamer and how this may connect it to clients and Hsp90 (Rivera-Calzada et al., 2017; commented in Eickhoff and Costa, 2017). Structure of R2TP core shows how RPAP3 provides a flexible tether for Hsp90 (Martino et al., 2018).

NMR analysis of dynamics of N-terminal domain bound to different ligands (Zhang et al., 2015a).

Structure of N-terminal domain with a peptide ligand in ATP pocket (Raman et al., 2015).

Folding kinetics of Hsp90 with single-molecule experiments (Jahn et al., 2016). High resolution structure and dynamics with FRET (Hellenkamp et al., 2017).

Cry-EM structure of Hsp90-Cdc37-Cdk4 complex reveals unexpected features and explanations for the effects of Cdc37 phosphorylation and substrate recognition: Cdc37 binds middle domain of closed Hsp90 conformation (possibly after rearranging from N-terminal contacts upon initial binding to Hsp90); Cdc37 mimics features of client kinase; client kinase and Cdc37 thread through and wrap around Hsp90, respectively (Verba et al., 2016).

Crosslinking / mass spec analysis of effects of Hsp90 inhibitors on conformation and chaperone and client interactions also reveals in vitro/in vivo and drug-specific differences (Chavez et al., 2016).

Structural studies and modelling of Tom70-Hsp90 interaction (Zanphorlin et al., 2016).

Cocrystal of FKBP8 with MEEVD (Blundell et al., 2017).

NMR structure of htpG (Pederson et al., 2017).

Cocrystal structure and molecular dynamics of FKBP51 with MEEVD (Kumar et al., 2017).
Structure of full-length human Hsp90β with FKBP51 and with/without Tau shows an extended Hsp90-51 interaction surface and N-terminal positioning of Tau and PPIase; binding site of Tau does not overlap with co-chaperone binding sites (Oroz et al., 2018).

Differences in folding and domain interactions of three isoforms (Jahn et al., 2018).

Favorable entropic contribution arises from conformational flexibility of Hsp90 in the drug-bound state (Amaral et al., 2017).

Impact of changing K112 of human Hsp90α to R as in *Leishmania braziliensis* (Tassone et al., 2018).

**Hsp90 chaperone machine:**

- **promotes folding of proteins** (some w/o ATP !!!) (Shaknovich et al., 1992; Wiech et al., 1992) and prevents protein unfolding and aggregation (Miyata and Yahara, 1992; Jakob et al., 1995a; Jakob et al., 1995b) by binding early unfolding intermediates (Jakob et al., 1995a) and preventing their aggregation. Maturation of lck (Hartson et al., 1996) and luciferase (Schneider et al., 1996; Thulasiraman and Matts, 1996) in retic. lysate inhibited by GA. GA promotes shift from folding to degradation of Hsp90 substrates like luciferase and Raf both in vitro and in vivo (Schneider et al., 1996). Cooperates with Hsp70 and DnaJ in in vitro folding (Schumacher et al., 1996). ATP binding mutants have some residual luciferase refolding activity (Grenert et al., 1999). Ydj1 important for positive effect of Hsp90 on luciferase refolding in multicompoment system and for functional transfer of substrate from Hsp70 to Hsp90 (Wegele et al., 2006). Overcomes folding block of high (physiological) levels of Hsp70 in vitro with ATP-dependence being limited to the earliest phase of folding (Morán Luengo et al., 2018).

- There is a balance between folding and degradation involving mutually exclusive Hsp90-HOP and Hsp90-CHIP complexes, respectively, determined by intracellular concentrations and affinities (Kundrat and Regan, 2010a).

- ATP-independent protection of tubulin against thermal denaturation and maintenance for polymerization; stoichiometry is 2:1 Hsp90: tubulin (Weis et al., 2010). Holdase function for bacterial tubulin homolog FtsZ also ATPase-independent (Balasubramanian et al., 2019).

- holds denatured proteins in folding competent state for other molecular chaperones (Freeman and Morimoto, 1996; Yonehara et al., 1996; see also Minami and Minami, 1999; Minami et al., 2000). Hsp90, Hsc70, Hsp40, and the proteasome activator PA28 are sufficient (Minami et al., 2000).

- *E. coli* htpG joins DnaK to remodel synergistically some substrates such as luciferase, after an initial action of DnaK (Genest et al., 2011). Cyanobacterial htpG binds to and collaborates with DnaJ2 and DnaK2 in substrate-specific holding/refolding (Nakamoto et al., 2014). Luciferase refolding with yeast proteins requires Sti1 and is defective for Hsp70-binding mutants of Hsp82 (Kravats et al., 2018).

- **Substrate recognition:** preference for early unfolding intermediates (Jakob et al., 1995a). Point mutations in Polo-like kinase I may point out binding site/specificity (Simizu and Osada, 2000). Several domains can bind short peptides in vitro (see "Domain mapping"; and Ishiwatari-Hayasaka et al., 2003). Short survivin peptide competes for binding of full-length, and a point mutant of full-length fails to bind (Fortugno et al., 2003). In kinases, it may recognize a hinge/loop region in the N-terminal lobe (Tikhomirov and Carpenter, 2003; Citri et al., 2004a; Xu et al., 2005; see also discussion in Citri et al., 2004b; Citri et al., 2006; Wang et al., 2014b). In Lck and HRI Hsp90 and Cdc37 also recognize primarily the N-terminal lobe, but more is required to form a salt stable complex; Hsp90 may facilitate folding by breaking interactions between subdomains (Scroggins et al., 2003; Prince and Matts, 2004). Similar results with Cdk2 (Prince et al., 2005b). Hsp90 may
recognize distinct motifs of nascent versus mature kinase clients such as ErbB2 (Xu et al., 2005). Truncations of JNK trigger differential binding of Hsp90 and Cdc37 (Prince and Matts, 2005). Recognition depends on surface features within \(\alpha\)C-\(\beta\)4 loop rather than sequence; substrates tend to have overall positive charge (Citri et al., 2006). Short peptide sequence appears to be Hsp90 binding site in eNOS (Xu et al., 2007a) and in IP6K2 (Chakraborty et al., 2008). Mapping of short peptide sequence, including the \(\alpha\)C-\(\beta\)4 loop, proximal to PXXP motif in PKCs (Gould et al., 2009). htpG recognizes a locally structured region in a globally unfolded model substrate (Street et al., 2011). Some overlap of of residues required for ligand binding and Hsp90 binding in AhR (Soshilov and Denison, 2011). Part of the p53 interaction surface on Hsp90 resembles DNA in charge and surface (Hagn et al., 2011). Binds the oxygenase domain of nNOS, which contains the heme/substrate binding cleft (Peng et al., 2012). Survey of large number of kinases, E3 ligases and transcription factors by immunoprecipitation reveals high proportion of structurally diverse and unrelated kinases as clients; most Cdc37-dependent; the key determinant is thermodynamic stability (liability) and not primary sequence; destabilizing mutations or stabilizing small molecule ligands increase and decrease interaction, respectively (Taipale et al., 2012; see also Taipale et al., 2014), and this does not correlate with activity (Kancha et al., 2013). This can be exploited as a drug screening tool (Taipale et al., 2013; see also Cho et al., 2020). Binding of Hsp90\(\alpha\) to AKR1B10 requires a specific helix (Luo et al., 2013). Hsp90 provides a large surface across N- and M-domains with discontinuous contacts to recognize late folding intermediates or intrinsically disordered proteins such as Tau (Karagöz et al., 2014). Hsp90 can recognize a native protein by interacting with partially folded states that are only transiently populated (Street et al., 2014). LRR, Argonaute, and \(\beta\)-propeller fold proteins associate primarily with co-chaperones SGT1, p23 and PP5, and NUDC family members, respectively, along with Hsp90 (Taipale et al., 2014). Of the latter, NUDC, NUDC2, and NUDC3 prefer WD40 repeats, RCC1 repeats and Kelch domains, respectively (Taipale et al., 2014). Hsp90-dependence of v-Src vs. c-Src correlates with compactness and folding cooperativity (Boczek et al., 2015; see also Luo et al., 2017). Cdc37 acts as a substrate recognition factor to select Hsp90-dependent kinases by "sensing" their conformational instability (Keramisanou et al., 2016) or their propensity to an open state with separated N- and C-lobes (Verba et al., 2016). Binds a short peptide within the tail of \(\alpha\)4 integrin (Lin et al., 2019). ADP-riboseyltransferse toxins (CtxA, Ptx, ArtAB) are bound through a short peptide sequence (Kellner et al., 2019).

**Role in quality control:** required for degradation of certain misfolded substrates, e.g. apoB (Gusarova et al., 2001) and VHL (McClellan et al., 2005); "early" Hsp90 complex with Hsp70, Sti1, and Sse1 is involved in targeting VHL for degradation, but not for folding nor for maintaining solubility (McClellan et al., 2005). Together with Sse1/Sse2 part of an early quality control step with Hsp70 in yeast (Mandal et al., 2010). In yeast, this involves the ubiquitin ligases Ubr1 and Ubr2 (Nillegoda et al., 2010). Recruited to unfolded membrane-associated proteins along with CHIP (Apaja et al., 2010) and to mutant CFTR in particular along with several co-chaperones (Okiyoneda et al., 2010); knock-down of Hsp90\(\alpha\) (and Aha1 and Hop) but not Hsp90\(\beta\) reduces ubiquitination and augments plasma membrane expression of mutant CFTR (Okiyoneda et al., 2010). Required for the dynamics (coalescence and movement) and degradation of Q-bodies, a cytoplasmic compartment that accumulates misfolded proteins to contribute to protein homeostasis (Escusa-Toret et al., 2013; discussed in Roth and Balch, 2013). Hsp90 complex with exclusively Hsp90\(\alpha\) retains adenosine A\(\beta\) receptor in endoplasmic reticulum prior to chaperone/COP2 exchange (Bergmayer et al., 2013). Hsp90\(\beta\) isoform (not \(\alpha\)) samples cytosolic domain of serotonin transporter (SERT) (El-Kasaby et al., 2014). Hsp90\(\beta\) complex promotes folding and trafficking, but destabilizes substrate CLC-
2 by stabilizing CUL4 (Peng et al., 2016b). With ZTL, part of a protein quality control system in Arabidopsis leading to polyubiquitination and clearance of protein aggregates following heat stress (Gil et al., 2017). HSC82 (not HSP82) in yeast is required for K48-ubiquitination-mediated degradation of cytoplasmic proteins, but not K11-ubiquitination-mediated degradation of nuclear proteins (Samant et al., 2018). Stress-induced increase of AtHsp90.1 may compete for substrates of E3 ligase MPSR1 leading to destabilization of the latter (Kim et al., 2019a).

- **in vivo (in yeast):** required for de novo folding of specific subset of proteins, not for most, does not generally protect from thermal inactivation, but may enhance rate of recovery (Nathan et al., 1997).

- promotes (even a small C-terminal Hsp90 fragment) MyoD1-E12 DNA binding in vitro (Shaknovich et al., 1992; Shue and Kohtz, 1994). No stable complex detectable. This seems to be the only evidence for an active role of Hsp90 as a folding chaperone.

- **assembly of steroid receptor complex in vitro:**
  - retic. lysate can do it (Smith et al., 1990; Scherrer et al., 1992) and requires ATP hydrolysis and other goodies (Hutchison et al., 1992b; Smith et al., 1992).
  - dynamic view of assembly and disassembly (Smith, 1993; Smith et al., 1995; Pratt and Toft, 1997); also reviewed in Kanelakis and Pratt, 2003.
  - Hop is an early component (Smith et al., 1993b; Smith and Toft, 1993) and it forms a 3-way complex of Hsp90-Hop-Hsp70 (Czar et al., 1994; Chen et al., 1996c) and is essential (Chen et al., 1996c; Dittmar et al., 1996). Hop functions as adaptor that directs Hsp90 to preexisting Hsp70-PR complexes, perhaps involving Hip (Chen and Smith, 1998).
  - p23 is essential (Johnson and Toft, 1994; Johnson and Toft, 1995; Johnson et al., 1996). Binding requires ATP (Johnson et al., 1996), inhibited by geldanamycin (Johnson et al., 1996), promoted by molybdate (Sullivan et al., 1997). Geldanamycin effect may be temperature-dependent (Owens-Grillo et al., 1996b).
  - wheat germ can do it with exogenous p23 (Hutchison et al., 1995; Stancato et al., 1996).
  - Hsp70 is required (Hutchison et al., 1994a)
  - factors are preassembled in foldosome (Hutchison et al., 1994b)
  - p48 (=Hip) cloning and association (Prapapanich et al., 1996)
  - FK506 (Hutchison et al., 1993) and CsA (Owens-Grillo et al., 1995) have no effect, and immunophilins are not required (Dittmar et al., 1996).
  - complete reconstitution from individual components (Dittmar et al., 1996).
  - purified Hsp70-Hop-Hsp90 + ATP sufficient to convert GR to the (unstable) steroid binding state; this step is GA sensitive; p23 or molybdate can stabilize complex (Dittmar et al., 1997; Dittmar and Pratt, 1997). Well, also need DnaJ protein (Dittmar et al., 1998). Toft lab needs p23 with PR; Hsp70 can bind PR alone in presence of DnaJ and ATP; 70, 90, and p23 are needed at 10-20-fold excess over PR (Kosano et al., 1998). BAG-1 blocks Hsp90-GR assembly at high ratio to Hsp70 (Kanelakis et al., 1999).
  - p23 (and molybdate) binds and stabilizes GR-heterocomplex in absence of ATP. Binding to free Hsp90 is ATP-dependent and Hsp90-Hop-Hsp70 heterocomplex is not bound at all (Dittmar et al., 1997) ----> p23 binding depends on nucleotides and proteins bound to Hsp90 (see also Johnson et al., 1998).
  - dominant-negative Hip mutant blocks assembly by blocking association with Hop-Hsp90 (Prapapanich et al., 1998).
  - FKBP51 binds preferentially to Hsp90-PR complexes (Nair et al., 1997). Maps to C-terminal peptide sequence of FKBP51 (Barent et al., 1998; Cheung-Flynn et al., 2003). Preference also seen with GR, but not ER complexes (Barent et al., 1998).
FKBP51 overexpression stimulates p23 recruitment to and function of AR (Ni et al., 2010).

- Hsp90 and Hsp70 are sufficient for GA-inhibitable folding of GR; Hop, Ydj1, and p23 accelerate, potentiate, and stabilize folding, respectively (Morishima et al., 2000a), but are also dispensable according to Rajapandi et al., 2000; assembly occurs through two (only one according to Rajapandi et al., 2000) sequential ATP- and K+-dependent events (iterative ratcheting), first with Hsp70 and then with Hsp70 and Hsp90 (Morishima et al., 2000b; Morishima et al., 2001). Hsp70 binds in first step in ATP-bound form, then Hsp90 can bind rapidly with ATP-dependent cleft opening being rate-limiting step (Kanelakis et al., 2002).

- a combination of Hsp90, Hsc70, and co-chaperones is required for DNA binding ability of EcR/USP heterodimer in vitro (not for hormone binding) (Arbeitman and Hogness, 2000).

- first protein to bind to native apo-PR is Hsp40 (J protein); binding is rapid, ATP-independent, and high affinity; it allows subsequent recruitment of Hsp70 and other components and persists except in presence of hormone (Hernández et al., 2002a; see also Cintron and Toft, 2006).

- priming of GR by Hsp70 for opening of the steroid binding cleft by Hsp90 does not require Hsp40, and takes place with a mutant GR lacking a segment required for assembly into Hsp90 complexes (Murphy et al., 2003).

- A multichaperone complex with Hsp90+Hsp70+Hop+Ydj1+p23 can mobilize nuclear GR in permeabilized cells (Elbi et al., 2004).

- GCUNC-45 inhibits PR hormone binding; countered by FKBP52 (Chadli et al., 2006). Inhibits preferentially Hsp90β reconstituted PR (Chadli et al., 2008b).

- Cdc37 has no effect on PR reconstitution (Felts et al., 2007).

- no significant difference between Hsp90α and Hsp90β for PR assembly (Chadli et al., 2008b).

- Tpr2 can replace type I and II J proteins for PR and Chk1. Over- and underexpression in vivo is inhibitory (Moffatt et al., 2008).

- Liganded and unliganded hormone binding domain (HBD) of the glucocorticoid receptor (GR) have the same affinity for Hsp90; while two molecules of HBD can bind initially, co-chaperone binding leads to an asymmetric structure; Aha1 and HBD cannot bind simultaneously (Lorenz et al., 2014).

- Hsp90 recovers and augments GR ligand binding by promoting Hsp70 release and preventing aggregation; Hsp40/Hsp70 inhibit ligand binding by partial unfolding and opening of ligand binding pocket; recovery (but not stabilization) requires ATP hydrolysis and 23 or Hop, and direct contacts and possibly coupling between ATPase domains of Hsp70 and Hsp70 (Kirschke et al., 2014).

- addition of p23 to client-loading complex Hsp90a-Hsp70a-Hop-GR with antiparallel Hsp70 dimer displaces Hop and Hsp70 (Morgner et al., 2015; see also Schmidt et al., 2015).

- Stable intermediate consists of (FKBP51)1(2)(GR)1(Hsp90)2(p23)2; when FKBP52 replaces FKBP51 to form dynamic transfer complex, p23 is expelled (Ebong et al., 2016), consistent with IP results with cell extracts (Schülke et al., 2010).

- Differential requirements of GR and MR HBDs for co-chaperones in vitro mimic functional requirements in yeast (Sahasrabudhe et al., 2017).

- Both Hsp90α and β assemble as homodimers with GR in vitro, unlike in vivo where heterodimers can also be found (Morishima et al., 2018).

* reconstitution of pp60<sup>v-src</sup> complex with retic. lysate (Hutchison et al., 1992a); complex with Hsp90 and p50 stabilized by molybdate, vanadate and tungstate (Hutchison et al., 1992c). Stimulation of kinase activity in purified system requires ATP binding (and in
some assays hydrolysis) and Hsp90 binding of phosphorylated Cdc37, and only the Hsp90β isoform is able to do it (Boczek et al., 2015).

- **subunit composition of Hsp90 complexes** with AhR (Chen and Perdew, 1994; Nair et al., 1996), eIF-2α kinase (Matts et al., 1992), fes tyrosine kinase and HSF-1 (Nair et al., 1996; see also Zou et al., 1998; Guo et al., 2001) is similar/identical (Hsp70, FKBP52, p23). Mutant p53 p53 complexes also contain Hsp70, p23 and Cyclophilin-40 (Whitesell et al., 1998). Co-IP of Achlya Hsp90 also brings down Hsp70, FKBP51 and p23 (Brun et al., 1998). FKBP52-Hsp90 complex may be targeted to GR by independent binding of FKBP52 to GR (Silverstein et al., 1999).

- **pp60v-src**, fes and Raf-1 complexes with Hsp90 also contain p50 (now known to be presumably Cdc37) (Brugge et al., 1981; Oppermann et al., 1981; Stancato et al., 1993; Stancato et al., 1994; Wartmann and Davis, 1994; Nair et al., 1996; Perdew et al., 1997). Cdc37 binds catalytic domain of Raf directly and may direct Hsp90 to it (Silverstein et al., 1998). Androgen receptor complexes may also contain and require Cdc37 (Rao et al., 2001; see also Gray et al., 2007).

- **subunit composition in yeast**: with GR there is Hsp90, Sti1, Ssa and Ssb, Ydj1 and Sba1 (Bohen, 1998). The latter is released most clearly with hormone (Bohen, 1998). The Lindquist lab has only seen Hsp90, Ydj1 and Ssa (Kimura et al., 1995).

- **maturation of reovirus protein σ1**: Hsp90 associates with immature homotrimer forms; release from Hsp90 and maturation blocked in vitro by GA; p23 also associated with σ1 and released by GA (Gilmore et al., 1998).

- **p53**: In purified system, Hsp90 prefers wild-type over conformationally mutant p53; inhibits binding of Hsp40 and Hsp70 to wild-type p53; Hsp90 and multi-chaperone complexes with wild-type p53 are disrupted by BAG-1 (King et al., 2001). Hsp90 binds and stabilizes native-like conformation (Müller et al., 2004; Walerych et al., 2004; Hagn et al., 2011). Hsp90 required for maintenance under heat stress and for refolding in collaboration with Hop-Hsp70 (Walerych et al., 2009). Release of partially unfolded wild-type p53 from Hsp90 is necessary for promoter binding and dependent on ATP-binding, but not hydrolysis (Walerych et al., 2010). Hsp90 protects DNA binding-competent conformation (Boysen et al., 2019) and restores native state from Hsp70-mediated unfolding in ATP hydrolysis- and HOP-dependent manner (Dahiya et al., 2019) of wild-type and mutant p53.

- **reconstitution of functional HBV reverse transcriptase in vitro**: purified Hsp90, Hsp70, Hsp40, and Hop are sufficient, p23 improves and accelerates; dependent on Hsp90 ATP hydrolysis (Hu et al., 2002; Hu et al., 2004).

- **reconstitution of functional Chk1** with Hsp90, Hsp70, Hsp40, Cdc37 and CK2 (p23 not needed, Hop enhances) (Arlander et al., 2006; Felts et al., 2007). Effect of Tpr2 (Moffatt et al., 2008).

- **Disaggregates Pih1 in ATP-dependent fashion in vitro** (Zhao et al., 2008).

- **Cdc37 and Hsp90 (M domain is critical)** suppress aggregation of the kinase domain of B-Raf and are released upon nucleotide binding of the kinase (Eckl et al., 2016).

- **Folding/maturation of Mal63 appears to be somewhat different from the steroid receptor paradigm** in that an Hsp70-Sti1-Hsp90 intermediate is the form responsive to inducer (Ran et al., 2008).

- **Sequential triage of ricin catalytic A chain** from Hsc70 system to Hsp90-CHIP protects cells (Sponer et al., 2008).

- **No binding and no stimulatory effects** of Aha1 on several clients in reticulocyte lysate (Sun et al., 2012).

- **Argonautes**:  
  - **Argonaute-1 (= Ago1)**: Cyp40, in contrast to other TPR co-chaperones, facilitates RISC assembly in an Hsp90-dependent way by promoting or stabilizing the binding
of small RNA duplexes to AGO1, but is not present in mature RISC in plants (Iki et al., 2012).

- **Argonaute-2 (Ago2 = GERp95):** GA inhibits interaction with Dicer (Tahbaz et al., 2004), and compromises RNA interference and miRNA action, but not siRNA loading (Pare et al., 2009). Instead, newer evidence indicates that Hsp90 is required to maintain stability of unloaded Ago2, and not for siRNA/miRNA loading or interaction with Dicer (Johnston et al., 2010; but see below). Concordant evidence now suggests that Hsp90 is required for dsRNA loading into Ago from Dicer in an ATP- and possibly even hydrolysis-dependent fashion (Iki et al., 2010; Iwasaki et al., 2010; Miyoshi et al., 2010; discussed by Landthaler, 2010). Aha1, Cdc37, p23 and FKBP4 (=FKBP52) are all required for RNA loading and p23 and FKBP4 are part of the Hsp90-Ago2 complex before loading (Pare et al., 2013). Human Ago2 also dependent on Hsp90 function in budding yeast (Wang et al., 2013d). Both FKBP4 and 5 promote Ago2 stability and facilitate RISC assembly (Martinez et al., 2013). The co-chaperone Coi12p of *Tetrahymena* promotes siRNA loading at least in part through an Hsp90- and ATP-dependent mechanism (Woehrer et al., 2015). In a purified fly system, the chaperone complex consisting of Hsp83, Hsc70, Hop, p23 and Droj2 does it by increasing the dwell time of the Dicer-R2D2-siRNA complex on Ago2; this depends on the 5′-phosphate of the guide strand and on the ATPase of both Hsc70 and Hsp83 (Iwasaki et al., 2015). Also required for the Dicer-independent loading of duplex RNA, but not single-stranded RNA, in the human system (Naruse et al., 2018). Single-molecule experiments show that the Hsp90 system extends the dwell time in an open/active conformation promoted by the Hsp70 system (Tsuboyama et al., 2018).

- **Argonaute-4 (Ago4):** binds and is required for loading of heterochromatic siRNAs in the cytoplasm in plants (Ye et al., 2012).
  - Assembly of functional Nox5, associated with isolated membranes, with Hsp90β, Hsp70, HOP, Hsp40 (Ydj1) and p23 (Chen et al., 2015a).
  - Molybdate fails to stabilize Hsf1-Hsp90 complexes (Kijima et al., 2018).

### Mapping of Hsp90 domains:

- only C-terminal half required for assembly with cPR in vitro (Sullivan and Toft, 1993).
- domains of yeast Hsp82 required for viability and signaling in yeast (Louvion et al., 1996).
- charged linker domain: dispensable in vivo in yeast (Louvion et al., 1996; Meng et al., 1996), but viable deletion mutant is defective for double-strand break repairs and Rad51 function, but not accumulation, is impaired (Suhane et al., 2015). A peptide (aa 232-266) and antibody against this peptide destabilizes GR-mHSP84 complex in vitro (Tbarka et al., 1993). Charged domain required in luciferase refolding assay (Johnson et al., 2000).
- Inhibits binding of C-terminal domain to novobiocin (Marcu et al., 2000a). Binds NPY (Ishiwatari-Hayasaka et al., 2003). More careful mapping in Hsp82 reveals that more extended deletions can affect co-chaperone regulation in vitro and viability, but that an unrelated spacer can partially rescue (Hainzl et al., 2009; see also Tsutsumi et al., 2012). Truncation of charged domain rescues secretion and chaperone defects of mutations in N-terminally adjacent hydrophobic strand (Tsutsumi et al., 2009). The sequence and/or charge, but not the length affect Hsp90 conformation, co-chaperone interaction and function (Tsutsumi et al., 2012). CPR7 becomes essential when the charged linker of Hsp90 is deleted; this synthetic lethality can be suppressed by Cns1 overexpression as well (Zuehlke and Johnson, 2012). Charged linker is important for the structural flexibility mediating docked and undocked states of the N- relative to the the M-domain (Jahn et al., 2014). Deletion reduces affinity for ATP but not other ligands (Olesen et al., 2015).
- Hsp82 chimeras with Grp94 N- or M2-C domains are viable, but no Hsp82 domain can substitute for a corresponding Grp94 domain (Maharaj et al., 2016). For viability in yeast
and some clients, charged linker per se is not important but the ability of the N-terminal domain to rotate (Daturpalli et al., 2017).

- C-terminal MEEVD dispensable in vitro (Sullivan and Toft, 1993) and in vivo (Louvion et al., 1996), except in cns1 yeast strain (Tesic et al., 2003).

- other internal deletions in Hsp90 of chicken (Cadepond et al., 1993; Binart et al., 1995; Meng et al., 1996) and yeast (Louvion et al., 1996).

- calmodulin-binding domain: positively charged amphilic helix of about 20 aa around aa 500 of mHSP90, also intramolecular interaction domain (this region may bind to another domain resembling calmodulin; binding inhibited by Ca\(^{2+}\)) (Minami et al., 1993).

- C-terminal dimerization domain (Minami et al., 1994; Nemoto et al., 1995; Meng et al., 1996; Nemoto et al., 2001a; Tanaka et al., 2001; Yamada et al., 2003); same dimerization affinity as full-length (Richter et al., 2001). Minimal dimerization domain comprises last 190 amino acids (Nemoto et al., 1995). A minimal domain comprising residues 650-697 with an essential hydrophobic segment within the C-terminal domain of human Hsp90\(\alpha\) (AA 621-732) interacts with middle plus C-terminal domain (Yamada et al., 2003). Point mutations in this region affect also chaperone function (Allan et al., 2006). Human Hsp90\(\alpha\) can heterodimerize with Grp94 and htpG through their middle - C-terminal domains (Yamada et al., 2003). Dispensable for ATPase of yeast Hsp90 provided dimerization is ensured otherwise (Wegele et al., 2003). Duplicated C-domain keeps Hsp82 monomeric and defective for ATPase and also in vivo in yeast (Wayne and Bolon, 2007). Poor dimerization of human Hsp90\(\beta\) compared to \(\alpha\) can be mapped to two amino acid changes \(\{A558\text{ and }M621\text{ of }\beta\}\) (Kobayakawa et al., 2008). Polymorphism Q488H in human Hsp90\(\alpha\) affects dimerization, but not Q488T as found in Trap1 (Kobayakawa et al., 2009). In silico and mutational analysis of hot spots (Ciglia et al., 2014).

- N-terminal dimerization domain (N-terminal 200 AA) (Prodromou et al., 1997a).

- domain mapping of in vitro assembly with Hop, Hip, Hsp70, Cyp40, FKBP51, p23 and PR (Chen et al., 1998; see also Scheibiel et al., 1999b; Chadli et al., 2000). N-terminal domain sufficient for hormone-insensitive interaction with ER\(\alpha\) HBD in purified system (Bouhouche-Chatelier et al., 2001).

- p23 binding requires N-terminal dimerization and about 200 amino acids beyond the charged domain (Chadli et al., 2000; Prodromou et al., 2000; Siligardi et al., 2004). Appears similar for RAR1 (Takahashi et al., 2003). Model for interaction based on evolutionary tracing (Zhu and Tytgat, 2004). Binding competed by Aha1 and Hop but not Cdc37 or Cpr6 (Harst et al., 2005). Evidence for Hsp90-FKBP52-Hop and Hsp90-FKBP52-p23-Hop complexes (Hildenbrand et al., 2011; see also Ebong et al., 2011; Ebong et al., 2016). Interaction between Hsp90\(\beta\) and p23 compatible with N-terminal fluorescent protein tags on both proteins (Picard et al., 2006).

- ATP and GA-binding domain (N-terminal 200 AA): see above.

- point mutations in N-terminal pocket block both GA and p23 binding (Grenert et al., 1997; see also Grenert et al., 1999).

- various yeast Hsp82 point mutants (A97I, G170D, S485Y, T525I) cannot bind Sba1 in vitro (Fang et al., 1998; see also Hawle et al., 2006).

- Chaperone domains: a small C-terminal Hsp90 fragment is sufficient to promote MyoD1-E12 DNA binding in vitro (Shaknovich et al., 1992; Shue and Kohtz, 1994). N-terminal domain of human Hsp90 (AA 9-236) prevents rhodanese aggregation in a GA-sensitive way and prevents (!) luciferase refolding; C-terminal AA 629-732 prevents rhodanese aggregation, binds a short peptide (low efficiency) and maintains unfolded luciferase in a folding-competent state (Young et al., 1997); not inhibited by TPR proteins that also bind there (Young et al., 1998). There are at least three different domains that can inhibit aggregation of substrates (Johnson et al., 2000; see also Tanaka et al., 2001), but
multiple domains are required in luciferase refolding assay (Johnson et al., 2000). Yeast Hsp82 also has two domains that inhibit aggregation of substrates; activity can be inhibited by peptides and N-terminal domain also by GA and ATP (Scheibel et al., 1998); charged domain confers higher affinity for nonnative proteins and lower ATP binding onto N-terminal chaperone domain (Scheibel et al., 1999a); charged domain required in luciferase refolding assay (Johnson et al., 2000). N- and C-terminus contribute differently to function as holder chaperone (Minami et al., 2001); the C-terminal domain presents trapped luciferase to CHIP for ubiquitinylation (Murata et al., 2001). The same minimal domain from the C-terminus that can mediate dimerization can suppress aggregation of citrate synthase (Yamada et al., 2003). Charged linker and C-terminal tail are necessary for anti-aggregation activity, and deletions in yeast Hsp82 can be rescued by appending the human charged linker at the C-terminus (Wayne and Bolon, 2010). This is also important in cis in yeast for maintaining viability at elevated temperature and the solubility of clients (Pursell et al., 2012).

- Amphipathic structure around W300 and residues 329 to 332 (in yeast) may be part of the client binding domain consisting of the opposing inner faces of the middle segments (Meyer et al., 2003).
- TPR binding domain: C-terminal 90-100 AA are sufficient (Young et al., 1998; Carrello et al., 1999; see also Chen et al., 1998; Russell et al., 1999; Bell and Poland, 2000; Ramsey et al., 2000; Connell et al., 2001); also for stimulating PP5 phosphatase activity (Ramsey and Chinkers, 2002). MEEVD is required for binding Cyp40, PP5, FKBP52, and Hop (Chen et al., 1998; Carrello et al., 1999; Ramsey et al., 2000). MEEVD sufficient to bind central TPR domain (TPR2A) of Hop (Scheuffler et al., 2000; Brinker et al., 2002) and Cyp40 (Onuoha et al., 2008), but there are multiple distinct binding determinants for PP5 and FKBP52 versus Hop (Ramsey et al., 2000; see also Haslbeck et al., 2015), and only full Hsp90 has wild-type affinity for Hop (Hernández et al., 2002b). Extreme N-terminus required for high affinity binding of Sti1 but not Cpr6 (Richter et al., 2003). Hop binding involves additional contacts in C-terminal and middle domains of Hsp90 (Onuoha et al., 2008). Phage display screen failed to identify specificity for binding particular TPRs (Ramsey et al., 2009). Multiple domains of Hsp90 interact with Sti/Hop resulting in inhibition of ATPase and slowing of dimer dissociation (Lee et al., 2012a; Schmid et al., 2012).

- Regions required for assembly with GR (aa 206-291 and 446-581 of chicken Hsp90) (Jibard et al., 1999).

- "Domain mapping" by limited proteolysis and bacterial two-hybrid (Nemoto et al., 1997; Scheibel et al., 1998; Bogatcheva et al., 1999; Nemoto et al., 2001a; Matsumoto et al., 2002). C-terminal portion (289-400) of domain A (1-400) interacts with N-terminal two thirds (401-546) of middle domain B (401-618); conserved residues important for structural integrity, interaction and complementation in yeast (Matsumoto et al., 2002).

- Overexpression of the two separated chaperone domains of yeast Hsp90 (N-terminal 210 and truncation of N-terminal 261 amino acids) has dominant-negative effect on cell growth and v-src activity in yeast; only N-terminal truncation affects GR activity in yeast, and arrests PR assembly at intermediate complex in vitro (Scheibel et al., 1999b).

- Novobiocin and ATP bind competitively to C-terminal half of chicken Hsp90, dependent on AA 657-677 and competed by a short peptide from this region (Marcu et al., 2000a; Marcu et al., 2000b). Second ATP-binding domain, specifically blocked by cisplatin (Sóti et al., 2002). May overlap with dimerization domain containing a Rossmann fold motif (Garnier et al., 2002b). Mapping of novologs to C-terminal site by methyl-TROSY and their long-range effects (Kumar Mv et al., 2018).

- N-terminal 302 AA of human Hsp90β binds both TP and RT domains of HBV polymerase whereas C-terminal 110 AA binds only RT domain (Cho et al., 2000b).
AA 405-578 of Hsp90α sufficient for interaction with Pim-1 (Mizuno et al., 2001).

Middle domain interacts with sGC (Papapetropoulos et al., 2005; Sarkar et al., 2015) through PAS domain (Sarkar et al., 2015).

Trap1-Hsp90 chimeras (Johnson et al., 2000).

Evidence for domain cross talk (see also dimerization): Cooperativity of two nucleotide-binding sites (Soti et al., 1998; Sóti et al., 2002). ATP/GA/radicicol binding to N-terminus antagonizes novobiocin binding to C-terminal domain (Marcu et al., 2000a; Marcu et al., 2000b). A conserved heat-labile interaction between a "middle" domain and the N-terminal chaperone domain appears to inhibit chaperone activity (Tanaka et al., 2001). Sequences within last fourth modulate ATP hydrolysis by N-terminal domain (Owen et al., 2002). Hydrophobic patch (residues 342-352 in yeast) N-terminal of catalytic loop required for interdomain communication between N- and middle domains (Meyer et al., 2003). Genetic evidence for complex interactions (see e.g. Johnson et al., 2007).

Oligomerization requires residues 311-350 of Hsp90α (Nemoto et al., 2004) -> activation of Hsp90 may involve opening of oligomerization/client-binding domain by disruption of intramolecular interaction between AA 289-389 and AA 401-546.

Aha1 binds to middle domain with Kd of 2.9 µM and may facilitate interaction between N-terminal and middle domains (Lotz et al., 2003; Meyer et al., 2003). It induces a conformational switch in the catalytic loop of the middle domain resulting in the release of the "catalytic" arginine 380 (yeast) (Meyer et al., 2004). Binding mutually exclusive with p23, Cdc37, and Hop but not Cpr6 (Harst et al., 2005); not in the case of C. elegans Cdc37 (Eckl et al., 2013). Hsp90α-specificity maps to the Hsp90α middle domain (Synoradzki and Bieganowski, 2015). Conserved N-terminal NxNNWHW motif of Aha1 binds N-terminal domain of Hsp90 (Mercier et al., 2019). Phosphorylation of Y313 of Hsp90 facilitates Aha1 recruitment including with Hsp90 N-terminal domain prior to N-terminal closure (Xu et al., 2019).

Cdc37 binds N-terminal ATPase domain (Roe et al., 2004) and blocks ATPase by insertion of a side chain into the pocket, by binding the open face of the lid, and by holding the Hsp90 clamp open like a brace (Roe et al., 2004). Binding blocked by Hop and Aha1 but not p23 and Cpr6 (Harst et al., 2005). Human and C. elegans Cdc37 preferentially bind N-terminal and middle domains, respectively (Eckl et al., 2013 also Eckl et al., 2015; Verba et al., 2016).

MDM2 binding peptide maps to AA 623-634 of human Hsp90 (Burch et al., 2004), but perhaps binding domain is the N-terminal ATPase domain of Hsp90 (He et al., 2019).

N-terminal domain binds CHORD-protein Chp1 in ATP-independent fashion (Hahn, 2005; Wu et al., 2005).

SGT1 also binds Hsp90 N-terminal domain with CS domain, without p23-like contacts to middle domain (Botêr et al., 2007). RAR1 and SGT1 bind overlapping surfaces that are distinct from the p23 and Aha1 binding sites (Kadota et al., 2008; Zhang et al., 2008a). Full-length SGT1 but not its CS domain alone compete with p23 for Hsp90 binding (Kadota et al., 2008).

N-terminal domain binds GCUNC-45 in TPR-dependent fashion (Chadli et al., 2006; Chadli et al., 2008a). Both FKBP52 and GCUNC-45 can bind the N-terminal domain through a non-contiguous MEEVD-like sequence within/near ATP binding pocket; binding reduced by nucleotides or GA (Chadli et al., 2008a).

Role of lid for ATPase (Richter et al., 2006).

Both N-termini are accessible in p23-Hsp90 complexes and can be tagged with fluorescent proteins without interfering with binding (Picard et al., 2006).

GR regulation depends on two solvent exposed hydrophobic sites in the C-terminus of Hsp90 that have the potential to bind GR as peptides (Fang et al., 2006).
Comprehensive survey of effects of Hsp82 point mutants, notably in middle domain, on ATPase activity, co-chaperone interaction, and GR and v-Src function; two mutants discriminate between the two substrates (Hawle et al., 2006; see also Johnson et al., 2007).

- N-terminus sufficient to bind melusin (Sbroggiò et al., 2008).
- Charged plus middle domain are sufficient to stimulate cell migration when added to medium; middle domain binds CD91 best (Cheng et al., 2008).
- Secreted Hsp90α lacks C-terminal EEVD motif and that motif anchors Hsp90α intracellularly through interaction with TPR co-chaperones, in particular PP5 (Wang et al., 2009b).
- Point mutants I578F and G313N in yeast Hsp82 fail to become nuclear in quiescent cells (Tapia and Morano, 2010).
- N-terminal plus charged domain sufficient to bind WT1 (Bansal et al., 2010).
- Changing R98 of P. falciparum Hsp90 to K as in human does not change higher affinity for GA (Pallavi et al., 2010).
- Hsp90α interacts with MMP-2 using the middle domain (Song et al., 2010b).
- Novobiocin-like inhibitors render a region of human Hsp90α encompassing residues 548-714 protease-resistant and can be crosslinked to residue 560, thereby suggesting a model of how they can stall the machinery in an open conformation (Matts et al., 2011b).
- Interaction with p53 is through several Hsp90 domains, including the outside of middle domain (Hagn et al., 2011). p53 DBD is positioned near middle domain (Quintana-Gallardo et al., 2019).
- A model substrate facilitates a repositioning of the N-terminal versus the middle domain through cross-monomer contacts with both (Street et al., 2012).
- Purified AMPKα/γ subunits bind N-terminal and middle domains with high affinity (Zhang et al., 2012c).
- Several structurally clustered point mutants in the middle domain severely affect substrate binding in the E. coli htpG (Genest et al., 2013). Biochemical experiments confirm that an extended surface of the middle domain with the C-terminal domain, even without the very C-terminal dimerization domain is able to bind a model substrate (Street et al., 2014). Flexibility and residues at the domain interface (e.g. H446 in htpG, T525 and others in yeast) are essential to adapt to the substrate (Street et al., 2014).
- N-terminal domain sufficient to bind substrates HAX-1 and Ire1 (Lam et al., 2013).
- Extended surfaces are involved in binding Tau and the GR HBD (Karagöz et al., 2014; Lorenz et al., 2014). Surface overlapping Tau binding surface across N and M of open conformation binds globular misfolded transthyretin monomer (Oroz et al., 2017). Structure of full-length human Hsp90β with FKBP51 and with/without Tau shows an extended Hsp90-51 interaction surface and N-terminal positioning of Tau and PPIase; binding site of Tau does not overlap with co-chaperone binding sites (Oroz et al., 2018).
- Both N- and middle domains bind PKCγ (Lu et al., 2014).
- Middle domain binds BTB domains of insect factors (Cai et al., 2014).
- C-terminal portion of middle domain of human Hsp90α is responsible for conferring the Hsp90α slow growth phenotype on complemented yeast (Synoradzki and Bieganowski, 2015; see also Synoradzki et al., 2018).
- Both IKKβ and eNOS bind to middle domain and compete (Natarajan et al., 2015).
- SDF2 binds M-domain (Siragusa et al., 2015).
- Nox5 binds M-domain (Chen et al., 2015a).
- Co-chaperones FNIP1/FNIP2 bind M- and C-domains (Woodford et al., 2016a).
- Tom70 TPR also binds internal peptide in C-terminal domain (Zanphorlin et al., 2016).
- NM and C bind GR and REB-ERBα, respectively (Okabe et al., 2016).
Short 27 amino acid peptide of Hsp90\(\alpha\) with dual lysine motif, from junction between charged region and middle domain, is sufficient to stimulate migration/invasion in vitro, but not completely in vivo (Zou et al., 2017).

Middle domain of htpG binds nucleotide-binding domain of DnaK (Kravats et al., 2017) directly (Doyle et al., 2019). Homologous domain in yeast also involved in binding Hsp82 and Ssa1 (Kravats et al., 2018) directly (Doyle et al., 2019). Analysis of Sti1-dependence in yeast supports this conclusion and shows a inverse correlation between Hsp70-binding and Sti1-dependence (Reidy et al., 2018).

C-terminal domain contributes to tighter binding of FKBP8 to MEEVD (Blundell et al., 2017).

M and C domain can bind a portion of Tsc1, but MEEVD is required for binding of full-length Tsc1 (Woodford et al., 2017).

Hsp90\(\beta\) binds Ni-NTA through charged domain (Asakawa et al., 2018).

Binds and deforms membranes through a conserved amphipathic \(\alpha\)-helix around K399 in the M domain (Lauwers et al., 2018).

Ids2 interacts with middle domain (Chen et al., 2018b).

Interaction domain with SMYD2 maps to the sequence motif (M/I/L/V)PXL about ten amino acids N-terminal of MEEVD, and shared with the very C-terminus of p23; nevertheless, binding to Hop and Aha1 may be sterically interfered with; peptides containing it block Smyd2-mediated methylation of ER\(\alpha\) (Obermann, 2018).

Both N- and C-terminal domain are able to bind tail of \(\alpha\)4 integrin in ATPase- and dimerization-independent mode and hence, one Hsp90 molecule can bind two molecules of integrin (Lin et al., 2019).

Short disordered sequence directly upstream of MEEVD is important for efficient ubiquitination of substrates by CHIP (Quintana-Gallardo et al., 2019).

TIMP2 and Aha1 competitively bind to middle domain and are sensitive to the mutation V411E (Baker-Williams et al., 2019).

Hsp90 and disease:

- major target of protective antibodies in candidal infections (Matthews and Burnie, 1992). Antibodies recognize Hsp90 both on the cell surface and in the cytoplasm (Burt et al., 2003).
- reduced Hsp90 levels in Candida albicans attenuate virulence in mouse model (Shapiro et al., 2009).
- tumor-specific antigens (Ullrich et al., 1986; Blachere et al., 1993; Srivastava et al., 1994; Udo no and Srivastava, 1994; Ishii et al., 1999), possibly by playing a role in antigen processing/presentation.
- Hsp90 like Grp94 (gp96) can promote re-presentation of peptides by MHC I molecules following binding of a common receptor, the \(\alpha\)2 macroglobulin receptor CD91 (Binder et al., 2000; Basu et al., 2001).
- Overexpression of Hsp90 in budding yeast enhances its virulence in mice (Hodgetts et al., 1996).
- Hsp90 is predominant antigen of humoral immune response of ovarian cancer patients with stage IV disease (Vidal et al., 2004).
- 17-AAG ameliorates an AR-mediated neurodegenerative polyQ disease by inducing degradation of AR (Waza et al., 2005). With USP19, Hsp90 promotes aggregation of polyQ proteins (He et al., 2016); Hsp90 brings together Htt and USP19 (He et al., 2017).
- Immunodominant epitope of human Hsp90 is the relatively conserved pentapeptide starting with P295 (Kishimoto et al., 2005).
- Associated with NSF, dynamin-1, Unc18-1 and Sumo in neuronal intranuclear inclusions (Pountney et al., 2008).
- Women with infertility have autoantibodies to Hsp90, β in particular (Pires and Khole, 2009). Immunization of mice with immunodominant peptide leads to ovarian dysfunction (Choudhury and Khole, 2013).
- Carotid atherosclerosis patients have increased soluble Hsp90 and anti-Hsp90 antibodies (Businaro et al., 2009), and Hsp90 is increased in atherosclerotic plaques (Madrigal-Matute et al., 2010) and Hsp90 inhibitors prevent migration of vascular smooth muscle cells into such lesions (Kim et al., 2014).
- Citrullinated Hsp90 as autoantigens as markers of interstitial lung diease associated with rheumatoid arthritis (Harlow et al., 2013). Citrullination is at buried arginine residues R502 and R510 in Hsp90β and Hsp90α, respectively, and leads to disruption of tertiary structure (Travers et al., 2016).
- Elevated serum levels of Hsp90α may be a marker for hypertension (Skórzyńska-Dziduszko et al., 2016).
- Serum levels of Hsp90α are dramatically elevated in children with severe sepsis and is associated with poor outcome parameters (Fitrolaki et al., 2016).
- Patients with idiopathic pulmonary fibrosis (IPF) have elevated Hsp90 levels, and Hsp90 inhibition and Hsp90β knock-down in lung fibroblasts reduce proliferation and ECM production, and Hsp90 inhibition fibrosis in a mouse model (Sontake et al., 2017); similar results and evidence that these effects are through TGFβ signaling (Dong et al., 2017a; Sibinska et al., 2017). Inhibitor reduces myocardial fibrosis through TGFβR1-Hsp90 complex (Cáceres et al., 2018).
- Plasma levels as biomarker for lung (Shi et al., 2014) and liver (Fu et al., 2017; Wei et al., 2020) cancers.
- Potentially relevant to allergy and asthma, eHsp90α mediates disruption of airway epithelial permeability induced by house dust mites; through autocrine activation of RhoA, mimicked by recombinant Hsp90α, and blocked by an antibody to Hsp90α (Dong et al., 2017b).

**Cell surface and extracellular Hsp90:**

- Hsp90 added to medium stimulates neurite outgrowth (Ishimoto et al., 1998). Hsp90α and Hsp90β on surface of neural cells and antibodies to them inhibit cell migration (Sidera et al., 2004). Hsp90 interacts with extracellular domain of HER-2, important for HER-2 function and HER-2 stimulated cell migration (Sidera et al., 2008).
- Vascular smooth muscle cells secrete Hsp90α (not Hsp90β) upon oxidative stress and this extracellular form can induce MAPK in the same cells (Liao et al., 2000), and IL-8 through TLR-4, MAPK and NF-κB (Chung et al., 2009).
- Role of Hsp90 in innate response to bacteria: FRAP evidence for immobile Hsp90 (and Hsp70) in cell membranes; antibodies block transfer of LPS from CD14 to an immobile multimeric complex (Triantafilou et al., 2001b); Hsp90 (and Hsp70) are LPS receptors, more important in the absence of CD14, and along with CXCR4 and GDF4 are part of an LPS-stimulated receptor cluster in lipid rafts (Triantafilou et al., 2001a; Triantafilou et al., 2002). A peptide matching the middle domain can block the interaction with LPS and its signaling, and in a cell-permeable form affects clients (Wu et al., 2012a).
- Hsp90 promotes prekallikrein activation in vitro and anti-Hsp90 antibodies in the medium block activation on endothelial cells (Joseph et al., 2002).
- Recombinant Leishmania Hsp83 acts as mitogen of mouse B-cells (Rico et al., 1999; Rico et al., 2002). So do plant Hsp90s through TLR4 but in an LPS-independent fashion (Corigliano et al., 2011).
Campylobacter jejuni protein JlpA interacts with cell surface Hsp90α to activate epithelial cells (Jin et al., 2003). Neisseria adhesin activates monocytes through a complex composed of Hsp90-Hsp70-TLR4 (Cecchini et al., 2011). Overexpressed and recombinant Hsp90α blocks Neisseria adhesion/invasion (Montanari et al., 2012).

Hsp90α, but not Hsp90β, is on the cell surface and in the tissue culture medium, and required for MMP2 maturation and cell invasiveness (Eustace et al., 2004; see comment in Picard, 2004; Wang et al., 2009b). Conversely, MMP2 is required for stimulatory effect of Hsp90α (Wang et al., 2009b). Antibodies to Hsp90α block metastasis in mouse model and plasma levels of Hsp90α (lacking MEEVD) are elevated in cancer patients (Wang et al., 2009b). Serum levels in patients with colorectal cancer are elevated (Chen et al., 2010a). Breast cancer cells secrete both isoforms and those interact with proenzymes and active forms of MMP2 and MMP9 (Stellas et al., 2010). Hsp90α stabilizes MMP-2 by preventing its autocatalytic cleavage even in the absence of ATP; Hsp90β is itself rapidly cleaved by MMP-2 explaining the apparent isoform-specificity (Song et al., 2010b). Hsp90 complex with secreted co-chaperones p23, Hop, Hsp70 and Hsp40 increases activation of MMP-2 (ATP-independent!) (Sims et al., 2011). Mammary epithelial cells secrete Hsp90β and its interaction with MMP3 is essential for invasion and morphogenesis (Correia et al., 2013). Antibody also blocks tumor growth of mammary tumor stem cells (Stivarou et al., 2016).

Glucose and diabetes increase levels of surface Hsp90α, association with annexin II and expression of the latter on the surface of endothelial cells (Lei et al., 2004). Cell surface localization of Hsp90α promoted by phosphorylation by PKA on T89 (T90); results in reduced eNOS activity (Lei et al., 2007).

Hsp90 and Hsp70 part of a membrane-associated, even raft-associated, receptor complex for Dengue virus (Reyes-del Valle et al., 2005).

Surface Hsp90 is part of a receptor for Infectious bursal disease virus (IBDV) on chicken cells (Lin et al., 2007). miRNA-mediated knock-down of Hsp90α but not β inhibits IBDV infection (Yuan et al., 2012). Interaction with VP2 induces autophagy and inactivation of the mTOR-Akt pathway (Hu et al., 2015).

Hsp90 on cell surface of some EBV-immortalized B-cells, and promotes activation of T cells by these cells (Kotsiopriftis et al., 2005).

MS patients make antibodies that target Hsp90β on the cell surface of oligodendrocyte precursors inducing cell death (Cid et al., 2004; Cid et al., 2005).

Hypoxia induces secretion of pre-existing Hsp90α, probably via exosome pathway, which in turn promotes wound healing (Li et al., 2007). TGFα stimulates massive secretion of Hsp90α by keratinocytes but not dermal fibroblasts through exosome pathway, and this Hsp90α stimulates migration of several cell types by binding to LRP1/CD91 (Cheng et al., 2008; Woodley et al., 2009). A 115 aa fragment of Hsp90 encompassing part of the charged region and the adjacent middle domain is sufficient to promote wound healing (Cheng et al., 2011). Burn wounds increase Hsp90α levels, which in turn accelerates wound healing (Zhang et al., 2014). Also works with pig model and human keratinocytes and even with a 27 AA fragment (AA 263-289) (O'Brien et al., 2014). Hypoxia induces secretion of both Hsp90α and Hsp90β, but only Hsp90α can protect cells against hypoxia through LRP1 signaling (Dong et al., 2016). C-terminally truncated Hsp90α has normal wound healing activity in the mouse (Bhatia et al., 2018).

Hsp90 and IL6 in cardiomyocyte exosomes (Datta et al., 2017).

Cachexia-inducing tumor cells secrete Hsp70 and Hsp90 associated with exosomes and this is required for the effect; recombinant Hsp70 and Hsp90 also function as cachexins and effect is through TLR4 (Zhang et al., 2017).
Stimulation of migration/invasion of Hsp90α KO MDA-MB-231 breast cancer cells by added full-length Hsp90α or 27 AA peptide depends on Hsp90α-specific dual lysine motif (K270/K277); when introduced into Hsp90β, it converts it to Hsp90α in these assays (Zou et al., 2017). A monoclonal antibody to this region blocks tumor growth and metastasis (Zou et al., 2017).

Hsp90α stimulates migration of glioblastoma cells by transactivating EGFR in an TLR4-dependent (and at least partially LPS-dependent) fashion (Thuringer et al., 2011). Stimulated by hypoxia and dependent on association with coreceptor LRP1 and EphA2, and Akt activity (Gopal et al., 2011); EphA2 and eHsp90 crosstalk to affect cytoskeleton (Daoud et al., 2017). Stimulates epithelial-mesenchymal transition (EMT) of prostate cancer cells in MMP-dependent manner; can be mimicked by overexpression of Hsp90α with N-terminal signal sequence (Hance et al., 2012; Nolan et al., 2015). Hypoxia-induced motility is specifically dependent on extracellular Hsp90α and intracellular Hsp90β binding to extracellular and cytosolic domains of LRP-1, respectively (Jayaprakash et al., 2015).

eHsp90 (α) promotes stemness of prostate cancer cells, its inhibition impairs spheroid formation, and surface Hsp90α is associated with CSC population (Nolan et al., 2017).

Hsp90α stimulates migration and invasion through CD91 and ErbB2 (Chen et al., 2010a). Skin cell migration induced through CD91/LRP-1 is mediated by Akt1/2 (Tseng et al., 2013).

Antibody to cell-surface Hsp90 blocks melanoma migration and metastasis in mice (Stellas et al., 2007).

Cell-impermeable Hsp90 inhibitor blocks cell migration and invasion (Tsenglas et al., 2008).

Extracellular Hsp90 has neuroprotective function by inducing cytokine production and Aβ clearance by microglia; Hsp90 also associates with Aβ plaques in Alzheimer diseased brains (Kakimura et al., 2002).

Secreted Hsp90 required by Eimeria tenella for invasion of vertebrate cells (Péroval et al., 2006).

Extracellular Hsp90 serves as cofactor for cellular entry of Karposi sarcoma-associated herpesvirus (KSHV) (Qin et al., 2010); may also relate to Hsp90 interaction with KSHV K1 protein (Wen and Damania, 2010).

Extracellular Hsp90 loaded with peptides is internalized to early endosomes through SREC-I in a Src-dependent fashion for antigen cross-presentation (Murshid et al., 2010).

Extracellular Hsp90 of tumor cells is internalized in presence of optically tethered and by themselves cell-impermeable Hsp90 inhibitors through an endosome-independent route; uptake is blocked by Hsp90 antibodies, may only occur in tumor cells and labelled compounds can be used to monitor tumors in mice (Barrott et al., 2013). Labelling by probe correlates with metastatic potential in culture and in mice (Osada et al., 2017).

Hsp90α is involved with annexin II in activating plasmin (McCready et al., 2010).

Secreted Hsp90β associates with TGFβ through LAP resulting in TGFβ inhibition in osteosarcoma cells (Suzuki and Kulkarni, 2010). Hsp90 promotes synthesis of collagen in TGFβ-activated fibroblasts (García et al., 2016).

Hsp90α, but not β, is secreted by activated endothelial cells and localizes to the leading edge to facilitate angiogenesis (Song and Luo, 2010).

Hsp90 may modulate adhesion and invasion via integrin-FAK-c-Src pathway (Liu et al., 2011; see also Radovanac et al., 2013), also potentially via interactions with secretory vesicles at the leading edge (Ghosh et al., 2015) and with integrin α2 and integrin αL (Ghosh et al., 2016). However, Hsp90 promotes inside-out activation of α4 integrin (Lin et al., 2019).
Secretion of Hsp90α by 293T and cranial mesenchymal cells is inhibited by Hectd1-mediated polyubiquitination; recombinant Hsp90α and an antibody promotes and inhibits, respectively, emigration of these mesenchymal cells (Sarkar and Zohn, 2012).

Hsp90α phosphorylated on T7 by DNA-PK still gets secreted, even preferentially (Quanz et al., 2012).

Cdc37 also on cell surface and antibodies to it block invasion and disrupt its interactions with Hsp90 and ErbB receptors (El Hamidieh et al., 2012).

Hsp90α/β is involved in the assembly and/or maintenance of the fibronectin matrix (Hunter et al., 2014).

Stimulation of migration may involve interaction with LOXL2 (McCready et al., 2014).

Elastin-derived peptides promote secretion of Hsp90α and stabilization of MMP-2 and uPA (Donet et al., 2014).

EGF stimulates Hsp90α surface display on membrane protrusions (and cell migration), and MMP9 activity, via PLCγ and PKCγ (Yang et al., 2014b).

Extracellular Hsp90 pool is involved in recycling of NadA, which highjacks the endosome pathway to enter cells, back to the cell surface (Bozza et al., 2014).

Stabilizes replication competent HCV RNA in complex with Ago2-miR-122 in exosomes (Bukong et al., 2014).

Extracellular levels of Hsp90α as markers for leukemia (ALL) (Milani et al., 2015).

Serum levels elevated in lupus patients (Saito et al., 2015).

Hsp90α serum levels elevated in lung cancer patients and correlating with stage and therapeutic response (Shi et al., 2014).

Plasma Hsp90α good marker for liver cancer and treatment response (Fu et al., 2017; see also Wei et al., 2020).

Hsp90α and β colocalize with heparan sulfate proteoglycans and binding is reduced by treatment of cells with heparin, heparinase or sodium chlorate (Snigireva et al., 2015). Interfering with its synthesis impairs Hsp90 stimulation of migration/invasion (Snigireva et al., 2019).

Apoptotic cells display Hsp90 with Hsp70 and Hsp60 on the surface and their interaction with LOX-1 facilitates uptake of dying cells (Zhu et al., 2016a).

Hsp90α stimulates migration of mesenchymal stem cells (Gao et al., 2015).

Primary cells from mouse carcinoma model secrete Hsp90β, but not Hsp90α, and specific inhibition of eHsp90 does not inhibit migration (Varholomaiou et al., 2017).

Hsp90 supports/buffers FANCA mutants associated with mild Fanconi anemia and possibly other genetic disabilities (Karras et al., 2017).

Only Hsp90β is secreted by two colon cancer cell lines (de la Mare et al., 2017).

Combination of TGFβ and (extracellularly) added Hsp90β stimulate adhesion, migration and anchorage-independent growth of a metastatic colon cancer cell line through integrin αvβ6 (de la Mare et al., 2017).

Both Hsp90α and Hsp90β on the surface of monocyte-derived macrophages and required for their stimulation by PAMPs; inhibitable by biotinylated GA Bzowska et al., 2017).

Antibodies to Hsp90 stain the cell surface/wall of Cryptococcus neoformans (Chatterjee and Tatu, 2017).

Exosome-mediated secretion of Hsp90α induced by hypoxia (see also Li et al., 2007), H2O2 and TGFα (through EGF receptor), and this is dependent on PRAS40 (Guo et al., 2017).
Hsp90 secretion also induced by heat stress and various inhibitors of endosomal trafficking and Ca²⁺ homeostasis (Takeuchi et al., 2015).

- eHsp90α increased in mouse model of pulmonary fibrosis and by TGF-β1, and a blocking antibody reduces inflammation and collagen deposition (Dong et al., 2017a). eHsp90α correlates with IPF and stimulates myofibroblasts through LRP1 (Bellaye et al., 2018).
- Potentially relevant to allergy and asthma, eHsp90α mediates disruption of airway epithelial permeability induced by house dust mites; through autocrine activation of RhoA, mimicked by recombinant Hsp90α, and blocked by an antibody to Hsp90α (Dong et al., 2017b).
- KD or anti-Hsp90α antibody prevent mite-induced epithelial barrier dysfunction (Ye et al., 2019).
- Promotes survival, anticancer drug resistance and signaling in SCLC cells (Du et al., 2018).
- Exosomes: critical reassessment shows that Hsp90 is not present in classical exosomes, but in other kinds of small extracellular vesicles and non-vesicular particles (Jeppesen et al., 2019).
- Interaction with S. aureus Lpl1 (Tribelli et al., 2019).
- TIMP2 and Aha1 are co-chaperones for eHsp90 with opposite effects on MMP2 as substrate; the ternary complex with TIMP2 as scaffold is in a standby less active state (Baker-Williams et al., 2019).
- Hsp90α secretion correlates with ADAM10 expression and is reduced upon "inhibition" of ADAM10; Hsp90α plasma levels correlate across a broad panel of cancers, notably when there is high expression of ADAM10 (Liu et al., 2019).
- eHsp90α and clusterin interact and synergize in a LRP1-mediated fashion to promote EMT, migration and metastasis of breast cancer cells (Tian et al., 2019).

Unusual stuff:

- Hsp90 gel shifts CpG oligonucleotides (ODN) known to stimulate immune responses (Bandholtz et al., 2003). Hsp90α but not Hsp90β binds CpG ODN to stimulate avian macrophages (Bhat et al., 2010). Extracellular Hsp90 converts CpG ODN into potent inducers of inflammatory responses in dendritic cells by trafficking into static early endosomes (Okuya et al., 2010). Associated with (self-) DNA, it strongly stimulates interferon-α production (Saito et al., 2015).
- Hsp90 specifically binds a domain of the 3’ UTR of the genomic RNA of Bamboo mosaic virus (Huang et al., 2012). Hsp90β binds BAZF mRNA and may mediate its VEGF-induced stabilization (Miwa et al., 2013). Recombinant Hsp90 binds genomic RNA of murine norovirus (Vashist et al., 2015; see also Vashist et al., 2012).
- Hsp90 binds both amorphous calcium phosphate precipitates and hydroxyapatite, possibly to protect cells from the formation of the latter; this also induces conformational changes in Hsp90 promoting oligomeric states (Ho et al., 2012).
- Hsp90 binds certain types of phosphorothioate oligonucleotides and enhances antisense oligonucleotide activity in vivo (Liang et al., 2016).
- Hsp90 may serve as receptor for internalization of oxalate monohydrate crystals (Fong-Ngern et al., 2016).
- Peptide from a specific monoclonal binds C-terminal region of Hsp90α and blocks CS anti-aggregation activity (Girola et al., 2016).

Hsp90 relatives:
Grp94 (=endoplasmin=HSP90B1) (Hsp90 family member in the endoplasmic reticulum).

- Hsp75, found as a protein that interacts with and chaperones Rb during M phase and after heat shock (Chen et al., 1996a). Trap1, probably identical to Hsp75, found in two-hybrid with type I TNF receptor (Song et al., 1995). Binds radicicol and GA (Schulte et al., 1999; Felts et al., 2000). New evidence shows Trap1 = Hsp75 is a mitochondrial protein with a GA / radicicol inhibitable ATPase (Felts et al., 2000). Not only in mitochondria in Dictyostelium (Morita et al., 2002).

- Hsp90 pseudogene (?) lacking GA-binding domain (Schweinfest et al., 1998). Instead, Hsp90N appears to contain an N-terminal myristoylation signal and activates Raf-1 by recruitment to the membrane; Hsp90N does not bind Cdc37 (Grammatikakis et al., 2002). Hsp90N is an artefact of a unique chromosomal translocation (Zurawska et al., 2008).

- Other members of GHKL ATPase superfamily: DNA gyrase B (Grenert et al., 1997; Prodomou et al., 1997a), the class I histidine kinase domain of EnvZ (Tanaka et al., 1998), the histidine kinase domain of CheA (Bilwes et al., 1999), pyruvate dehydrogenase kinase (PDHK) (Bowker-Kinley and Popov, 1999) and MutL have a similar fold (four β-strands and three α-helices) in their ATP-binding region (reviewed in Dutta and Inouye, 2000), suggesting a common mechanism linking ATP hydrolysis and relative subunit motion. However, domain arrangements are different (Huai et al., 2005).

- p52rIPK, the inhibitor of p58IPK, has a very (!) limited homology to the charged region of Hsp90 (Gale et al., 1998).


- Plants have an additional Hsp90 homolog targeted to the chloroplast stroma: in Arabidopsis, it is heat- and light-inducible, and a point mutant is chlorate-resistant and partially defective in greening (Cao et al., 2003).

- N- and C-terminal regions of α-spectrin and β-spectrin, respectively may have more than 50% sequence similarity with human Hsp90 (Bhattacharyya et al., 2004; see also Kudlicki et al., 1987).

- Sacsin: contains several sacsin repeating region (SRR), which is characterized by an Hsp90-like ATPase domain with a larger repeat unit. The SRR has ATPase activity but is not inhibited by geldanamycin or radicicol (Anderson et al., 2010), and is contained within a larger region with chaperone activity (Anderson et al., 2011). Structure of an Hsp90-like domain (Menade et al., 2018).

- Smchd1 is a member of the GHKL ATPase superfamily with structural similarity to Hsp90 and its ATPase can be inhibited by radicicol (Chen et al., 2016).
References:


Adkins, B., Hunter, T., and Sefton, B. M. (1982). The transforming proteins of PRCII virus and Rous sarcoma virus form a complex with the same two cellular phosphoproteins. J. Virol. 43, 448-455


Buzon, L., Guan, J., and Denker, B. M. (2000). Degradation of heterotrimeric Gα subunits via the proteosome pathway is induced by the hsp90-specific compound geldanamycin. J. Biol. Chem. 275, 1565-1569


Chen, B., and Wagner, A. (2012). Hsp90 is important for fecundity, longevity, and buffering of cryptic deleterious variation in wild fly populations. BMC Evol. Biol. 12, 25


Chen, F., Pandey, D., Chadli, A., Catravas, J. D., Chen, T., and Fulton, D. J. (2011). Hsp90 regulates NADPH oxidase activity and is necessary for superoxide production. Antioxid. Redox Signal. 14, 2107-2119

Chen, G. (2016). The Hop/Sti1 chaperone complex facilitates the maturation and transport of a PAMP receptor in rice innate immunity. Cell Host Microbe 17, 112-113


Chen, W., Sin, S. H., Wen, K. W., Damania, B., and Dittmer, D. P. (2012b). Hsp90 inhibitors are efficacious against Kaposi sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteins. PLoS Pathog. 8, e1003048


Codina, M., Li, J., Gutierrez, J., Kao, J. P., and Du, S. J. (2010). Loss of Smyhc1 or Hsp90α1 function results in different effects on myofibril organization in skeletal muscles of zebrafish embryos. PLoS ONE 5, e8416


In p53 by the Hsp70 and Hsp90 chaperone molecular chaperone module in interleukin -

Large rotation of the N protein 90 regulates distinct regions of the tomato I Sarkar, S. (2015).


- 105 -

Didier Picard – 02/2020


Donzé, O., Abbas-Terki, T., and Picard, D. (2001). The Hsp90 chaperone complex is both a facilitator and a repressor of the dsRNA-dependent kinase PKR. EMBO J. 20, 3771-3780


Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 100, 721-726

Torso, a receptor tyrosine kinase required for embryonic pattern formation, shares substrates with the Sevenless and EGF-R pathways in Drosophila. Genes Dev. 7, 633-646

Intermolecular interactions between Hsp90 and Hsp70. J. Mol. Biol. 431, 2729-2746


Nonapoptotic death of Saccharomyces cerevisiae cells that is stimulated by Hsp90 and inhibited by calcineurin and Cmk2 in response to endoplasmic reticulum stresses. Eukaryot. Cell 7, 2037-2051


A cyclophilin function in Hsp90-dependent signal transduction. Science 274, 1713-1715

Requirement for Hsp90 and a CyP-40-type cyclophilin in negative regulation of the heat shock response. J. Biol. Chem. 273, 18974-18978

c-Abl mediated tyrosine phosphorylation of Aha1 activates its co-chaperone function in cancer cells. Cell Rep. 12, 1006-1018

Active participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3). J. Biol. Chem. 286, 20065-20077

GHKL, an emergent ATPase/kinase superfAMILY. Trends Biochem. Sci. 25, 24-28

Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol. Biol. Cell 18, 4659-4668

Dibenzylation of nicotinamide. J. Mol. Biol. 228, 673-690

Direct participation of cellular chaperone Hsp90 in regulating the function of rotavirus nonstructural protein 3 (NSP3). J. Biol. Chem. 286, 20065-20077

In vivo functional analysis of compendia of proteins. PLoS ONE 6, e21032

An interaction network predicted from public data as a discovery tool: application to the Hsp90 molecular chaperone machine. PLoS ONE 6, e26044

The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity. PLoS ONE 14, e0208287

A remodelled Hsp90 molecular chaperone ensemble with the novel co-chaperone Aarsd1 is required for muscle differentiation. Mol. Cell. Biol. 36, 1310-1321

Detection of changes in gene regulatory patterns, elicited by perturbations of the Hsp90 molecular chaperone complex, by visualizing multiple experiments with an animation. BioData Mining 4, 15

Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. J. Mol. Biol. 350, 723-734


Emelyanov, V. V. (2002). Phylogenetic relationships of organellar Hsp90 homologs reveal fundamental differences to organellar Hsp70 and Hsp60 evolution. Gene 299, 125-133


Didier Picard – 02/2020

- 109 -


- 110 -
Freeman, B. C., and Morimoto, R. I. (1996). The human cytosolic molecular chaperones hsp90, hsp70 (hsc70) and hdj-1 have different roles in recognition of a non-native protein and protein refolding. EMBO J. 15, 2969-2979


Iwai, C., Li, P., Kurata, Y., Hoshikawa, Y., Morikawa, K., Maharani, N., Higaki, K., Sasano, T., Notsu, T., Ishido, Y. et al. (2013). Hsp90 prevents interaction between CHIP and HERG proteins to facilitate maturation of wild-type and mutant HERG proteins. Cardiovasc. Res. 100, 520-528


Jing, R., Duncan, C. B., and Duncan, S. A. (2017). A small-molecule screen reveals that HSP90β promotes the conversion of induced pluripotent stem cell-derived endoderm to a hepatic fate and regulates HNF4A turnover. Development 144, 1764-1774.


Kitam, V. O., Maksymchuk, O. V., and Chashchyn, M. O. (2012). The possible mechanisms of CYP2E1 interactions with HSP90 and the influence of ethanol on them. BMC Struct. Biol. 12, 33


Kobayakawa, T., Yamada, S., Mizuno, A., Ohara-Nemoto, Y., Baba, T. T., and Nemoto, T. K. (2009). Single nucleotide polymorphism that accompanies a missense mutation (Gln488His) impedes the dimerization of Hsp90. Protein J. 28, 24-28


Kudlicki, W., Fullilove, S., Read, R., Kramer, G., and Hardesty, B. (1987). Identification of spectrin-related peptides associated with the reticulocyte heme-controlled alpha subunit of eukaryotic translational initiation factor 2 kinase and of Mr 95,000 peptide that appears to be the catalytic subunit. J. Biol. Chem. 262, 9695-9701


- 130 -
Lachowiec, J., Lemus, T., Thomas, J. H., Murphy, P. J., Nemhauser, J. L., and Queitsch, C. (2013). The protein chaperone HSP90 can facilitate the divergence of gene duplicates. Genetics 193, 1269-1277

- 131 -


Lee, Y. T., Jacob, J., Michowski, W., Nowotny, M., Kuznicki, J., and Chazin, W. J. (2004b). Human Sgt1 binds HSP90 through the CHORD-Sgt1 domain and not the tetra-tricopeptide repeat domain. J. Biol. Chem. 279, 16511-16517


Liu, X., Main, D., Ma, Y., and He, B. (2018). Herpes Simplex Virus 1 inhibits TANK-Binding Kinase 1 through formation of the Us11-Hsp90 complex. J. Virol. 92, e00402-00418

Liu, X. D., Morano, K. A., and Thiele, D. J. (1999). The yeast Hsp110 family member, Sse1, is an Hsp90 cochaperone. J. Biol. Chem. 274, 26654-26660


Mahony, D., Parry, D. A., and Lees, E. (1998). Active cdk6 complexes are predominantly nuclear and represent only a minority of the cdk6 in T cells. Oncogene 17, 603-611


- 138 -


Millson, S. H., Truman, A. W., Rácz, A., Hu, B., Panaretou, B., Nuttall, J., Mollapour, M., Söti, C., and Piper, P. W. (2007). Expressed as the sole Hsp90 of yeast, the α and β isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90β generates sensitivity to the Hsp90 inhibitor radicicol. FEBS J. 274, 4453-4463


Morishima, Y., Murphy, P. J., Li, D. P., Sanchez, E. R., and Pratt, W. B. (2000b). Stepwise assembly of a glucocorticoid receptor-hsp90 heterocomplex resolves two sequential ATP-dependent events involving first hsp70 and then hsp90 in opening of the steroid binding pocket. J. Biol. Chem. 275, 18054-18060


Muller, P., Ruckova, E., Halada, P., Coates, P. J., Hrstka, R., Lane, D. P., and Vojtesek, B. (2013). C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/folding degradation balances. Oncogene 32, 3101-3110


(Hsp) 90 and Hsp70 chaperones mediates their cooperative action to refold denatured proteins. J. Biol. Chem. 289, 6110-6119


Nemoto, T. K., Fukuma, Y., Yamada, S. I., Kobayakawa, T., Ono, T., and Ohara-Nemoto, Y. (2004). The region adjacent to the highly immunogenic site and shielded by the middle domain is responsible for self-oligomerization/client binding of the Hsp90 molecular chaperone. Biochem. 43, 7628-7636


Nguyen, N., Francoeur, N., Chartrand, V., Klarskov, K., Guillemette, G., and Boulay, G. (2009). Insulin promotes the association of heat shock protein 90 with the inositol 1,4,5-trisphosphate receptor to dampen its Ca2+ release activity. Endocrinology 150, 2190-2196


Obermann, W. M. J. (2018). A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor α methylation by the lysine methyltransferase SMYD2. J. Biol. Chem. 293, 16479-16487


Ommen, G., Chrobak, M., and Clos, J. (2010). The co-chaperone SGT of Leishmania donovani is essential for the parasite's viability. Cell Stress Chaperones 15, 443-455


Owens-Grillo, J. K., Stancato, L. F., Hoffmann, K., Pratt, W. B., and Krishna, P. (1996b). Binding of immunophilins to the 90 kDa heat shock protein (hsp90) via a tetratricopeptide repeat domain is a conserved protein interaction in plants. Biochem. 35, 15249-15255


that generate immunogenic fragments of this molecular chaperone in C. albicans infections. Microbiology 145, 3455-3463


Perdew, G. H., and Whitelaw, M. L. (1991). Evidence that the 90-kDa heat shock protein (HSP90) exists in cytosol in heteromeric complexes containing HSP70 and three other proteins with Mr of 63,000, 56,000, and 50,000. J. Biol. Chem. 266, 6708-6713


- 152 -


Peterson, L. B., Eskew, J. D., Vielhauer, G. A., and Blagg, B. S. (2012). The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Mol. Pharmacuetics 9, 1841-1846

Pfeiffer, J., Tarbashevich, K., Bandemer, J., Palm, T., and Raz, E. (2018). Rapid progression through the cell cycle ensures efficient migration of primordial germ cells - The role of Hsp90. Dev. Biol. 436, 84-93


Didier Picard – 02/2020


Radanyi, C., Renoir, J.-M., Sabbah, M., and Baulieu, E.-E. (1989). Chicken heat-shock protein of Mr=90,000, free or released from progesterone receptor, is in a dimeric form. J. Biol. Chem. 264, 2568-2573


Rajapandi, T., Greene, L. E., and Eisenberg, E. (2000). The molecular chaperones hsp90 and hsc70 are both necessary and sufficient to activate hormone binding by glucocorticoid receptor. J. Biol. Chem. 275, 22597-22604


- 156 -
Richter, K., Walter, S., and Buchner, J. (2004). The co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J. Mol. Biol. 342, 1403-1413


Segnitz, B., and Gehring, U. (1997). The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin. J. Biol. Chem. 272, 18694-18701


Seraphim, T. V., Alves, M. M., Silva, I. M., Gomes, F. E., Silva, K. P., Murta, S. M., Barbosa, L. R., and Borges, J. C. (2013). Low resolution structural studies indicate that the activator of Hsp90 ATPase 1 (Aha1) of Leishmania braziliensis has an elongated shape which allows its interaction with both N- and M-domains of Hsp90. PLoS ONE 8, e66822


Silverstein, A. M., Grammatikakis, N., Cochran, B. H., Chinkers, M., and Pratt, W. B. (1998). p50(cdc37) binds directly to the catalytic domain of Raf as well as to a site on hsp90 that is topologically adjacent to the tetra-tricopeptide repeat binding site. J. Biol. Chem. 273, 20090-20095


- 165 -


Singh, N., Sintiprungrat, K., and Thongboonkerd, V. (2013). Alterations in macrophage cellular proteome induced by calcium oxalate crystals: the association of Hsp90 and F-actin is important for phagosome formation. J. Proteome Res. 12, 3561-3572


- 166 -


Soshilov, A., and Denison, M. S. (2011). Ligand displaces heat shock protein 90 from overlapping binding sites within the aryl hydrocarbon receptor ligand-binding domain. J. Biol. Chem. 286, 35275-35282


Tortosa, E., Santa-Maria, I., Moreno, F., Lim, F., Perez, M., and Avila, J. (2009). Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J. Alzheimers Dis. 17, 319-325


- 172 -


Woodford, M. R., Sager, R. A., Marris, E., Dunn, D. M., Blanden, A. R., Murphy, R. L., Rensing, N., Shapiro, O., Panaretou, B., Proksch, C. et al. (2017). Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. EMBO J. 36, 3650-3665


- 179 -


Wu, M., and Hardwidge, P. R. (2018). Hsp90 interacts with the bacterial effector NleH1. Pathogens 7, 87


- 181 -


Young, J. C., and Hartl, F. U. (2000). Polypeptide release by hsp90 involves ATP hydrolysis and is enhanced by the co-chaperone p23. EMBO J. 19, 5930-5940


Young, J. C., Schneider, C., and Hartl, F. U. (1997). In vitro evidence that hsp90 contains two independent chaperone sites. FEBS Lett. 418, 139-143


Zhang, D., Li, J., Costa, M., Gao, J., and Huang, C. (2010a). JNK1 mediates degradation HIF-1α by a VHL-independent mechanism that involves the chaperones Hsp90/Hsp70. Cancer Res. 70, 813-823


